uric acid has been researched along with Heart Failure in 312 studies
Uric Acid: An oxidation product, via XANTHINE OXIDASE, of oxypurines such as XANTHINE and HYPOXANTHINE. It is the final oxidation product of purine catabolism in humans and primates, whereas in most other mammals URATE OXIDASE further oxidizes it to ALLANTOIN.
uric acid : An oxopurine that is the final oxidation product of purine metabolism.
6-hydroxy-1H-purine-2,8(7H,9H)-dione : A tautomer of uric acid having oxo groups at C-2 and C-8 and a hydroxy group at C-6.
7,9-dihydro-1H-purine-2,6,8(3H)-trione : An oxopurine in which the purine ring is substituted by oxo groups at positions 2, 6, and 8.
Heart Failure: A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Our study demonstrated the efficiency of benzbromarone in hypertensive patients with concomitant asymptomatic hyperuricemia, including the benefits on ameliorating LV diastolic dysfunction as well as improving composite endpoints." | 9.69 | Uric acid-lowering therapy with benzbromarone in hypertension with asymptomatic hyperuricemia: a randomized study focusing left ventricular diastolic function. ( Gu, J; Han, Z; Ke, J; Lin, H; Pan, J, 2023) |
| "The sodium-glucose cotransporter-2 inhibitor empagliflozin decreases the risk of cardiovascular death or hospitalization for heart failure (HF) in patients with HF with reduced ejection fraction." | 9.51 | Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the EMPEROR-reduced trial. ( Anker, SD; Brueckmann, M; Butler, J; Doehner, W; Ferreira, JP; Filippatos, G; Januzzi, JL; Kaempfer, C; Packer, M; Pocock, SJ; Salsali, A; Zannad, F, 2022) |
| "Febuxostat is potentially more effective than allopurinol for treating patients with chronic HF and hyperuricemia." | 9.41 | Comparison between febuxostat and allopurinol uric acid-lowering therapy in patients with chronic heart failure and hyperuricemia: a multicenter randomized controlled trial. ( Ishibashi, T; Kobayashi, A; Konno, I; Kunii, H; Machii, H; Miyamoto, T; Nakazato, K; Niizeki, T; Nozaki, N; Suzuki, S; Takeishi, Y; Tsuda, A; Tsuda, T; Yamaguchi, O; Yamaki, T; Yokokawa, T; Yoshihisa, A, 2021) |
| "Gout is common in patients with heart failure (HF), and sodium-glucose cotransporter 2 inhibitors, a foundational treatment for HF, reduce uric acid levels." | 9.41 | Association of Dapagliflozin Use With Clinical Outcomes and the Introduction of Uric Acid-Lowering Therapy and Colchicine in Patients With Heart Failure With and Without Gout: A Patient-Level Pooled Meta-analysis of DAPA-HF and DELIVER. ( Butt, JH; Claggett, BL; de Boer, RA; Desai, AS; Docherty, KF; Hernandez, AF; Inzucchi, SE; Jhund, PS; Kosiborod, MN; Køber, L; Lam, CSP; Langkilde, AM; Martinez, FA; McMurray, JJV; Petersson, M; Ponikowski, P; Sabatine, MS; Shah, SJ; Solomon, SD; Vaduganathan, M, 2023) |
| "We aimed to 1) describe characteristics of patients with heart failure with preserved ejection fraction (HFpEF) enrolled in RELAX stratified by normal or elevated baseline serum uric acid (sUA) level; 2) evaluate the association between sUA level and surrogate clinical measures; and 3) assess associations between changes in sUA level over time and changes in surrogate clinical measures." | 9.34 | Elevated Uric Acid Prevalence and Clinical Outcomes in Patients with Heart Failure with Preserved Ejection Fraction: Insights from RELAX. ( Alhanti, B; Bjursell, M; Carnicelli, AP; Lytle, B; Mentz, RJ; Perl, S; Roe, MT; Sun, JL, 2020) |
| "Clinical studies have shown that large doses of prednisone could lower serum uric acid (SUA) in patients with decompensated heart failure (HF); however, the optimal dose of prednisone and underlying mechanisms are unknown." | 9.22 | Prednisone lowers serum uric acid levels in patients with decompensated heart failure by increasing renal uric acid clearance. ( Liu, C; Liu, K; Zhai, JL; Zhang, JX; Zhao, Q; Zhen, Y, 2016) |
| "Treatment of congestive heart failure (CHF) with loop diuretics, such as furosemide, may be associated with complications, including worsening renal function and metabolic or electrolyte disturbances." | 9.20 | Safety of add-on tolvaptan in patients with furosemide-resistant congestive heart failure complicated by advanced chronic kidney disease: a sub-analysis of a pharmacokinetics/ pharmacodynamics study. ( Akashi, YJ; Kida, K; Kimura, K; Matsumoto, N; Miyake, F; Shibagaki, Y; Tominaga, N, 2015) |
| "Thirty-four symptomatic CHF participants with hyperuricemia (≥ 565 μmol/L) were randomized to receive prednisone (1 mg/kg/d, orally) or allopurinol (100 mg, thrice daily, orally) for 4 weeks." | 9.17 | Prednisone in Uric Acid lowering in Symptomatic Heart Failure Patients With Hyperuricemia (PUSH-PATH) study. ( Gao, Y; Ji, L; Ji, Z; Liu, C; Liu, G; Liu, K; Tian, L; Wang, L; Zhao, Q; Zhen, Y, 2013) |
| "To evaluate the independent impact of congestive heart failure (CHF) status (compensation or decompensation) on serum uric acid levels among men with high cardiovascular risk profile." | 9.15 | The independent impact of congestive heart failure status and diuretic use on serum uric acid among men with a high cardiovascular risk profile: a prospective longitudinal study. ( Choi, HK; Misra, D; Zhang, Y; Zhu, Y, 2011) |
| " The treatment effect of the uricosuric agent benzbromarone was tested in 14 patients with CHF with hyperuricemia in a double-blind, placebo-controlled, randomized crossover study design." | 9.14 | Uric acid-lowering treatment with benzbromarone in patients with heart failure: a double-blind placebo-controlled crossover preliminary study. ( Anker, SD; Doehner, W; Furuse, Y; Hisatome, I; Igawa, O; Ishida, K; Kato, M; Kinugasa, Y; Kinugawa, T; Ogino, K; Osaki, S; Shigemasa, C, 2010) |
| "This study evaluated whether a xanthine oxidase (XO) inhibitor, oxypurinol, produces clinical benefits in patients with New York Heart Association functional class III to IV heart failure due to systolic dysfunction receiving optimal medical therapy." | 9.13 | Impact of oxypurinol in patients with symptomatic heart failure. Results of the OPT-CHF study. ( Brown, J; Colucci, WS; Fisher, C; Freudenberger, R; Givertz, MM; Hare, JM; Liu, P; Mangal, B; Mann, DL; Schwarz, RP, 2008) |
| "This network meta-analysis aimed to assess the current efficacy of decreasing the uric acid (UA) level with drugs to reduce mortality in patients with heart failure (HF)." | 9.12 | Network Meta-Analysis of Drug Therapies for Lowering Uric Acid and Mortality Risk in Patients with Heart Failure. ( Fujihara, K; Horikawa, C; Kitazawa, M; Kodama, S; Matsubayashi, Y; Sato, T; Sone, H; Watanabe, K; Yaguchi, Y; Yamada, M; Yamada, T; Yamamoto, M, 2021) |
| "We studied effects of beta-adrenoblocker carvedilol vs placebo in 60 patients with chronic cardiac failure (CCF) of functional classes III-IV in a 6-month open randomized trial." | 9.10 | [Endothelial protection in patients with apparent cardiac failure in long-term therapy by carvedilol]. ( Shliakhto, EV; Sitnikova, MIu, 2003) |
| " All patients underwent at entry a physical examination, measurement of body weight (BW), blood pressure (BP), heart rate (HR), evaluation of signs of CHF, and controls of serum Na, K, Cl, bicarbonate, albumin, uric acid, creatinine, urea and glycemia and daily during hospitalization, as well as the daily output of urine for, Na, K and Cl measurements." | 9.09 | Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as a bolus, in refractory congestive heart failure. ( Amato, P; Cardinale, A; Di Pasquale, P; Follone, G; Giubilato, A; Licata, G; Parrinello, G; Paterna, S, 2000) |
| "Several trials have been completed in patients with heart failure (HF) treated with uric acid (UA)-lowering agents with inconsistent results." | 9.05 | Effect of Uric Acid-Lowering Agents on Cardiovascular Outcome in Patients With Heart Failure: A Systematic Review and Meta-Analysis of Clinical Studies. ( Afsar, B; Cherney, D; Covic, A; Dincer, N; Erden, N; Kanbay, M; Kuwabara, M; Ortiz, A; Rossignol, P; Sag, AA; Siriopol, D; Yilmaz, O, 2020) |
| "14 patients with congestive heart failure requiring diuretic therapy were randomly assigned to treatment with ticrynafen (TCRN) 250 mg or hydrochlorothiazide (HCTZ) 50 mg once or twice daily." | 9.04 | Renal function during therapy in patients with congestive cardiac failure. Ticrynafen vs. hydrochlorothiazide. ( Clements, P; Smith, JW, 1979) |
| "1 This study has compared the diuresis produced by a single oral administration of 6 mg piretanide, 9 mg piretanide and 1 mg bumetanide in a group of nine patients with cardiac failure using a balanced randomized design." | 9.04 | A single dose comparison of piretanide and bumetanide in congestive cardiac failure. ( Dombey, SL; Homeida, M; Roberts, CJ, 1979) |
| "Conflicting results have been reported on the prognostic significance of serum uric acid (SUA) in patients with acute heart failure (AHF)." | 9.01 | Prognostic value of serum uric acid in patients with acute heart failure: A meta-analysis. ( Deng, X; Huang, G; Luo, G; Qin, J; Wang, L; Yu, D; Zhang, M; Zhou, S, 2019) |
| "We aimed to perform a systematic review and meta-analysis to assess the association between serum uric acid and incident heart failure (HF)/prognosis of HF patients." | 8.90 | Uric acid and risk of heart failure: a systematic review and meta-analysis. ( Chen, J; Huang, B; Huang, H; Huang, Y; Jing, X; Li, J; Li, Y; Wang, J; Yao, H, 2014) |
| "Patients with mild-moderate chronic heart failure (CHF) often have raised levels of serum uric acid (UA)." | 8.82 | The increase in serum uric acid concentration caused by diuretics might be beneficial in heart failure. ( Reyes, AJ, 2005) |
| " Patients (N = 133) with chronic heart failure and comorbid hyperuricemia who enrolled in the Excited-UA study were divided into three tertiles based on their serum uric acid level 24 weeks after initiating xanthine oxidase inhibitor treatment with topiroxostat or allopurinol (i." | 8.31 | Optimal uric acid reduction to improve vascular endothelial function in patients with chronic heart failure complicated by hyperuricemia. ( Abe, S; Iida, K; Inoue, K; Inoue, R; Inoue, T; Kato, T; Kitahara, K; Kohno, Y; Koshiji, N; Naganuma, J; Sakuma, M; Toyoda, S; Yamauchi, F; Yokomachi, J, 2023) |
| "Serum uric acid (SUA) may play a role in heart failure (HF)." | 8.31 | Association between serum uric acid levels and the prevalence of heart failure due to acute coronary syndrome in Chinese hospitalized patients: A cross-sectional study. ( Liang, X; Liu, Y; Rong, D; Sun, G, 2023) |
| "Increased circulating uric acid (UA) concentration may disrupt cardiac function in heart failure patients, but the specific mechanism remains unclear." | 8.31 | Increased circulating uric acid aggravates heart failure via impaired fatty acid metabolism. ( Bennewitz, K; Kroll, J; Liu, H; Lou, B; Ott, H; Poschet, G; She, J; Wang, C; Wu, H; Yuan, Z, 2023) |
| "It remains unclear whether the long-term prognostic value of serum uric acid (SUA) at admission differs in acute decompensated heart failure (HF) patients across the spectrum of left ventricular ejection fraction (EF)." | 8.31 | Associations of long-term mortality with serum uric acid at admission in acute decompensated heart failure with different phenotypes. ( Cauwenberghs, N; Chen, S; Chen, X; Cheng, W; Dong, Y; He, J; Huang, J; Liu, C; Wei, FF; Wu, Y; Yu, Z; Zhao, J, 2023) |
| "Data on the association between uric acid (UA) levels and clinical outcomes, such as readmission and mortality, in patients with heart failure are scarce." | 8.31 | Relation of serum uric acid levels to readmission and mortality in patients with heart failure. ( Hu, E; Li, Z; Wei, D; Yuan, J, 2023) |
| "Elevated serum uric acid (SUA) levels have been associated with poor outcome in patients with heart failure (HF)." | 8.31 | Serum uric acid and outcome in hospitalized elderly patients with chronic heart failure through the whole spectrum of ejection fraction phenotypes. ( He, KL; Tang, HY; Yan, W; Yang, YQ, 2023) |
| " Using the data from a nationwide, prospective registry on patients with chronic coronary syndromes (CCS), we assessed the impact of serum uric acid (SUA) levels on quality of life (QoL) and major adverse CV events (MACE), a composite of CV death and hospitalization for myocardial infarction, heart failure (HF), angina or revascularization at 1-year." | 8.12 | Impact of serum uric acid levels on cardiovascular events and quality of life in patients with chronic coronary syndromes: Insights from a contemporary, prospective, nationwide registry. ( Borghi, C; Colivicchi, F; D'Urbano, M; De Luca, L; Desideri, G; Gabrielli, D; Gulizia, MM; Mattei, L; Meessen, J; Temporelli, PL, 2022) |
| "We focused on the role of Uric Acid (UA) as a possible determinant of Heart Failure (HF) related issues in Acute Coronary Syndromes (ACS) patients." | 8.12 | Uric acid associated with acute heart failure presentation in Acute Coronary Syndrome patients. ( Carugo, S; Castini, D; Centola, M; Ferrante, G; Giannattasio, C; Lucreziotti, S; Maloberti, A; Morici, N; Occhino, G; Oliva, F; Oreglia, J; Persampieri, S; Rebora, P; Sabatelli, L; Sacco, A; Valsecchi, MG; Viola, G, 2022) |
| "The association between serum uric acid (SUA) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentrations in patients with coronary artery disease (CAD) is unclear." | 8.12 | Association between higher serum uric acid levels and plasma N-terminal pro-B-type natriuretic peptide concentrations in patients with coronary artery disease and without overt heart failure. ( Beatrice, G; Bonapace, S; Cappelli, D; Csermely, A; Dugo, C; Mantovani, A; Molon, G; Petracca, G; Targher, G, 2022) |
| "The role of hyperuricaemia as a prognostic maker has been established in chronic heart failure (HF) but limited information on the association between plasma uric acid (UA) levels and central haemodynamic measurements is available." | 8.12 | Uric acid in advanced heart failure: relation to central haemodynamics and outcome. ( Deis, T; Ersbøll, MK; Gustafsson, F; Rossing, K; Wolsk, E, 2022) |
| "This study aimed to investigate the adverse effects of serum uric acid concentration on the severity of chronic congestive heart failure." | 8.12 | The effect of serum uric acid concentration on the severity of chronic congestive heart failure. ( Al-Mohana, SJA; Alshamari, AHI; Kadhim, RK, 2022) |
| "Increased uric acid levels predict higher mortality in heart failure (HF) patients." | 8.02 | The prognostic impact of uric acid in acute heart failure according to coexistence of diabetes mellitus. ( Bettencourt, P; Cidade-Rodrigues, C; Cunha, FM; Elias, C; Lourenço, P; Oliveira, D, 2021) |
| "To evaluate the prognostic impact of serum uric acid (SUA) on clinical outcomes in patients with acute decompensated heart failure, as well as identify the correlation between hyperuricemia and renal function and diuretic resistance in these patients." | 8.02 | [Prognostic impact of uric acid in patients with acute decompensated heart failure]. ( Lapteva, AE; Mindzaev, DR; Nasonova, SN; Tereshchenko, SN; Zhirov, IV, 2021) |
| "To assess the prognostic cut-off values of serum uric acid (SUA) in predicting fatal and morbid heart failure in a large Italian cohort in the frame of the Working Group on Uric Acid and Cardiovascular Risk of the Italian Society of Hypertension." | 8.02 | Serum uric acid, predicts heart failure in a large Italian cohort: search for a cut-off value the URic acid Right for heArt Health study. ( Barbagallo, CM; Bombelli, M; Borghi, C; Casiglia, E; Cicero, AFG; Cirillo, M; Cirillo, P; D'Eliak, L; Desideri, G; Ferri, C; Galletti, F; Gesualdo, L; Giannattasio, C; Grassi, G; Iaccarino, G; Mallamaci, F; Maloberti, A; Masi, S; Mazza, A; Muiesan, ML; Nazzaro, P; Palatini, P; Parati, G; Pontremoli, R; Rattazzi, M; Rivasi, G; Salvetti, M; Tikhonoff, V; Tocci, G; Ungar, A; Verdecchia, P; Viazzi, F; Virdis, A; Volpe, M, 2021) |
| "Prognostic impacts of serum uric acid (UA) levels in patients with chronic heart failure (CHF) remain inconclusive, especially for the whole range of serum UA levels." | 8.02 | Prognostic impacts of serum uric acid levels in patients with chronic heart failure: insights from the CHART-2 study. ( Abe, R; Aoyanagi, H; Fujihashi, T; Hayashi, H; Kasahara, S; Miura, M; Miyata, S; Nochioka, K; Sakata, Y; Sato, M; Shimokawa, H; Shiroto, T; Sugimura, K; Takahashi, J; Yamanaka, S, 2021) |
| "In this nonrandomized, open-label, single-arm trial, we administered topiroxostat 40-160 mg/day to HFpEF patients with hyperuricemia or gout to achieve a target uric acid level of 6." | 8.02 | Effect of Topiroxostat on Brain Natriuretic Peptide Level in Patients with Heart Failure with Preserved Ejection Fraction: A Pilot Study. ( Asai, K; Koen, M; Kubota, Y; Shimizu, W; Wakita, M, 2021) |
| "Retrospective analyses of clinical trials indicate that elevated serum uric acid (sUA) predicts poor outcome in heart failure (HF)." | 8.02 | Serum uric acid and outcomes in patients with chronic heart failure through the whole spectrum of ejection fraction phenotypes: Analysis of the ESC-EORP Heart Failure Long-Term (HF LT) Registry. ( Almenar-Bonet, L; Ambrosio, G; Anker, SD; Cardona, A; Coats, AJS; Coiro, S; Ferrari, R; Filippatos, G; Frisinghelli, A; Laroche, C; Leiro, MGC; Lund, LH; Maggioni, AP; Piepoli, MF; Poder, P; Valero, DB, 2021) |
| "To investigate the association of serum uric acid levels with in-hospital heart failure (HF) in patients with acute myocardial infarction (AMI) who are undergoing percutaneous coronary intervention (PCI)." | 8.02 | Association between Uric Acid and In-Hospital Heart Failure in Patients with Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention. ( Liu, CF; Song, KY; Wei, YJ; Zhou, WN, 2021) |
| " placebo on high-sensitivity C-reactive protein (hsCRP) and serum uric acid (SUA) were assessed in patients with heart failure with reduced ejection fraction (HFrEF) in the Phase 2 SOCRATES-REDUCED study (NCT01951625)." | 7.96 | Evaluation of high-sensitivity C-reactive protein and uric acid in vericiguat-treated patients with heart failure with reduced ejection fraction. ( Butler, J; Igl, BW; Kramer, F; Lam, CSP; Maggioni, AP; Pieske, B; Roessig, L; Shah, SJ; Voss, S, 2020) |
| "Although serum uric acid (SUA) level is correlated with oxidative stress and serves as a marker of poor prognosis in heart failure patients, its possible association with subclinical left ventricular (LV) dysfunction has not been evaluated." | 7.96 | Serum uric acid level and subclinical left ventricular dysfunction: a community-based cohort study. ( Daimon, M; Di Tullio, MR; Hirokawa, M; Homma, S; Ishiwata, J; Kaneko, H; Komuro, I; Mizuno, Y; Morita, H; Nakanishi, K; Nakao, T; Sawada, N; Yoshida, Y, 2020) |
| " This study was designed to evaluate the influences of long-term xanthine oxidase inhibitor (febuxostat) prescription on left ventricular hypertrophy (LVH), left ventricular (LV) diastolic function, and new-onset heart failure with preserved ejection fraction (HFpEF) in these patients." | 7.96 | Association between long-term prescription of febuxostat and the progression of heart failure with preserved ejection fraction in patients with hypertension and asymptomatic hyperuricemia. ( Gu, J; Lin, H; Pan, JA; Wang, CQ; Zhang, JF, 2020) |
| "Elevated serum uric acid (UA) is associated with an increased risk of adverse outcome in patients with heart failure (HF), but it remains unknown whether the change of serum UA level during the treatment of acute decompensated HF (ADHF) predicts adverse events." | 7.96 | In-Hospital Serum Uric Acid Change Predicts Adverse Outcome in Patients With Heart Failure. ( Mahara, K; Nagatomo, Y; Yamamoto, H; Yoshikawa, T, 2020) |
| "This study aimed to determine the prognostic value of serum uric acid (SUA) on outcomes in heart failure (HF) with preserved ejection fraction (HFpEF), and whether sacubitril-valsartan reduces SUA and use of SUA-related therapies." | 7.96 | Serum uric acid, influence of sacubitril-valsartan, and cardiovascular outcomes in heart failure with preserved ejection fraction: PARAGON-HF. ( Anand, IS; Claggett, BL; Cleland, JGF; Desai, AS; Janssens, S; Kober, L; Lefkowitz, MP; Mc Causland, FR; McGrath, MM; McMurray, JJV; Pfeffer, MA; Pieske, B; Rouleau, JL; Selvaraj, S; Shi, VC; Solomon, SD; van Veldhuisen, DJ; Zile, MR, 2020) |
| "To examine the relationship of uric acid levels in the last one year with exitus due to heart failure (HF) with clinical and demographic data of patients." | 7.96 | Serum Uric Acid Levels among Patients who Died in Recent Year due to Heart Failure with Reduced Ejection Fraction. ( Ardahanli, I; Celik, M, 2020) |
| "Increased concentration of uric acid (UA) is positively associated with the clinical severity but negatively associated with the prognosis of heart failure (HF)." | 7.91 | Uric acid level is positively associated with NT-proBNP concentration in Slovak heart failure patients. ( Bendzala, M; Caprnda, M; Dukat, A; Gajdosik, J; Sabaka, P; Simko, F, 2019) |
| "There is limited evidence examining the relationship between elevated serum uric acid (sUA) concentration and heart failure (HF) in United States (US) adults." | 7.91 | Elevated Serum Uric Acid and Self-Reported Heart Failure in US Adults: 2007-2016 National Health and Nutrition Examination Survey. ( Churilla, JR; Guevara, L; Rand, BG; Richardson, MR; Stone, ML, 2019) |
| "The role of serum uric acid (SUA) as a prognostic marker for incident heart failure (HF) in hypertensive subjects is uncertain." | 7.88 | Serum uric acid as a potential marker for heart failure risk in men on antihypertensive treatment: The British Regional Heart Study. ( Lennon, L; Papacosta, O; Wannamethee, SG; Whincup, PH, 2018) |
| "The objective of the present study was to evaluate clinical implications of serum uric acid (UA) on the progression of heart failure with preserved ejection fraction (HFpEF) in hypertensive patients." | 7.88 | Serum uric acid is associated with incidence of heart failure with preserved ejection fraction and cardiovascular events in patients with arterial hypertension. ( Fan, YQ; Gu, J; Wang, CQ; Zhang, HL; Zhang, JF, 2018) |
| "Elevated serum uric acid (sUA) concentrations have been associated with worse prognosis in heart failure (HF) but little is known about elderly patients." | 7.88 | Elevated serum uric acid concentration at discharge confers additive prognostic value in elderly patients with acute heart failure. ( Alunni, G; Ambrosio, G; Biagioli, P; Borghi, C; Carluccio, E; Coiro, S; D'Antonio, A; Girerd, N; Mengoni, A; Murrone, A; Zuchi, C, 2018) |
| "The uric acid (UA) level is related to cardiac events and mortality, but little is known about the clinical significance of serum UA with regard to the ventricular tachyarrhythmia (VT) risk in patients with heart failure." | 7.88 | Association between Serum Uric Acid Level and Ventricular Tachyarrhythmia in Heart Failure Patients with Implantable Cardioverter-Defibrillator. ( Kamioka, M; Kaneshiro, T; Matsumoto, Y; Nodera, M; Ohira, T; Suzuki, H; Takeishi, Y; Yoshihisa, A, 2018) |
| " Age ≥80 years, duration since discharge from the hospital after previous heart failure <6 months, diabetes mellitus, hemoglobin <10 g/dl, uric acid >7." | 7.88 | A novel validated method for predicting the risk of re-hospitalization for worsening heart failure and the effectiveness of the diuretic upgrading therapy with tolvaptan. ( Hada, T; Kawano, M; Muramatsu, T; Nakano, M; Nishio, S; Takimura, H; Takimura, Y; Tsukahara, R; Yabe, T, 2018) |
| "The aim of this study was to evaluate relationships between serum uric acid (SUA) and newly emergent acute myocardial infarction (AMI), congestive heart failure (CHF), coronary artery disease (CAD), composite cardiovascular (CV) events (AMI, CHF, CAD), hypertension, hyperlipidemia, and renal disease in gout patients." | 7.85 | Evaluation of the Relationship Between Serum Uric Acid Levels and Cardiovascular Events in Patients With Gout: A Retrospective Analysis Using Electronic Medical Record Data. ( Bienen, EJ; Essex, MN; Hopps, M; Makinson, GT; Mardekian, J; Udall, M, 2017) |
| "The present study aimed to compare the serum level of uric acid in patients with and without heart failure and also to determine the association between uric acid level and clinical status by Killip class in patients with STEMI." | 7.85 | Study of Serum Uric Acid Levels in Myocardial Infarction and Its Association With Killip Class. ( Larti, F; Mehrpooya, M; Nozari, Y; Sattarzadeh-Badkoobeh, R; Shahbazi, F; Tavoosi, A; Zand Parsa, AF; Zebardast, J, 2017) |
| "This study sought to observe the effects of allopurinol on the cardiac function of non-hyperuricaemic patients with chronic heart failure and determine the safety of allopurinol for clinical applications." | 7.83 | Allopurinol ameliorates cardiac function in non-hyperuricaemic patients with chronic heart failure. ( Deng, SB; Kao, GY; Li, J; Ma, Y; She, Q; Wang, JS; Xiao, J, 2016) |
| "The serum level of uric acid (UA) is a well-known prognostic factor for heart failure (HF) patients." | 7.83 | The prognostic impact of uric acid in patients with severely decompensated acute heart failure. ( Asai, K; Hata, N; Kobayashi, N; Matsushita, M; Nishigoori, S; Okazaki, H; Shibuya, J; Shimizu, W; Shinada, T; Shiomura, R; Shirakabe, A; Yamamoto, Y, 2016) |
| "To compare the effects carvedilol and nebivolol on oxidative stress status in non-ischaemic heart failure (HF) patients." | 7.81 | The effects of carvedilol and nebivolol on oxidative stress status in patients with non-ischaemic heart failure. ( Bas, HA; Dogan, A; Karabacak, M; Tayyar, S, 2015) |
| "Prednisone therapy was administered for a short time to 191 symptomatic HF patients with hyperuricemia (serum uric acid > 7 mg/dl)." | 7.81 | Prednisone in Uric Acid Lowering in Symptomatic Heart Failure Patients with Hyperuricemia -- The PUSH-PATH3 Study. ( Duan, L; Ji, L; Li, L; Liu, C; Liu, G; Liu, K; Ma, G; Meng, H; Tian, L; Wang, L; Zhai, J; Zhao, Q; Zhen, Y; Zheng, M, 2015) |
| "Uric acid and gamma-glutamyl transferase are prognostic indicators in chronic heart failure." | 7.80 | Uric acid and gamma-glutamyl transferase activity are associated with left ventricular remodeling indices in patients with chronic heart failure. ( Jelic, S; Markovic, O; Memon, L; Pekmezovic, T; Pljesa-Ercegovac, M; Radic, T; Radovanovic, S; Savic-Radojevic, A; Simic, D; Simic, T, 2014) |
| "We investigated the clinical profiles associated with serum uric acid (sUA) levels in a large cohort of patients hospitalized for worsening chronic heart failure with ejection fraction (EF) ≤40%, with specific focus on gender, race, and renal function based interactions." | 7.80 | Relation of serum uric acid levels and outcomes among patients hospitalized for worsening heart failure with reduced ejection fraction (from the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan trial). ( Ambrosy, AP; Butler, J; Chioncel, O; Gheorghiade, M; Givertz, MM; Greene, SJ; Konstam, MA; Maggioni, AP; Mentz, RJ; Senni, M; Subacius, HP; Swedberg, K; Vaduganathan, M; Zannad, F, 2014) |
| "We evaluated the association between serum uric acid (SUA) and atrial fibrillation (AF) in patients with chronic heart failure (HF)." | 7.79 | Serum uric acid levels are associated with atrial fibrillation in patients with ischemic heart failure. ( Erbay, AR; Tekin, G; Tekin, YK; Turhan, H; Yetkin, E, 2013) |
| "The aim of this study was to explore the prognostic role of serum uric acid (UA) measurement in the hospital and long-term mortality assessment in subjects with acute heart failure (AHF) from the Acute HEart FAilure Database registry (AHEAD)." | 7.78 | Uric acid, allopurinol therapy, and mortality in patients with acute heart failure--results of the Acute HEart FAilure Database registry. ( Coufal, Z; Fedorco, M; Jarkovský, J; Krűger, A; Linhart, A; Málek, F; Miklík, R; Ošťádal, P; Pařenica, J; Špinar, J; Vítovec, J; Vondraková, D; Widimský, P, 2012) |
| "Uric acid (UA) levels are frequently increased in patients with heart failure (HF), and may be an indicator of a poor prognosis and an innovative target for treatment." | 7.78 | Changes in uric acid levels and allopurinol use in chronic heart failure: association with improved survival. ( Gotsman, I; Keren, A; Lotan, C; Zwas, DR, 2012) |
| "Few studies have simultaneously analysed the influence of elevated serum uric acid (UA) on acute myocardial infarction (AMI), ischaemic and haemorrhagic stroke (IS, HS) and congestive heart failure (CHF) in large healthy populations." | 7.75 | Uric acid and risk of myocardial infarction, stroke and congestive heart failure in 417,734 men and women in the Apolipoprotein MOrtality RISk study (AMORIS). ( Aastveit, AH; Hammar, N; Holme, I; Jungner, I; Walldius, G, 2009) |
| "To explore the correlation of serum uric acid, invasive hemodynamic parameters, plasma N-terminal proBNP (NT-proBNP) and Hs-C reactive protein (Hs-CRP) in patients with heart failure." | 7.75 | [Association of serum uric acid, plasma NT-proBNP, Hs-C reactive protein and invasive hemodynamic parameters in patients with heart failure]. ( Kang, LM; Lü, R; Yang, YJ; Zhang, J; Zhang, YH; Zhao, XY, 2009) |
| "We prospectively investigated the diagnostic and prognostic value of uric acid in 743 unselected patients presenting to the Emergency Department with acute dyspnea." | 7.75 | Diagnostic and prognostic value of uric acid in patients with acute dyspnea. ( Breidthardt, T; Burri, E; Christ, M; Hartwiger, S; Klima, T; Laule, K; Mebazaa, A; Mueller, C; Noveanu, M; Potocki, M; Reichlin, T; Stelzig, C, 2009) |
| "To determine the prognostic value of serum uric acid (UA) in patients with primary systemic (light chain) amyloidosis (AL)." | 7.74 | Serum uric acid: novel prognostic factor in primary systemic amyloidosis. ( Buadi, FK; Dispenzieri, A; Gertz, MA; Hayman, SR; Kumar, S; Kyle, RA; Lacy, MQ; Leung, N; Rajkumar, SV; Zeldenrust, SR, 2008) |
| "The aim of this study was to elucidate whether in patients with heart failure (HF) serum uric acid (UA) levels correlated with left ventricular ejection fraction (LVEF) and systolic pulmonary artery pressure (SPAP)." | 7.74 | [Serum uric acid levels correlate with left ventricular ejection fraction and systolic pulmonary artery pressure in patients with heart failure]. ( Bindi, M; Castiglioni, M; Filardo, FP; Moroni, F; Pinelli, M, 2007) |
| "To evaluate uric acid renal excretion, hyperuricemia, renal dysfunction, and prognosis in patients with decompensated severe heart failure, as there are few data available." | 7.73 | Uric acid renal excretion and renal insufficiency in decompensated severe heart failure. ( Barretto, AC; Morgado, PC; Munhoz, RT; Ochiai, ME; Oliveira, MT; Ramires, JA, 2005) |
| "The aim of this study was to determine the value of serum uric acid levels in predicting in-hospital mortality of chronic heart failure patients hospitalized for decompensation in spite of appropriate medical therapy." | 7.73 | Serum uric acid levels as a predictor of in-hospital death in patients hospitalized for decompensated heart failure. ( Boyaci, B; Cengel, A; Turfan, M; Türkoğlu, S, 2005) |
| "The plasma level of the uric acid is frequently elevated in heart failure, due to increased production and/or to reduced renal excretion of this antioxidant metabolite." | 7.73 | Allopurinol or oxypurinol in heart failure therapy - a promising new development or end of story? ( Leary, WP; Reyes, AJ, 2005) |
| "Serum uric acid (UA) could be a valid prognostic marker and useful for metabolic, hemodynamic, and functional (MFH) staging in chronic heart failure (CHF)." | 7.72 | Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging. ( Anker, SD; Cicoira, M; Coats, AJ; Davos, CH; Doehner, W; Francis, D; Hetzer, R; Kemp, M; Knosalla, C; Leyva, F; Osterziel, KJ; Ponikowski, P; Rauchhaus, M; Segal, R; Shamim, W; Sharma, R, 2003) |
| " The purpose of this study was to assess the relationship between levels of serum uric acid, activity of the renin-angiotensin-aldosterone system and TNF-alpha in heart failure patients with respect to the extent of left ventricular dysfunction." | 7.71 | Uric acid--a marker for systemic inflammatory response in patients with congestive heart failure? ( Gonsorcík, J; Kisel'ová, J; Olejníková, M; Olexa, P; Olexová, M; Tkác, I, 2002) |
| " We aimed to study the relationship between serum uric acid levels and leg vascular resistance in patients with CHF with and without cachexia and in healthy control subjects." | 7.71 | Uric acid in cachectic and noncachectic patients with chronic heart failure: relationship to leg vascular resistance. ( Anker, SD; Bolger, AP; Coats, AJ; Davos, CH; Doehner, W; Florea, VG; Rauchhaus, M; Sharma, R, 2001) |
| "Circulating uric acid and markers of inflammation were measured in 39 male patients with chronic heart failure and 16 healthy controls." | 7.70 | Uric acid in chronic heart failure: a marker of chronic inflammation. ( Anker, SD; Coats, AJ; Godsland, IF; Hellewell, PG; Kox, WJ; Leyva, F; Poole-Wilson, PA; Teixeira, M, 1998) |
| "To evaluate uric acid (UA) levels in patients with postinfarction chronic cardiac failure (CCF) and to investigate correlation between accumulation of uric acid, CCF severity and some other parameters." | 7.70 | [Level of blood uric acid in patients with postinfarction heart failure]. ( Drozdov, VN; Levchuk, NN; Moiseev, VS; Tereshchenko, SN, 2000) |
| "We analyzed the serum anion gap (AG = sodium plus potassium minus chloride plus bicarbonate, N = 11-21 mEq/l), serum uric acid and urea concentrations in hyponatremia of various origins." | 7.69 | Uric acid, anion gap and urea concentration in the diagnostic approach to hyponatremia. ( Brimioulle, S; Coffernils, M; Decaux, G; Namias, B; Prospert, F; Schlesser, M; Soupart, A, 1994) |
| "There is an inverse relationship between serum uric acid concentrations and measures of functional capacity in patients with cardiac failure." | 7.69 | Serum uric acid as an index of impaired oxidative metabolism in chronic heart failure. ( Anker, S; Chua, TP; Coats, AJ; Godsland, IF; Leyva, F; Stevenson, JC; Swan, JW; Wingrove, CS, 1997) |
| "To determine whether lower limb blood flow is related to serum uric acid concentrations in patients with chronic heart failure, taking into account the hyperuricaemic effects of diuretic treatment and insulin resistance." | 7.69 | Relation between serum uric acid and lower limb blood flow in patients with chronic heart failure. ( Anker, SD; Coats, AJ; Kox, WJ; Leyva, F; Poole-Wilson, PA; Stevenson, JC, 1997) |
| "The concentrations of urea, urate, phosphate and creatinine were measured in the plasma of 30 consecutive patients admitted acutely with heart failure." | 7.66 | The cause of the raised plasma urea of acute heart failure. ( Morgan, DB; Newill, A; Thomas, RD, 1979) |
| " Serum uric acid levels may rise slightly, but no clinical gout was seen in this study." | 7.64 | TREATMENT OF CONGESTIVE HEART FAILURE WITH TRIAMTERENE. ( FRIEDMAN, R; SCHUCHER, R; WENER, J, 1965) |
| "Calcium antagonists are used in the treatment of hypertension and angina." | 6.44 | The ACTION study: nifedipine in patients with symptomatic stable angina and hypertension. ( Coca, A; Sierra, C, 2008) |
| " The potential risk factors for the discontinuation events caused by sac/val-related adverse events (AEs) were explored." | 5.72 | Effectiveness and safety of sacubitril/valsartan for patients with hypertension and heart failure in the real-world setting: A retrospective study in China. ( Chen, C; Fan, L; Li, J; Li, X; Lv, Q; Tian, D; Zuo, C, 2022) |
| "Serum uric acid (SUA) is activated in catabolic, hypoxic, and inflammatory conditions characteristic of heart failure (HF) and is a source of reactive oxygen species." | 5.69 | High- versus low-dose losartan and uric acid: An analysis from HEAAL. ( Ferreira, JP; Kiernan, MS; Konstam, MA; Zannad, F, 2023) |
| "Our study demonstrated the efficiency of benzbromarone in hypertensive patients with concomitant asymptomatic hyperuricemia, including the benefits on ameliorating LV diastolic dysfunction as well as improving composite endpoints." | 5.69 | Uric acid-lowering therapy with benzbromarone in hypertension with asymptomatic hyperuricemia: a randomized study focusing left ventricular diastolic function. ( Gu, J; Han, Z; Ke, J; Lin, H; Pan, J, 2023) |
| "Hyperuricemia is independently associated with cardiovascular disease (CVD) and is considered to be one of the major risk factors for CVD." | 5.56 | Association of variability in uric acid and future clinical outcomes of patient with coronary artery disease undergoing percutaneous coronary intervention. ( Chan, WL; Charng, MJ; Chen, JW; Chen, SC; Chen, YH; Cheng, HM; Chou, CY; Hsu, PF; Huang, CC; Huang, PH; Huang, SS; Leu, HB; Lim, SS; Lin, SJ; Lin, YJ; Lu, TM; Pan, JP; Sung, SH; Wu, CH; Wu, TC; Yang, YL, 2020) |
| "Hyperuricemia was defined as serum UA ≥7 mg/dl in men and ≥ 6 mg/dl in women." | 5.56 | The relationship between serum uric acid and cognitive function in patients with chronic heart failure. ( Lu, C; Niu, W; Yang, H, 2020) |
| "Blood uric acid (UA) levels are frequently elevated in patients with heart failure and reduced ejection fraction (HFrEF), may lead to gout and are associated with worse outcomes." | 5.51 | Dapagliflozin reduces uric acid concentration, an independent predictor of adverse outcomes in DAPA-HF. ( de Boer, RA; Docherty, KF; Hammarstedt, A; Inzucchi, SE; Jhund, PS; Kosiborod, MN; Køber, L; Langkilde, AM; Lindholm, D; Martinez, FA; McDowell, K; McMurray, JJV; Morrow, DA; O'Meara, E; Ponikowski, P; Sabatine, MS; Sattar, N; Sjöstrand, M; Solomon, SD; Welsh, P, 2022) |
| "The sodium-glucose cotransporter-2 inhibitor empagliflozin decreases the risk of cardiovascular death or hospitalization for heart failure (HF) in patients with HF with reduced ejection fraction." | 5.51 | Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the EMPEROR-reduced trial. ( Anker, SD; Brueckmann, M; Butler, J; Doehner, W; Ferreira, JP; Filippatos, G; Januzzi, JL; Kaempfer, C; Packer, M; Pocock, SJ; Salsali, A; Zannad, F, 2022) |
| " In-hospital UA-increase was associated with higher risk of mortality even after adjusting for confounding variables including creatine change and diuretic dosage [harzard ratio (HR) 1." | 5.51 | Association of serum uric acid change with mortality, renal function and diuretic dose administered in treatment of acute heart failure. ( Bai, YJ; Huang, XF; Liu, SR; Xu, DL; Xu, TY; Zeng, QC; Zhan, Q; Zhou, HB, 2019) |
| "Febuxostat is potentially more effective than allopurinol for treating patients with chronic HF and hyperuricemia." | 5.41 | Comparison between febuxostat and allopurinol uric acid-lowering therapy in patients with chronic heart failure and hyperuricemia: a multicenter randomized controlled trial. ( Ishibashi, T; Kobayashi, A; Konno, I; Kunii, H; Machii, H; Miyamoto, T; Nakazato, K; Niizeki, T; Nozaki, N; Suzuki, S; Takeishi, Y; Tsuda, A; Tsuda, T; Yamaguchi, O; Yamaki, T; Yokokawa, T; Yoshihisa, A, 2021) |
| "Gout is common in patients with heart failure (HF), and sodium-glucose cotransporter 2 inhibitors, a foundational treatment for HF, reduce uric acid levels." | 5.41 | Association of Dapagliflozin Use With Clinical Outcomes and the Introduction of Uric Acid-Lowering Therapy and Colchicine in Patients With Heart Failure With and Without Gout: A Patient-Level Pooled Meta-analysis of DAPA-HF and DELIVER. ( Butt, JH; Claggett, BL; de Boer, RA; Desai, AS; Docherty, KF; Hernandez, AF; Inzucchi, SE; Jhund, PS; Kosiborod, MN; Køber, L; Lam, CSP; Langkilde, AM; Martinez, FA; McMurray, JJV; Petersson, M; Ponikowski, P; Sabatine, MS; Shah, SJ; Solomon, SD; Vaduganathan, M, 2023) |
| " Epidemiological and genetic studies have shown an independent role of uric acid in the risk of coronary artery disease, heart failure, chronic kidney disease, and cardiovascular mortality." | 5.41 | Advances in pharmacotherapies for hyperuricemia. ( Agnoletti, D; Borghi, C; Piani, F, 2023) |
| " We examined whether differences in methylation potential, measured as plasma levels of S-adenosyl methionine (SAM) and S-adenosyl homocysteine (SAH), occur at baseline and during anti-oxidant therapy with the xanthine oxidase inhibitor allopurinol in patients with heart failure with reduced ejection fraction." | 5.41 | Associations of methyl donor and methylation inhibitor levels during anti-oxidant therapy in heart failure. ( Alhanti, B; Cheema, AK; Giczewska, A; Givertz, MM; Handy, DE; Joseph, J; Loscalzo, J; Mann, DL, 2021) |
| "Uric acid (UA) is a strong marker of cardiovascular disease." | 5.40 | The association between serum uric acid level and heart failure and mortality in the early period of ST-elevation acute myocardial infarction. ( Altun, B; Barutçu, A; Bekler, A; Gazi, E; Gazi, S; Güngör, O; Kurt, T; Ozcan, S; Temiz, A; Yener, AU, 2014) |
| "Hyperuricemia is often found in patients with chronic heart failure (CHF)." | 5.35 | Is uric acid itself a player or a bystander in the pathophysiology of chronic heart failure? ( Duan, X; Ling, F, 2008) |
| "We aimed to 1) describe characteristics of patients with heart failure with preserved ejection fraction (HFpEF) enrolled in RELAX stratified by normal or elevated baseline serum uric acid (sUA) level; 2) evaluate the association between sUA level and surrogate clinical measures; and 3) assess associations between changes in sUA level over time and changes in surrogate clinical measures." | 5.34 | Elevated Uric Acid Prevalence and Clinical Outcomes in Patients with Heart Failure with Preserved Ejection Fraction: Insights from RELAX. ( Alhanti, B; Bjursell, M; Carnicelli, AP; Lytle, B; Mentz, RJ; Perl, S; Roe, MT; Sun, JL, 2020) |
| "Hyperuricemia has been identified in patients who have congestive heart failure and is a marker of poor prognosis in such patients." | 5.33 | Prognostic usefulness of serum uric acid after acute myocardial infarction (the Japanese Acute Coronary Syndrome Study). ( Hiraoka, H; Honda, T; Ishihara, M; Kimura, K; Kojima, S; Matsui, K; Miyazaki, S; Ogata, Y; Ogawa, H; Sakamoto, T; Shimoyama, N; Sonoda, M; Tei, C; Tsuchihashi, K; Yamagishi, M, 2005) |
| " We examined the association between SUA and outcomes as well as the effect of sacubitril/valsartan on SUA in patients with heart failure with reduced ejection fraction (HFrEF) in PARADIGM-HF." | 5.27 | Sacubitril/valsartan reduces serum uric acid concentration, an independent predictor of adverse outcomes in PARADIGM-HF. ( Chen, CH; Desai, AS; Dukát, A; Jhund, PS; Kristensen, SL; Køber, L; Lefkowitz, MP; McMurray, JJV; Mogensen, UM; Packer, M; Prescott, MF; Ramires, F; Rouleau, JL; Senni, M; Shi, VC; Solomon, SD; Swedberg, K, 2018) |
| "The relation between uric acid (UA) and heart failure has been described; however, there is little detail concerning acute heart failure (AHF) in patients with reduced versus preserved ejection fraction heart failure (HFrEF, HFpEF)." | 5.24 | Prevalence of Hyperuricemia in Patients With Acute Heart Failure With Either Reduced or Preserved Ejection Fraction. ( De Vivo, O; McCullough, PA; Nuti, R; Palazzuoli, A; Ruocco, G, 2017) |
| "Hyperuricemia is a prognostic factor in patients with chronic heart failure, but whether uric acid level can predict clinical outcome of acute heart failure (AHF) remains to be elucidated." | 5.22 | Determinants and Prognostic Impact of Hyperuricemia in Hospitalization for Acute Heart Failure. ( Chen, CH; Cheng, HM; Cheng, YL; Guo, CY; Hsu, PF; Huang, WM; Lu, DY; Sung, SH; Yu, WC, 2016) |
| "Serum uric acid (UA) is associated with death and hospitalization in chronic heart failure (HF)." | 5.22 | Prognostic Significance of Hyperuricemia in Patients With Acute Heart Failure. ( Beltrami, M; Giordano, N; McCullough, PA; Nuti, R; Palazzuoli, A; Pellegrini, M; Ruocco, G, 2016) |
| "Clinical studies have shown that large doses of prednisone could lower serum uric acid (SUA) in patients with decompensated heart failure (HF); however, the optimal dose of prednisone and underlying mechanisms are unknown." | 5.22 | Prednisone lowers serum uric acid levels in patients with decompensated heart failure by increasing renal uric acid clearance. ( Liu, C; Liu, K; Zhai, JL; Zhang, JX; Zhao, Q; Zhen, Y, 2016) |
| "Treatment of congestive heart failure (CHF) with loop diuretics, such as furosemide, may be associated with complications, including worsening renal function and metabolic or electrolyte disturbances." | 5.20 | Safety of add-on tolvaptan in patients with furosemide-resistant congestive heart failure complicated by advanced chronic kidney disease: a sub-analysis of a pharmacokinetics/ pharmacodynamics study. ( Akashi, YJ; Kida, K; Kimura, K; Matsumoto, N; Miyake, F; Shibagaki, Y; Tominaga, N, 2015) |
| "Thirty-four symptomatic CHF participants with hyperuricemia (≥ 565 μmol/L) were randomized to receive prednisone (1 mg/kg/d, orally) or allopurinol (100 mg, thrice daily, orally) for 4 weeks." | 5.17 | Prednisone in Uric Acid lowering in Symptomatic Heart Failure Patients With Hyperuricemia (PUSH-PATH) study. ( Gao, Y; Ji, L; Ji, Z; Liu, C; Liu, G; Liu, K; Tian, L; Wang, L; Zhao, Q; Zhen, Y, 2013) |
| "To evaluate the independent impact of congestive heart failure (CHF) status (compensation or decompensation) on serum uric acid levels among men with high cardiovascular risk profile." | 5.15 | The independent impact of congestive heart failure status and diuretic use on serum uric acid among men with a high cardiovascular risk profile: a prospective longitudinal study. ( Choi, HK; Misra, D; Zhang, Y; Zhu, Y, 2011) |
| " The treatment effect of the uricosuric agent benzbromarone was tested in 14 patients with CHF with hyperuricemia in a double-blind, placebo-controlled, randomized crossover study design." | 5.14 | Uric acid-lowering treatment with benzbromarone in patients with heart failure: a double-blind placebo-controlled crossover preliminary study. ( Anker, SD; Doehner, W; Furuse, Y; Hisatome, I; Igawa, O; Ishida, K; Kato, M; Kinugasa, Y; Kinugawa, T; Ogino, K; Osaki, S; Shigemasa, C, 2010) |
| "This study evaluated whether a xanthine oxidase (XO) inhibitor, oxypurinol, produces clinical benefits in patients with New York Heart Association functional class III to IV heart failure due to systolic dysfunction receiving optimal medical therapy." | 5.13 | Impact of oxypurinol in patients with symptomatic heart failure. Results of the OPT-CHF study. ( Brown, J; Colucci, WS; Fisher, C; Freudenberger, R; Givertz, MM; Hare, JM; Liu, P; Mangal, B; Mann, DL; Schwarz, RP, 2008) |
| " Xanthine oxidase (XO) induced uric acid (UA) serves as a risk factor and has the independent prognostic and functional impact of heart failure (HF), but whether it plays a positive role in the pathogenesis of HF has remained unclear." | 5.12 | Hyperuricemia and the Risk of Heart Failure: Pathophysiology and Therapeutic Implications. ( Chen, Y; Dong, B; Huang, Y; Lv, W; Si, K; Wang, Y; Wang, Z; Wei, C; Xu, L; Zhou, Y, 2021) |
| "This network meta-analysis aimed to assess the current efficacy of decreasing the uric acid (UA) level with drugs to reduce mortality in patients with heart failure (HF)." | 5.12 | Network Meta-Analysis of Drug Therapies for Lowering Uric Acid and Mortality Risk in Patients with Heart Failure. ( Fujihara, K; Horikawa, C; Kitazawa, M; Kodama, S; Matsubayashi, Y; Sato, T; Sone, H; Watanabe, K; Yaguchi, Y; Yamada, M; Yamada, T; Yamamoto, M, 2021) |
| "We studied effects of beta-adrenoblocker carvedilol vs placebo in 60 patients with chronic cardiac failure (CCF) of functional classes III-IV in a 6-month open randomized trial." | 5.10 | [Endothelial protection in patients with apparent cardiac failure in long-term therapy by carvedilol]. ( Shliakhto, EV; Sitnikova, MIu, 2003) |
| " All patients underwent at entry a physical examination, measurement of body weight (BW), blood pressure (BP), heart rate (HR), evaluation of signs of CHF, and controls of serum Na, K, Cl, bicarbonate, albumin, uric acid, creatinine, urea and glycemia and daily during hospitalization, as well as the daily output of urine for, Na, K and Cl measurements." | 5.09 | Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as a bolus, in refractory congestive heart failure. ( Amato, P; Cardinale, A; Di Pasquale, P; Follone, G; Giubilato, A; Licata, G; Parrinello, G; Paterna, S, 2000) |
| "Uric acid, the metabolic mediator of gout and urate renal stones, is associated with increased cardiovascular risk burden." | 5.05 | Hyperuricemia: a novel old disorder-relationship and potential mechanisms in heart failure. ( Borghi, C; Cosentino, E; Landolfo, M; Palazzuoli, A, 2020) |
| "Several trials have been completed in patients with heart failure (HF) treated with uric acid (UA)-lowering agents with inconsistent results." | 5.05 | Effect of Uric Acid-Lowering Agents on Cardiovascular Outcome in Patients With Heart Failure: A Systematic Review and Meta-Analysis of Clinical Studies. ( Afsar, B; Cherney, D; Covic, A; Dincer, N; Erden, N; Kanbay, M; Kuwabara, M; Ortiz, A; Rossignol, P; Sag, AA; Siriopol, D; Yilmaz, O, 2020) |
| "The efficacy and safety of a combination of Persantine and aspirin, of aspirin alone and of a placebo as a regimen for preventing reinfarction were compared in 2026 patients who had recovered from a documented acute myocardial infarction (MI) that had occurred 8 weeks to 5 years previously." | 5.05 | The Persantine-aspirin reinfarction study. The Persantine-aspirin Reinfarction Study (PARIS) research group. ( , 1980) |
| "14 patients with congestive heart failure requiring diuretic therapy were randomly assigned to treatment with ticrynafen (TCRN) 250 mg or hydrochlorothiazide (HCTZ) 50 mg once or twice daily." | 5.04 | Renal function during therapy in patients with congestive cardiac failure. Ticrynafen vs. hydrochlorothiazide. ( Clements, P; Smith, JW, 1979) |
| "1 This study has compared the diuresis produced by a single oral administration of 6 mg piretanide, 9 mg piretanide and 1 mg bumetanide in a group of nine patients with cardiac failure using a balanced randomized design." | 5.04 | A single dose comparison of piretanide and bumetanide in congestive cardiac failure. ( Dombey, SL; Homeida, M; Roberts, CJ, 1979) |
| " These initial studies demonstrate that tienilic acid is safe and effective in the treatment of mild to moderate essential hypertension, salt and water retention states, including oedema associated with congestive cardiac failure or mild to moderate renal dysfunction, and in the management of elevated serum uric acid levels associated with gout." | 5.04 | Safety of tienilic acid. ( Beg, MA; Ragland, R, 1979) |
| "Conflicting results have been reported on the prognostic significance of serum uric acid (SUA) in patients with acute heart failure (AHF)." | 5.01 | Prognostic value of serum uric acid in patients with acute heart failure: A meta-analysis. ( Deng, X; Huang, G; Luo, G; Qin, J; Wang, L; Yu, D; Zhang, M; Zhou, S, 2019) |
| "We aimed to perform a systematic review and meta-analysis to assess the association between serum uric acid and incident heart failure (HF)/prognosis of HF patients." | 4.90 | Uric acid and risk of heart failure: a systematic review and meta-analysis. ( Chen, J; Huang, B; Huang, H; Huang, Y; Jing, X; Li, J; Li, Y; Wang, J; Yao, H, 2014) |
| " Data are accumulated on existence of links between elevated uric acid level and arterial hypertension, diabetes mellitus, ischemic heart disease, and chronic heart failure (CHF)." | 4.87 | [Hyperuricemia in chronic heart failure]. ( Bart, BIa; Brodskiĭ, MS; Larina, VN, 2011) |
| "Patients with mild-moderate chronic heart failure (CHF) often have raised levels of serum uric acid (UA)." | 4.82 | The increase in serum uric acid concentration caused by diuretics might be beneficial in heart failure. ( Reyes, AJ, 2005) |
| " Patients (N = 133) with chronic heart failure and comorbid hyperuricemia who enrolled in the Excited-UA study were divided into three tertiles based on their serum uric acid level 24 weeks after initiating xanthine oxidase inhibitor treatment with topiroxostat or allopurinol (i." | 4.31 | Optimal uric acid reduction to improve vascular endothelial function in patients with chronic heart failure complicated by hyperuricemia. ( Abe, S; Iida, K; Inoue, K; Inoue, R; Inoue, T; Kato, T; Kitahara, K; Kohno, Y; Koshiji, N; Naganuma, J; Sakuma, M; Toyoda, S; Yamauchi, F; Yokomachi, J, 2023) |
| "Serum uric acid (SUA) may play a role in heart failure (HF)." | 4.31 | Association between serum uric acid levels and the prevalence of heart failure due to acute coronary syndrome in Chinese hospitalized patients: A cross-sectional study. ( Liang, X; Liu, Y; Rong, D; Sun, G, 2023) |
| "Increased circulating uric acid (UA) concentration may disrupt cardiac function in heart failure patients, but the specific mechanism remains unclear." | 4.31 | Increased circulating uric acid aggravates heart failure via impaired fatty acid metabolism. ( Bennewitz, K; Kroll, J; Liu, H; Lou, B; Ott, H; Poschet, G; She, J; Wang, C; Wu, H; Yuan, Z, 2023) |
| "In conclusion, even in a short period of only 3 months, the administration of ARNI improved insulin resistance and consequently reduced the serum uric acid levels in patients with stable chronic heart failure." | 4.31 | Effects of angiotensin receptor-neprilysin inhibitor on insulin resistance in patients with heart failure. ( Inoue, Y; Kashiwagi, Y; Kawai, M; Kimura, H; Nagoshi, T; Ogawa, K; Oi, Y; Tanaka, Y; Yoshimura, M, 2023) |
| "It remains unclear whether the long-term prognostic value of serum uric acid (SUA) at admission differs in acute decompensated heart failure (HF) patients across the spectrum of left ventricular ejection fraction (EF)." | 4.31 | Associations of long-term mortality with serum uric acid at admission in acute decompensated heart failure with different phenotypes. ( Cauwenberghs, N; Chen, S; Chen, X; Cheng, W; Dong, Y; He, J; Huang, J; Liu, C; Wei, FF; Wu, Y; Yu, Z; Zhao, J, 2023) |
| "Data on the association between uric acid (UA) levels and clinical outcomes, such as readmission and mortality, in patients with heart failure are scarce." | 4.31 | Relation of serum uric acid levels to readmission and mortality in patients with heart failure. ( Hu, E; Li, Z; Wei, D; Yuan, J, 2023) |
| " There were statistically significant differences between the two groups in terms of age, body mass index (BMI), N-terminal prohormone of brain natriuretic peptide NT-probNP, fibrinogen, CHA2DS2-VASC [congestive Heart Failure, Hypertension, Age (75 or older), diabetes mellitus, stroke, vascular disease, age (65-74), sex category] score, paroxysmal atrial fibrillation, renal insufficiency, D-dimer, heart failure, and serum uric acid (p<0." | 4.31 | Predictive value of echocardiography combined with CT angiography for left atrial appendage thrombosis in patients with non-valvular atrial fibrillation. ( Xing, LM; Zhong, J, 2023) |
| "Elevated serum uric acid (SUA) levels have been associated with poor outcome in patients with heart failure (HF)." | 4.31 | Serum uric acid and outcome in hospitalized elderly patients with chronic heart failure through the whole spectrum of ejection fraction phenotypes. ( He, KL; Tang, HY; Yan, W; Yang, YQ, 2023) |
| " Using the data from a nationwide, prospective registry on patients with chronic coronary syndromes (CCS), we assessed the impact of serum uric acid (SUA) levels on quality of life (QoL) and major adverse CV events (MACE), a composite of CV death and hospitalization for myocardial infarction, heart failure (HF), angina or revascularization at 1-year." | 4.12 | Impact of serum uric acid levels on cardiovascular events and quality of life in patients with chronic coronary syndromes: Insights from a contemporary, prospective, nationwide registry. ( Borghi, C; Colivicchi, F; D'Urbano, M; De Luca, L; Desideri, G; Gabrielli, D; Gulizia, MM; Mattei, L; Meessen, J; Temporelli, PL, 2022) |
| "We focused on the role of Uric Acid (UA) as a possible determinant of Heart Failure (HF) related issues in Acute Coronary Syndromes (ACS) patients." | 4.12 | Uric acid associated with acute heart failure presentation in Acute Coronary Syndrome patients. ( Carugo, S; Castini, D; Centola, M; Ferrante, G; Giannattasio, C; Lucreziotti, S; Maloberti, A; Morici, N; Occhino, G; Oliva, F; Oreglia, J; Persampieri, S; Rebora, P; Sabatelli, L; Sacco, A; Valsecchi, MG; Viola, G, 2022) |
| "The association between serum uric acid (SUA) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentrations in patients with coronary artery disease (CAD) is unclear." | 4.12 | Association between higher serum uric acid levels and plasma N-terminal pro-B-type natriuretic peptide concentrations in patients with coronary artery disease and without overt heart failure. ( Beatrice, G; Bonapace, S; Cappelli, D; Csermely, A; Dugo, C; Mantovani, A; Molon, G; Petracca, G; Targher, G, 2022) |
| "Abnormal A Disintegrin and Metalloproteinase with Thrombospondin Motifs 2 (ADAMTS2) and V-set and immunoglobulin domain-containing 4 (VSIG4) were explored in serum of heart failure (HF) patients and its association with C-reactive protein (CRP), uric acid (UA), and homocysteine (HCY) indexes was manifested." | 4.12 | Abnormal ADAMTS2 and VSIG4 in Serum of HF Patients and their Relationship with CRP, UA, and HCY. ( Huang, S; Liu, J; Shen, W; Shen, Y; Xie, Z, 2022) |
| "The role of hyperuricaemia as a prognostic maker has been established in chronic heart failure (HF) but limited information on the association between plasma uric acid (UA) levels and central haemodynamic measurements is available." | 4.12 | Uric acid in advanced heart failure: relation to central haemodynamics and outcome. ( Deis, T; Ersbøll, MK; Gustafsson, F; Rossing, K; Wolsk, E, 2022) |
| "This study aimed to investigate the adverse effects of serum uric acid concentration on the severity of chronic congestive heart failure." | 4.12 | The effect of serum uric acid concentration on the severity of chronic congestive heart failure. ( Al-Mohana, SJA; Alshamari, AHI; Kadhim, RK, 2022) |
| "Increased uric acid levels predict higher mortality in heart failure (HF) patients." | 4.02 | The prognostic impact of uric acid in acute heart failure according to coexistence of diabetes mellitus. ( Bettencourt, P; Cidade-Rodrigues, C; Cunha, FM; Elias, C; Lourenço, P; Oliveira, D, 2021) |
| "To evaluate the prognostic impact of serum uric acid (SUA) on clinical outcomes in patients with acute decompensated heart failure, as well as identify the correlation between hyperuricemia and renal function and diuretic resistance in these patients." | 4.02 | [Prognostic impact of uric acid in patients with acute decompensated heart failure]. ( Lapteva, AE; Mindzaev, DR; Nasonova, SN; Tereshchenko, SN; Zhirov, IV, 2021) |
| "To assess the prognostic cut-off values of serum uric acid (SUA) in predicting fatal and morbid heart failure in a large Italian cohort in the frame of the Working Group on Uric Acid and Cardiovascular Risk of the Italian Society of Hypertension." | 4.02 | Serum uric acid, predicts heart failure in a large Italian cohort: search for a cut-off value the URic acid Right for heArt Health study. ( Barbagallo, CM; Bombelli, M; Borghi, C; Casiglia, E; Cicero, AFG; Cirillo, M; Cirillo, P; D'Eliak, L; Desideri, G; Ferri, C; Galletti, F; Gesualdo, L; Giannattasio, C; Grassi, G; Iaccarino, G; Mallamaci, F; Maloberti, A; Masi, S; Mazza, A; Muiesan, ML; Nazzaro, P; Palatini, P; Parati, G; Pontremoli, R; Rattazzi, M; Rivasi, G; Salvetti, M; Tikhonoff, V; Tocci, G; Ungar, A; Verdecchia, P; Viazzi, F; Virdis, A; Volpe, M, 2021) |
| "Prognostic impacts of serum uric acid (UA) levels in patients with chronic heart failure (CHF) remain inconclusive, especially for the whole range of serum UA levels." | 4.02 | Prognostic impacts of serum uric acid levels in patients with chronic heart failure: insights from the CHART-2 study. ( Abe, R; Aoyanagi, H; Fujihashi, T; Hayashi, H; Kasahara, S; Miura, M; Miyata, S; Nochioka, K; Sakata, Y; Sato, M; Shimokawa, H; Shiroto, T; Sugimura, K; Takahashi, J; Yamanaka, S, 2021) |
| "In this nonrandomized, open-label, single-arm trial, we administered topiroxostat 40-160 mg/day to HFpEF patients with hyperuricemia or gout to achieve a target uric acid level of 6." | 4.02 | Effect of Topiroxostat on Brain Natriuretic Peptide Level in Patients with Heart Failure with Preserved Ejection Fraction: A Pilot Study. ( Asai, K; Koen, M; Kubota, Y; Shimizu, W; Wakita, M, 2021) |
| "Uric acid has long been considered responsible for a single specific disease, namely gout." | 4.02 | The URRAH study. ( Carubbi, F; Del Pinto, R; Ferri, C; Pontremoli, R; Russo, E; Viazzi, F, 2021) |
| "Retrospective analyses of clinical trials indicate that elevated serum uric acid (sUA) predicts poor outcome in heart failure (HF)." | 4.02 | Serum uric acid and outcomes in patients with chronic heart failure through the whole spectrum of ejection fraction phenotypes: Analysis of the ESC-EORP Heart Failure Long-Term (HF LT) Registry. ( Almenar-Bonet, L; Ambrosio, G; Anker, SD; Cardona, A; Coats, AJS; Coiro, S; Ferrari, R; Filippatos, G; Frisinghelli, A; Laroche, C; Leiro, MGC; Lund, LH; Maggioni, AP; Piepoli, MF; Poder, P; Valero, DB, 2021) |
| "To investigate the association of serum uric acid levels with in-hospital heart failure (HF) in patients with acute myocardial infarction (AMI) who are undergoing percutaneous coronary intervention (PCI)." | 4.02 | Association between Uric Acid and In-Hospital Heart Failure in Patients with Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention. ( Liu, CF; Song, KY; Wei, YJ; Zhou, WN, 2021) |
| " placebo on high-sensitivity C-reactive protein (hsCRP) and serum uric acid (SUA) were assessed in patients with heart failure with reduced ejection fraction (HFrEF) in the Phase 2 SOCRATES-REDUCED study (NCT01951625)." | 3.96 | Evaluation of high-sensitivity C-reactive protein and uric acid in vericiguat-treated patients with heart failure with reduced ejection fraction. ( Butler, J; Igl, BW; Kramer, F; Lam, CSP; Maggioni, AP; Pieske, B; Roessig, L; Shah, SJ; Voss, S, 2020) |
| "Although serum uric acid (SUA) level is correlated with oxidative stress and serves as a marker of poor prognosis in heart failure patients, its possible association with subclinical left ventricular (LV) dysfunction has not been evaluated." | 3.96 | Serum uric acid level and subclinical left ventricular dysfunction: a community-based cohort study. ( Daimon, M; Di Tullio, MR; Hirokawa, M; Homma, S; Ishiwata, J; Kaneko, H; Komuro, I; Mizuno, Y; Morita, H; Nakanishi, K; Nakao, T; Sawada, N; Yoshida, Y, 2020) |
| " This study was designed to evaluate the influences of long-term xanthine oxidase inhibitor (febuxostat) prescription on left ventricular hypertrophy (LVH), left ventricular (LV) diastolic function, and new-onset heart failure with preserved ejection fraction (HFpEF) in these patients." | 3.96 | Association between long-term prescription of febuxostat and the progression of heart failure with preserved ejection fraction in patients with hypertension and asymptomatic hyperuricemia. ( Gu, J; Lin, H; Pan, JA; Wang, CQ; Zhang, JF, 2020) |
| "Elevated serum uric acid (UA) is associated with an increased risk of adverse outcome in patients with heart failure (HF), but it remains unknown whether the change of serum UA level during the treatment of acute decompensated HF (ADHF) predicts adverse events." | 3.96 | In-Hospital Serum Uric Acid Change Predicts Adverse Outcome in Patients With Heart Failure. ( Mahara, K; Nagatomo, Y; Yamamoto, H; Yoshikawa, T, 2020) |
| " The AHEAD (A: atrial fibrillation; H: hemoglobin; E: elderly; A: abnormal renal parameters; D: diabetes mellitus) and AHEAD-U (A: atrial fibrillation; H: hemoglobin; E: elderly; A: abnormal renal parameters; D: diabetes mellitus, U: uric acid) are popular prognostic scoring systems." | 3.96 | A statistical predictive model consistent within a 5-year follow-up period for patients with acute heart failure. ( Chan, CH; Cheng, HM; Chou, YC; Guo, CY; Sung, SH, 2020) |
| "This study aimed to determine the prognostic value of serum uric acid (SUA) on outcomes in heart failure (HF) with preserved ejection fraction (HFpEF), and whether sacubitril-valsartan reduces SUA and use of SUA-related therapies." | 3.96 | Serum uric acid, influence of sacubitril-valsartan, and cardiovascular outcomes in heart failure with preserved ejection fraction: PARAGON-HF. ( Anand, IS; Claggett, BL; Cleland, JGF; Desai, AS; Janssens, S; Kober, L; Lefkowitz, MP; Mc Causland, FR; McGrath, MM; McMurray, JJV; Pfeffer, MA; Pieske, B; Rouleau, JL; Selvaraj, S; Shi, VC; Solomon, SD; van Veldhuisen, DJ; Zile, MR, 2020) |
| "Hyperuricemia increases the risk of heart failure, and higher levels of serum uric acid are seen in patients who have worse ventricular function, functional capacity, and prognosis." | 3.96 | Uric Acid Is a Biomarker of Oxidative Stress in the Failing Heart: Lessons Learned from Trials With Allopurinol and SGLT2 Inhibitors. ( Packer, M, 2020) |
| "To examine the relationship of uric acid levels in the last one year with exitus due to heart failure (HF) with clinical and demographic data of patients." | 3.96 | Serum Uric Acid Levels among Patients who Died in Recent Year due to Heart Failure with Reduced Ejection Fraction. ( Ardahanli, I; Celik, M, 2020) |
| "Increased concentration of uric acid (UA) is positively associated with the clinical severity but negatively associated with the prognosis of heart failure (HF)." | 3.91 | Uric acid level is positively associated with NT-proBNP concentration in Slovak heart failure patients. ( Bendzala, M; Caprnda, M; Dukat, A; Gajdosik, J; Sabaka, P; Simko, F, 2019) |
| "There is limited evidence examining the relationship between elevated serum uric acid (sUA) concentration and heart failure (HF) in United States (US) adults." | 3.91 | Elevated Serum Uric Acid and Self-Reported Heart Failure in US Adults: 2007-2016 National Health and Nutrition Examination Survey. ( Churilla, JR; Guevara, L; Rand, BG; Richardson, MR; Stone, ML, 2019) |
| "The prospective acute heart failure registry (AHEAD) was used to select 3160 hospitalized patients with a known level of uric acid (UA) who were discharged in a stable condition." | 3.91 | Hyperuricemia treatment in acute heart failure patients does not improve their long-term prognosis: A propensity score matched analysis from the AHEAD registry. ( Al-Hiti, H; Bambuch, M; Belohlavek, J; Benesova, K; Bohacova, S; Cihalik, C; Dostalova, G; Dusek, L; Fedorco, M; Felsoci, M; Fojt, R; Havranek, S; Jarkovsky, J; Kettner, J; Kruger, A; Linhart, A; Malek, F; Malek, J; Miklik, R; Mikusova, T; Monhart, Z; Ostadal, P; Parenica, J; Pavlusova, M; Pohludkova, L; Rohac, F; Spac, J; Spinar, J; Spinarova, L; Svobodová, I; Vaclavik, J; Vitovec, J; Vondrakova, D; Vyskocilova, K; Widimsky, P; Zeman, K, 2019) |
| "The role of serum uric acid (SUA) as a prognostic marker for incident heart failure (HF) in hypertensive subjects is uncertain." | 3.88 | Serum uric acid as a potential marker for heart failure risk in men on antihypertensive treatment: The British Regional Heart Study. ( Lennon, L; Papacosta, O; Wannamethee, SG; Whincup, PH, 2018) |
| "The objective of the present study was to evaluate clinical implications of serum uric acid (UA) on the progression of heart failure with preserved ejection fraction (HFpEF) in hypertensive patients." | 3.88 | Serum uric acid is associated with incidence of heart failure with preserved ejection fraction and cardiovascular events in patients with arterial hypertension. ( Fan, YQ; Gu, J; Wang, CQ; Zhang, HL; Zhang, JF, 2018) |
| "Elevated serum uric acid (sUA) concentrations have been associated with worse prognosis in heart failure (HF) but little is known about elderly patients." | 3.88 | Elevated serum uric acid concentration at discharge confers additive prognostic value in elderly patients with acute heart failure. ( Alunni, G; Ambrosio, G; Biagioli, P; Borghi, C; Carluccio, E; Coiro, S; D'Antonio, A; Girerd, N; Mengoni, A; Murrone, A; Zuchi, C, 2018) |
| "The uric acid (UA) level is related to cardiac events and mortality, but little is known about the clinical significance of serum UA with regard to the ventricular tachyarrhythmia (VT) risk in patients with heart failure." | 3.88 | Association between Serum Uric Acid Level and Ventricular Tachyarrhythmia in Heart Failure Patients with Implantable Cardioverter-Defibrillator. ( Kamioka, M; Kaneshiro, T; Matsumoto, Y; Nodera, M; Ohira, T; Suzuki, H; Takeishi, Y; Yoshihisa, A, 2018) |
| " Age ≥80 years, duration since discharge from the hospital after previous heart failure <6 months, diabetes mellitus, hemoglobin <10 g/dl, uric acid >7." | 3.88 | A novel validated method for predicting the risk of re-hospitalization for worsening heart failure and the effectiveness of the diuretic upgrading therapy with tolvaptan. ( Hada, T; Kawano, M; Muramatsu, T; Nakano, M; Nishio, S; Takimura, H; Takimura, Y; Tsukahara, R; Yabe, T, 2018) |
| " The diagnostic value of changes in serum uric acid levels has been established in chronic heart failure, but no data are available on the prognostic value of hyperuricemia in a CRT population." | 3.88 | Hyperuricemia predicts adverse clinical outcomes after cardiac resynchronization therapy. ( Boros, AM; Gellér, L; Merkely, B; Perge, P; Széplaki, G; Zima, E, 2018) |
| "Atherosclerosis induces the elevation of uric acid (UA), and an elevated UA level is well known to lead to a poor prognosis in patients with acute heart failure (AHF)." | 3.85 | Are atherosclerotic risk factors associated with a poor prognosis in patients with hyperuricemic acute heart failure? The evaluation of the causal dependence of acute heart failure and hyperuricemia. ( Asai, K; Hata, N; Kobayashi, N; Matsushita, M; Nishigoori, S; Okazaki, H; Shibata, Y; Shibuya, J; Shimizu, W; Shinada, T; Shiomura, R; Shirakabe, A; Yamamoto, Y, 2017) |
| "Uric acid (UA) may not only prevent development of cognitive dysfunction owing to its antioxidant efficacy, but also may worsen cognitive functions by gaining pro-oxidant character." | 3.85 | Uric acid may be protective against cognitive impairment in older adults, but only in those without cardiovascular risk factors. ( Isik, AT; Kaya, D; Soysal, P; Tuven, B; Unutmaz, G, 2017) |
| "The aim of this study was to evaluate relationships between serum uric acid (SUA) and newly emergent acute myocardial infarction (AMI), congestive heart failure (CHF), coronary artery disease (CAD), composite cardiovascular (CV) events (AMI, CHF, CAD), hypertension, hyperlipidemia, and renal disease in gout patients." | 3.85 | Evaluation of the Relationship Between Serum Uric Acid Levels and Cardiovascular Events in Patients With Gout: A Retrospective Analysis Using Electronic Medical Record Data. ( Bienen, EJ; Essex, MN; Hopps, M; Makinson, GT; Mardekian, J; Udall, M, 2017) |
| "The present study aimed to compare the serum level of uric acid in patients with and without heart failure and also to determine the association between uric acid level and clinical status by Killip class in patients with STEMI." | 3.85 | Study of Serum Uric Acid Levels in Myocardial Infarction and Its Association With Killip Class. ( Larti, F; Mehrpooya, M; Nozari, Y; Sattarzadeh-Badkoobeh, R; Shahbazi, F; Tavoosi, A; Zand Parsa, AF; Zebardast, J, 2017) |
| "This study sought to observe the effects of allopurinol on the cardiac function of non-hyperuricaemic patients with chronic heart failure and determine the safety of allopurinol for clinical applications." | 3.83 | Allopurinol ameliorates cardiac function in non-hyperuricaemic patients with chronic heart failure. ( Deng, SB; Kao, GY; Li, J; Ma, Y; She, Q; Wang, JS; Xiao, J, 2016) |
| "The serum level of uric acid (UA) is a well-known prognostic factor for heart failure (HF) patients." | 3.83 | The prognostic impact of uric acid in patients with severely decompensated acute heart failure. ( Asai, K; Hata, N; Kobayashi, N; Matsushita, M; Nishigoori, S; Okazaki, H; Shibuya, J; Shimizu, W; Shinada, T; Shiomura, R; Shirakabe, A; Yamamoto, Y, 2016) |
| "To compare the effects carvedilol and nebivolol on oxidative stress status in non-ischaemic heart failure (HF) patients." | 3.81 | The effects of carvedilol and nebivolol on oxidative stress status in patients with non-ischaemic heart failure. ( Bas, HA; Dogan, A; Karabacak, M; Tayyar, S, 2015) |
| "Serum uric acid (UA, mg/dl) levels associate with the pathophysiology and prognosis in patients with chronic heart failure." | 3.81 | Hyperuricemia reflects global Fontan pathophysiology and associates with morbidity and mortality in patients after the Fontan operation. ( Hayama, Y; Miyazaki, A; Negishi, J; Noritake, K; Ohuchi, H; Sasaki, O; Taniguchi, Y; Yamada, O, 2015) |
| "Prednisone therapy was administered for a short time to 191 symptomatic HF patients with hyperuricemia (serum uric acid > 7 mg/dl)." | 3.81 | Prednisone in Uric Acid Lowering in Symptomatic Heart Failure Patients with Hyperuricemia -- The PUSH-PATH3 Study. ( Duan, L; Ji, L; Li, L; Liu, C; Liu, G; Liu, K; Ma, G; Meng, H; Tian, L; Wang, L; Zhai, J; Zhao, Q; Zhen, Y; Zheng, M, 2015) |
| "Serum uric acid (SUA) is associated with the severity and prognosis of systolic heart failure." | 3.81 | Serum uric acid is associated with cardiac diastolic dysfunction among women with preserved ejection fraction. ( Fujita, S; Hoshiga, M; Ishizaka, N; Ito, T; Kizawa, S; Morita, H; Nogi, S; Okamoto, Y; Sakane, K; Sohmiya, K, 2015) |
| "Preliminary data suggest that serum uric acid (SUA) could be involved in the prognosis of chronic heart failure (HF)." | 3.80 | Uricaemia and ejection fraction in elderly heart failure outpatients. ( Borghi, C; Cicero, AF; Cosentino, ER; Rinaldi, ER, 2014) |
| "Uric acid and gamma-glutamyl transferase are prognostic indicators in chronic heart failure." | 3.80 | Uric acid and gamma-glutamyl transferase activity are associated with left ventricular remodeling indices in patients with chronic heart failure. ( Jelic, S; Markovic, O; Memon, L; Pekmezovic, T; Pljesa-Ercegovac, M; Radic, T; Radovanovic, S; Savic-Radojevic, A; Simic, D; Simic, T, 2014) |
| "We investigated the clinical profiles associated with serum uric acid (sUA) levels in a large cohort of patients hospitalized for worsening chronic heart failure with ejection fraction (EF) ≤40%, with specific focus on gender, race, and renal function based interactions." | 3.80 | Relation of serum uric acid levels and outcomes among patients hospitalized for worsening heart failure with reduced ejection fraction (from the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan trial). ( Ambrosy, AP; Butler, J; Chioncel, O; Gheorghiade, M; Givertz, MM; Greene, SJ; Konstam, MA; Maggioni, AP; Mentz, RJ; Senni, M; Subacius, HP; Swedberg, K; Vaduganathan, M; Zannad, F, 2014) |
| "We evaluated the association between serum uric acid (SUA) and atrial fibrillation (AF) in patients with chronic heart failure (HF)." | 3.79 | Serum uric acid levels are associated with atrial fibrillation in patients with ischemic heart failure. ( Erbay, AR; Tekin, G; Tekin, YK; Turhan, H; Yetkin, E, 2013) |
| "The aim of this study was to explore the prognostic role of serum uric acid (UA) measurement in the hospital and long-term mortality assessment in subjects with acute heart failure (AHF) from the Acute HEart FAilure Database registry (AHEAD)." | 3.78 | Uric acid, allopurinol therapy, and mortality in patients with acute heart failure--results of the Acute HEart FAilure Database registry. ( Coufal, Z; Fedorco, M; Jarkovský, J; Krűger, A; Linhart, A; Málek, F; Miklík, R; Ošťádal, P; Pařenica, J; Špinar, J; Vítovec, J; Vondraková, D; Widimský, P, 2012) |
| "Uric acid (UA) levels are frequently increased in patients with heart failure (HF), and may be an indicator of a poor prognosis and an innovative target for treatment." | 3.78 | Changes in uric acid levels and allopurinol use in chronic heart failure: association with improved survival. ( Gotsman, I; Keren, A; Lotan, C; Zwas, DR, 2012) |
| "There is significant controversy around whether chlorthalidone (CTD) is superior to hydrochlorothiazide (HCTZ) in hypertension management." | 3.77 | Chlorthalidone reduces cardiovascular events compared with hydrochlorothiazide: a retrospective cohort analysis. ( Bleske, BE; Dorsch, MP; Erickson, SR; Gillespie, BW; Weder, AB, 2011) |
| "In addition to conventional prognostic markers, uric acid and LA dimension appear to be important novel risk prediction markers in elderly patients with heart failure, and could be useful in guiding management." | 3.77 | Predictors of clinical outcomes in elderly patients with heart failure. ( Anker, SD; Babalis, D; Coats, AJ; Cohen-Solal, A; Flather, MD; Ghio, S; Manzano, L; Poole-Wilson, PP; Roughton, M; Shibata, M; van Veldhuisen, DJ, 2011) |
| "Of the 5461 community-dwelling older adults, >or=65 years, in the Cardiovascular Health Study without HF at baseline, 1505 had hyperuricemia (baseline serum uric acid >or=6 mg/dL for women and >or=7 mg/dL for men)." | 3.76 | Association between hyperuricemia and incident heart failure among older adults: a propensity-matched study. ( Aban, I; Ahmed, A; Anker, SD; Arnett, D; Bakris, G; Dell'Italia, LJ; Ekundayo, OJ; Filippatos, G; Lloyd-Jones, DM; Love, TE; Mujib, M; Sanders, PW, 2010) |
| "Increased serum uric acid (UA) is associated with incident heart failure (HF)." | 3.76 | Effect of serum insulin on the association between hyperuricemia and incident heart failure. ( Aban, IB; Ahmed, A; Ahmed, MI; Aronow, WS; Desai, RV; Filippatos, GS; Fonarow, GC; White, M, 2010) |
| "Few studies have simultaneously analysed the influence of elevated serum uric acid (UA) on acute myocardial infarction (AMI), ischaemic and haemorrhagic stroke (IS, HS) and congestive heart failure (CHF) in large healthy populations." | 3.75 | Uric acid and risk of myocardial infarction, stroke and congestive heart failure in 417,734 men and women in the Apolipoprotein MOrtality RISk study (AMORIS). ( Aastveit, AH; Hammar, N; Holme, I; Jungner, I; Walldius, G, 2009) |
| "To explore the correlation of serum uric acid, invasive hemodynamic parameters, plasma N-terminal proBNP (NT-proBNP) and Hs-C reactive protein (Hs-CRP) in patients with heart failure." | 3.75 | [Association of serum uric acid, plasma NT-proBNP, Hs-C reactive protein and invasive hemodynamic parameters in patients with heart failure]. ( Kang, LM; Lü, R; Yang, YJ; Zhang, J; Zhang, YH; Zhao, XY, 2009) |
| "We prospectively investigated the diagnostic and prognostic value of uric acid in 743 unselected patients presenting to the Emergency Department with acute dyspnea." | 3.75 | Diagnostic and prognostic value of uric acid in patients with acute dyspnea. ( Breidthardt, T; Burri, E; Christ, M; Hartwiger, S; Klima, T; Laule, K; Mebazaa, A; Mueller, C; Noveanu, M; Potocki, M; Reichlin, T; Stelzig, C, 2009) |
| "We prospectively analyzed the relationship between serum uric acid concentration at baseline and subsequent heart failure among the participants of the Framingham Offspring cohort (n=4912; mean baseline age, 36 years; 52% women)." | 3.75 | Hyperuricemia and incident heart failure. ( Krishnan, E, 2009) |
| "In severe chronic heart failure (CHF) elevated serum levels of uric acid (UA) predict poor survival." | 3.74 | Hyperuricaemia predicts poor outcome in patients with mild to moderate chronic heart failure. ( Banasiak, W; Borodulin-Nadzieja, L; Jankowska, EA; Majda, J; Ponikowska, B; Ponikowski, P; Reczuch, K; Trzaska, M; Zymlinski, R, 2007) |
| "Uric acid (UA) may be involved in chronic heart failure (HF) pathogenesis, entailing a worse outcome." | 3.74 | Hyperuricaemia and long-term outcome after hospital discharge in acute heart failure patients. ( Antolinos, MJ; Hurtado-Martínez, JA; Pascual-Figal, DA; Redondo, B; Ruiperez, JA; Valdes, M, 2007) |
| "The role of serum uric acid (SUA) as an independent risk factor for cardiovascular disease (CVD) remains controversial, and little is known about its prognostic importance for mortality from congestive heart failure (CHF) and stroke." | 3.74 | Serum uric acid and risk of cardiovascular mortality: a prospective long-term study of 83,683 Austrian men. ( Brant, L; Concin, H; Diem, G; Kelleher, C; Klenk, J; Pfeiffer, K; Ruttmann, E; Strasak, A; Ulmer, H, 2008) |
| "To determine the prognostic value of serum uric acid (UA) in patients with primary systemic (light chain) amyloidosis (AL)." | 3.74 | Serum uric acid: novel prognostic factor in primary systemic amyloidosis. ( Buadi, FK; Dispenzieri, A; Gertz, MA; Hayman, SR; Kumar, S; Kyle, RA; Lacy, MQ; Leung, N; Rajkumar, SV; Zeldenrust, SR, 2008) |
| "The aim of this study was to elucidate whether in patients with heart failure (HF) serum uric acid (UA) levels correlated with left ventricular ejection fraction (LVEF) and systolic pulmonary artery pressure (SPAP)." | 3.74 | [Serum uric acid levels correlate with left ventricular ejection fraction and systolic pulmonary artery pressure in patients with heart failure]. ( Bindi, M; Castiglioni, M; Filardo, FP; Moroni, F; Pinelli, M, 2007) |
| "We conducted PubMed/MEDLINE searches (1966-January 2008) of primary literature using the following key words: ACE inhibitors, allopurinol, angiotensin-receptor antagonists, cardiomyopathy, chemokines, cytokines, diuretics, heart failure, inflammation, interleukins, HMG-CoA reductase inhibitors, immunotherapy, medications used in heart failure, thalidomide, tumor necrosis factor, and uric acid." | 3.74 | Inflammation in chronic heart failure. ( Evans, JD; Parish, RC, 2008) |
| "To evaluate uric acid renal excretion, hyperuricemia, renal dysfunction, and prognosis in patients with decompensated severe heart failure, as there are few data available." | 3.73 | Uric acid renal excretion and renal insufficiency in decompensated severe heart failure. ( Barretto, AC; Morgado, PC; Munhoz, RT; Ochiai, ME; Oliveira, MT; Ramires, JA, 2005) |
| "The aim of this study was to determine the value of serum uric acid levels in predicting in-hospital mortality of chronic heart failure patients hospitalized for decompensation in spite of appropriate medical therapy." | 3.73 | Serum uric acid levels as a predictor of in-hospital death in patients hospitalized for decompensated heart failure. ( Boyaci, B; Cengel, A; Turfan, M; Türkoğlu, S, 2005) |
| "The plasma level of the uric acid is frequently elevated in heart failure, due to increased production and/or to reduced renal excretion of this antioxidant metabolite." | 3.73 | Allopurinol or oxypurinol in heart failure therapy - a promising new development or end of story? ( Leary, WP; Reyes, AJ, 2005) |
| "Serum uric acid (UA) could be a valid prognostic marker and useful for metabolic, hemodynamic, and functional (MFH) staging in chronic heart failure (CHF)." | 3.72 | Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging. ( Anker, SD; Cicoira, M; Coats, AJ; Davos, CH; Doehner, W; Francis, D; Hetzer, R; Kemp, M; Knosalla, C; Leyva, F; Osterziel, KJ; Ponikowski, P; Rauchhaus, M; Segal, R; Shamim, W; Sharma, R, 2003) |
| " The purpose of this study was to assess the relationship between levels of serum uric acid, activity of the renin-angiotensin-aldosterone system and TNF-alpha in heart failure patients with respect to the extent of left ventricular dysfunction." | 3.71 | Uric acid--a marker for systemic inflammatory response in patients with congestive heart failure? ( Gonsorcík, J; Kisel'ová, J; Olejníková, M; Olexa, P; Olexová, M; Tkác, I, 2002) |
| " We aimed to study the relationship between serum uric acid levels and leg vascular resistance in patients with CHF with and without cachexia and in healthy control subjects." | 3.71 | Uric acid in cachectic and noncachectic patients with chronic heart failure: relationship to leg vascular resistance. ( Anker, SD; Bolger, AP; Coats, AJ; Davos, CH; Doehner, W; Florea, VG; Rauchhaus, M; Sharma, R, 2001) |
| "To assess whether serum uric acid, which is a marker of impaired oxidative metabolism, might correlate with left ventricular systolic and diastolic dysfunction in patients with chronic heart failure (CHF)." | 3.71 | Elevated serum uric acid levels are associated with diastolic dysfunction in patients with dilated cardiomyopathy. ( Brighetti, G; Cicoira, M; Franceschini, L; Golia, G; Rossi, A; Zanolla, L; Zardini, P; Zeni, P, 2002) |
| "Circulating uric acid and markers of inflammation were measured in 39 male patients with chronic heart failure and 16 healthy controls." | 3.70 | Uric acid in chronic heart failure: a marker of chronic inflammation. ( Anker, SD; Coats, AJ; Godsland, IF; Hellewell, PG; Kox, WJ; Leyva, F; Poole-Wilson, PA; Teixeira, M, 1998) |
| "To evaluate uric acid (UA) levels in patients with postinfarction chronic cardiac failure (CCF) and to investigate correlation between accumulation of uric acid, CCF severity and some other parameters." | 3.70 | [Level of blood uric acid in patients with postinfarction heart failure]. ( Drozdov, VN; Levchuk, NN; Moiseev, VS; Tereshchenko, SN, 2000) |
| "We analyzed the serum anion gap (AG = sodium plus potassium minus chloride plus bicarbonate, N = 11-21 mEq/l), serum uric acid and urea concentrations in hyponatremia of various origins." | 3.69 | Uric acid, anion gap and urea concentration in the diagnostic approach to hyponatremia. ( Brimioulle, S; Coffernils, M; Decaux, G; Namias, B; Prospert, F; Schlesser, M; Soupart, A, 1994) |
| "There is an inverse relationship between serum uric acid concentrations and measures of functional capacity in patients with cardiac failure." | 3.69 | Serum uric acid as an index of impaired oxidative metabolism in chronic heart failure. ( Anker, S; Chua, TP; Coats, AJ; Godsland, IF; Leyva, F; Stevenson, JC; Swan, JW; Wingrove, CS, 1997) |
| "To determine whether lower limb blood flow is related to serum uric acid concentrations in patients with chronic heart failure, taking into account the hyperuricaemic effects of diuretic treatment and insulin resistance." | 3.69 | Relation between serum uric acid and lower limb blood flow in patients with chronic heart failure. ( Anker, SD; Coats, AJ; Kox, WJ; Leyva, F; Poole-Wilson, PA; Stevenson, JC, 1997) |
| "The concentrations of urea, urate, phosphate and creatinine were measured in the plasma of 30 consecutive patients admitted acutely with heart failure." | 3.66 | The cause of the raised plasma urea of acute heart failure. ( Morgan, DB; Newill, A; Thomas, RD, 1979) |
| "Dark red nodules that drained an opaque amber liquid developed on the extensor surfaces of both legs in a 69-year-old woman receiving furosemide and spironolactone for congestive heart failure." | 3.65 | Panniculitis of the legs with urate crystal deposition. ( Niemi, KM, 1977) |
| " Serum uric acid levels may rise slightly, but no clinical gout was seen in this study." | 3.64 | TREATMENT OF CONGESTIVE HEART FAILURE WITH TRIAMTERENE. ( FRIEDMAN, R; SCHUCHER, R; WENER, J, 1965) |
| "Ten patients with congestive heart failure, on full digitalis treatment, were given TA (dose range 250-1000 mg/die): in each patient a prompt diuretic effect was observed, associated to a significant reduction of body weight and to a marked improvement of the clinical signs of heart failure." | 2.65 | [Tienilic acid in the treatment of arterial hypertension and congestive cardiac insufficiency]. ( Agabiti-Rosei, E; Alicandri, C; Corea, L; Fariello, R; Muiesan, G; Oldoni, T, 1979) |
| "Hyperuricemia is considered to be a component of cardiovascular continuum, risk factor of chronic heart failure and marker of its unfavourable outcome." | 2.49 | [Hyperuricemia and cardiovascular continuum]. ( Bart, BIa; Donskov, AS; Larin, VG; Larina, VN, 2013) |
| "Calcium antagonists are used in the treatment of hypertension and angina." | 2.44 | The ACTION study: nifedipine in patients with symptomatic stable angina and hypertension. ( Coca, A; Sierra, C, 2008) |
| " The potential risk factors for the discontinuation events caused by sac/val-related adverse events (AEs) were explored." | 1.72 | Effectiveness and safety of sacubitril/valsartan for patients with hypertension and heart failure in the real-world setting: A retrospective study in China. ( Chen, C; Fan, L; Li, J; Li, X; Lv, Q; Tian, D; Zuo, C, 2022) |
| "Hyperuricemia is independently associated with cardiovascular disease (CVD) and is considered to be one of the major risk factors for CVD." | 1.56 | Association of variability in uric acid and future clinical outcomes of patient with coronary artery disease undergoing percutaneous coronary intervention. ( Chan, WL; Charng, MJ; Chen, JW; Chen, SC; Chen, YH; Cheng, HM; Chou, CY; Hsu, PF; Huang, CC; Huang, PH; Huang, SS; Leu, HB; Lim, SS; Lin, SJ; Lin, YJ; Lu, TM; Pan, JP; Sung, SH; Wu, CH; Wu, TC; Yang, YL, 2020) |
| "Although hyperuricemia is associated with congestive heart failure (CHF), hyperuricemic patients frequently have other comorbidities." | 1.56 | Asymptomatic hyperuricemia and incident congestive heart failure in elderly patients without comorbidities. ( Cheng, H; Jian, G; Tang, Y; Wang, N; Wu, J; Wu, X, 2020) |
| "Hyperuricemia and gout are common in patients with heart failure (HF) and are associated with poor outcomes." | 1.56 | Comparison of Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection Fraction With Versus Without Hyperuricemia or Gout. ( Andersson, K; Bjursell, M; Carnicelli, AP; Chiswell, K; Clare, R; Hedman, K; Lytle, B; Mentz, RJ; Pagidipati, N; Perl, S; Roe, MT; Vemulapalli, S, 2020) |
| "Patients with cancer were older and more often former smokers, had lower body mass index, lower left ventricular ejection fraction (LVEF), less implanted devices, lower glucose and haemoglobin and higher uric acid levels than those without cancer." | 1.56 | Cancer in chronic heart failure patients in the GISSI-HF trial. ( Ameri, P; Canepa, M; Latini, R; Luigi Nicolosi, G; Maggioni, AP; Marchioli, R; Tavazzi, L, 2020) |
| "Hyperuricemia was defined as serum UA ≥7 mg/dl in men and ≥ 6 mg/dl in women." | 1.56 | The relationship between serum uric acid and cognitive function in patients with chronic heart failure. ( Lu, C; Niu, W; Yang, H, 2020) |
| " In-hospital UA-increase was associated with higher risk of mortality even after adjusting for confounding variables including creatine change and diuretic dosage [harzard ratio (HR) 1." | 1.51 | Association of serum uric acid change with mortality, renal function and diuretic dose administered in treatment of acute heart failure. ( Bai, YJ; Huang, XF; Liu, SR; Xu, DL; Xu, TY; Zeng, QC; Zhan, Q; Zhou, HB, 2019) |
| "People with gout are at an increased risk of readmission for heart failure and have longer hospital stays." | 1.51 | Associations of Gout and Baseline Serum Urate Level With Cardiovascular Outcomes: Analysis of the Coronary Disease Cohort Study. ( Doughty, RN; Drake, J; Frampton, C; Richards, AM; Stamp, LK; Troughton, RW, 2019) |
| "Hyperuricemia is significantly associated with hypertension, renal dysfunction, MACE, and independently confers a higher risk of mortality in patients with AMI." | 1.46 | Association Between Hyperuricemia and Major Adverse Cardiac Events in Patients with Acute Myocardial Infarction. ( Mayise, C; Myeni, NN; Ranjith, N; Sartorius, B, 2017) |
| "Heart failure is not simply a single organ disease; rather it is a complex multi-system clinical syndrome, with impairment of endocrine, haematological, musculoskeletal, renal, respiratory and vascular systems, which influence morbidity and mortality." | 1.42 | Heart failure: not a single organ disease but a multisystem syndrome. ( Lawford, P; Sheridan, P; Warriner, D, 2015) |
| "Uric acid (UA) is a strong marker of cardiovascular disease." | 1.40 | The association between serum uric acid level and heart failure and mortality in the early period of ST-elevation acute myocardial infarction. ( Altun, B; Barutçu, A; Bekler, A; Gazi, E; Gazi, S; Güngör, O; Kurt, T; Ozcan, S; Temiz, A; Yener, AU, 2014) |
| "Hyperuricemia is associated with worse outcomes of patients with chronic heart failure (HF)." | 1.37 | Hyperuricemia predicts adverse outcomes in patients with heart failure. ( Furumoto, T; Goto, D; Goto, K; Hamaguchi, S; Kinugawa, S; Takeshita, A; Tsuchihashi-Makaya, M; Tsutsui, H; Yokoshiki, H; Yokota, T, 2011) |
| "Hyperuricemia is a prevalent condition in chronic heart failure (CHF), describing increased oxidative stress and inflammation." | 1.35 | Hyperuricemia in acute heart failure. More than a simple spectator? ( Alimonda, AL; Bodí, V; Darmofal, H; Husser, O; Llácer, A; Mainar, L; Merlos, P; Miñana, G; Núñez, E; Núñez, J; Robles, R; Sanchis, J, 2009) |
| "Hyperuricemia is often found in patients with chronic heart failure (CHF)." | 1.35 | Is uric acid itself a player or a bystander in the pathophysiology of chronic heart failure? ( Duan, X; Ling, F, 2008) |
| "Hyperuricemia has been identified in patients who have congestive heart failure and is a marker of poor prognosis in such patients." | 1.33 | Prognostic usefulness of serum uric acid after acute myocardial infarction (the Japanese Acute Coronary Syndrome Study). ( Hiraoka, H; Honda, T; Ishihara, M; Kimura, K; Kojima, S; Matsui, K; Miyazaki, S; Ogata, Y; Ogawa, H; Sakamoto, T; Shimoyama, N; Sonoda, M; Tei, C; Tsuchihashi, K; Yamagishi, M, 2005) |
| "Uric acid levels were analyzed in 247 CHF patients, and patients were followed up for 451 +/- 235 days (mean +/- SD)." | 1.33 | Hyperuricemia associated with high cardiac event rates in the elderly with chronic heart failure. ( Arimoto, T; Hirono, O; Koyama, Y; Kubota, I; Miyashita, T; Niizeki, T; Nitobe, J; Nozaki, N; Okuyama, H; Takahashi, H; Takeishi, Y; Tsunoda, Y; Watanabe, T, 2006) |
| "Furthermore, congestive heart failure is associated with impaired creatinine clearance and increased urea and urate, and osteoporosis and hip fractures are characterized by low albumin and cholesterol." | 1.32 | Association of biochemical values with morbidity in the elderly: a population-based Swedish study of persons aged 82 or more years. ( Berg, S; Evrin, PE; Johansson, B; McClearn, G; Nilsson, SE; Takkinen, S; Tryding, N, 2003) |
| "In patients with severe heart decompensation, there was an appreciable activation of xanthine oxidase, which correlated, as a rule, with high hyperuricemia." | 1.28 | [Changes in xanthine oxidase activity in patients with circulatory failure]. ( Bakhtiiarov, ZA, 1989) |
| "Post-operative care of cancer patients has to take into consideration additional diseases not related to the basic disease, too." | 1.26 | [Secondary diseases complicating cancer]. ( Kirsch, JJ; Müller, J; Pitule-Schödel, H, 1981) |
| "Ticrynafen is an orally administered diuretic that is similar to the thiazides in its therapeutic actions, but unlike the thiazides, it increases urate excretion and lowers serum uric acid levels." | 1.26 | Evaluation of a new uricosuric diuretic--ticrynafen. ( Kosman, ME, 1979) |
| "A nearly 72-old black male with sickle cell anemia suffered from heart failure, hypertension, chronic impaired kidney function with hyperuricemia and gout." | 1.25 | Long survival in sickle cell anemia. ( Huisman, TH; Sar, AV, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 57 (18.27) | 18.7374 |
| 1990's | 10 (3.21) | 18.2507 |
| 2000's | 65 (20.83) | 29.6817 |
| 2010's | 100 (32.05) | 24.3611 |
| 2020's | 80 (25.64) | 2.80 |
| Authors | Studies |
|---|---|
| Cidade-Rodrigues, C | 1 |
| Cunha, FM | 1 |
| Elias, C | 1 |
| Oliveira, D | 1 |
| Bettencourt, P | 1 |
| Lourenço, P | 1 |
| Si, K | 1 |
| Wei, C | 1 |
| Xu, L | 1 |
| Zhou, Y | 3 |
| Lv, W | 1 |
| Dong, B | 1 |
| Wang, Z | 2 |
| Huang, Y | 3 |
| Wang, Y | 3 |
| Chen, Y | 5 |
| De Luca, L | 1 |
| Gulizia, MM | 1 |
| Gabrielli, D | 1 |
| Meessen, J | 1 |
| Mattei, L | 1 |
| D'Urbano, M | 1 |
| Colivicchi, F | 1 |
| Temporelli, PL | 2 |
| Borghi, C | 7 |
| Desideri, G | 2 |
| Suzuki, S | 3 |
| Yoshihisa, A | 2 |
| Yokokawa, T | 1 |
| Kobayashi, A | 1 |
| Yamaki, T | 1 |
| Kunii, H | 1 |
| Nakazato, K | 1 |
| Tsuda, A | 1 |
| Tsuda, T | 1 |
| Ishibashi, T | 1 |
| Konno, I | 1 |
| Yamaguchi, O | 1 |
| Machii, H | 1 |
| Nozaki, N | 2 |
| Niizeki, T | 3 |
| Miyamoto, T | 1 |
| Takeishi, Y | 5 |
| Rebora, P | 1 |
| Centola, M | 1 |
| Morici, N | 1 |
| Sacco, A | 1 |
| Occhino, G | 1 |
| Viola, G | 1 |
| Oreglia, J | 1 |
| Castini, D | 1 |
| Persampieri, S | 1 |
| Sabatelli, L | 1 |
| Ferrante, G | 1 |
| Lucreziotti, S | 1 |
| Carugo, S | 1 |
| Valsecchi, MG | 1 |
| Oliva, F | 1 |
| Giannattasio, C | 2 |
| Maloberti, A | 2 |
| McDowell, K | 2 |
| Welsh, P | 1 |
| Docherty, KF | 2 |
| Morrow, DA | 1 |
| Jhund, PS | 4 |
| de Boer, RA | 2 |
| O'Meara, E | 1 |
| Inzucchi, SE | 2 |
| Køber, L | 3 |
| Kosiborod, MN | 2 |
| Martinez, FA | 2 |
| Ponikowski, P | 5 |
| Hammarstedt, A | 1 |
| Langkilde, AM | 2 |
| Sjöstrand, M | 1 |
| Lindholm, D | 1 |
| Solomon, SD | 4 |
| Sattar, N | 1 |
| Sabatine, MS | 2 |
| McMurray, JJV | 4 |
| Singhal, R | 1 |
| Hechanova, LA | 1 |
| Mantovani, A | 2 |
| Bonapace, S | 1 |
| Dugo, C | 1 |
| Beatrice, G | 1 |
| Petracca, G | 1 |
| Cappelli, D | 1 |
| Csermely, A | 1 |
| Molon, G | 1 |
| Targher, G | 3 |
| Zhang, Y | 8 |
| Jiang, W | 1 |
| Carter, S | 1 |
| Hendren, NS | 1 |
| Grodin, JL | 1 |
| Xie, Z | 1 |
| Shen, Y | 1 |
| Huang, S | 1 |
| Shen, W | 1 |
| Liu, J | 2 |
| Yang, F | 1 |
| Hu, T | 1 |
| Cui, H | 1 |
| Segar, MW | 1 |
| Kolkailah, AA | 1 |
| Frederich, R | 1 |
| Pong, A | 1 |
| Cannon, CP | 1 |
| Cosentino, F | 1 |
| Dagogo-Jack, S | 1 |
| McGuire, DK | 1 |
| Pratley, RE | 1 |
| Liu, CC | 1 |
| Maldonado, M | 1 |
| Cater, NB | 1 |
| Pandey, A | 1 |
| Cherney, DZI | 1 |
| Zuo, C | 1 |
| Li, X | 12 |
| Fan, L | 1 |
| Li, J | 11 |
| Tian, D | 1 |
| Chen, C | 1 |
| Lv, Q | 1 |
| Mohd Ghazi, A | 1 |
| Teoh, CK | 1 |
| Abdul Rahim, AA | 1 |
| Zhu, Y | 3 |
| Peng, X | 1 |
| Wu, M | 3 |
| Huang, H | 3 |
| Li, N | 1 |
| Xiao, S | 1 |
| Zhang, H | 2 |
| Chen, S | 4 |
| Liu, Z | 3 |
| Yi, L | 1 |
| Peng, Y | 1 |
| Fan, J | 1 |
| Zeng, J | 1 |
| Doehner, W | 13 |
| Anker, SD | 20 |
| Butler, J | 4 |
| Zannad, F | 5 |
| Filippatos, G | 4 |
| Ferreira, JP | 3 |
| Salsali, A | 1 |
| Kaempfer, C | 1 |
| Brueckmann, M | 2 |
| Pocock, SJ | 2 |
| Januzzi, JL | 2 |
| Packer, M | 5 |
| Baliga, RR | 1 |
| Bossone, E | 1 |
| Mackenzie, IS | 1 |
| MacDonald, TM | 1 |
| McMurray, JJ | 1 |
| Siddiqi, TJ | 1 |
| Bocchi, E | 1 |
| Böhm, M | 1 |
| Chopra, VK | 1 |
| Giannetti, N | 1 |
| Iwata, T | 1 |
| Kaul, S | 1 |
| Piña, IL | 1 |
| Rauch-Kröhnert, U | 1 |
| Shah, SJ | 3 |
| Senni, M | 3 |
| Sumin, M | 1 |
| Verma, S | 1 |
| Zhang, J | 5 |
| Yousaf, M | 1 |
| Khan, WA | 1 |
| Shahzad, K | 1 |
| Khan, HN | 1 |
| Ali, B | 1 |
| Hussain, M | 2 |
| Awan, FR | 1 |
| Mustafa, H | 1 |
| Sheikh, FN | 1 |
| Yang, CD | 1 |
| Feng, S | 1 |
| Chen, JW | 2 |
| Aihemaiti, M | 1 |
| Shu, XY | 1 |
| Quan, JW | 1 |
| Ding, FH | 1 |
| Lu, L | 1 |
| Shen, WF | 1 |
| Zhang, RY | 1 |
| Wang, XQ | 1 |
| Nasonova, SN | 1 |
| Lapteva, AE | 1 |
| Zhirov, IV | 1 |
| Mindzaev, DR | 1 |
| Tereshchenko, SN | 2 |
| Shiina, K | 3 |
| Tomiyama, H | 3 |
| Tanaka, A | 3 |
| Imai, T | 3 |
| Hisauchi, I | 3 |
| Taguchi, I | 3 |
| Sezai, A | 3 |
| Toyoda, S | 4 |
| Dohi, K | 3 |
| Kamiya, H | 3 |
| Kida, K | 4 |
| Anzai, T | 4 |
| Chikamori, T | 3 |
| Node, K | 4 |
| Deis, T | 3 |
| Rossing, K | 3 |
| Ersbøll, MK | 3 |
| Wolsk, E | 3 |
| Gustafsson, F | 3 |
| Naganuma, J | 1 |
| Sakuma, M | 1 |
| Kitahara, K | 1 |
| Kato, T | 1 |
| Yokomachi, J | 1 |
| Yamauchi, F | 1 |
| Inoue, R | 1 |
| Iida, K | 1 |
| Kohno, Y | 1 |
| Inoue, K | 1 |
| Koshiji, N | 1 |
| Abe, S | 1 |
| Inoue, T | 2 |
| Kuwabara, M | 2 |
| Kanbay, M | 3 |
| Hisatome, I | 2 |
| Sun, G | 1 |
| Liu, Y | 5 |
| Rong, D | 1 |
| Liang, X | 1 |
| Alshamari, AHI | 1 |
| Kadhim, RK | 1 |
| Al-Mohana, SJA | 1 |
| Butt, JH | 1 |
| Claggett, BL | 2 |
| Desai, AS | 3 |
| Petersson, M | 1 |
| Hernandez, AF | 2 |
| Lam, CSP | 2 |
| Vaduganathan, M | 2 |
| Lou, B | 1 |
| Wu, H | 1 |
| Ott, H | 1 |
| Bennewitz, K | 1 |
| Wang, C | 4 |
| Poschet, G | 1 |
| Liu, H | 2 |
| Yuan, Z | 2 |
| Kroll, J | 1 |
| She, J | 1 |
| Kashiwagi, Y | 1 |
| Nagoshi, T | 1 |
| Kimura, H | 1 |
| Tanaka, Y | 1 |
| Oi, Y | 1 |
| Inoue, Y | 2 |
| Ogawa, K | 1 |
| Kawai, M | 1 |
| Yoshimura, M | 1 |
| Piani, F | 1 |
| Agnoletti, D | 1 |
| Kiernan, MS | 1 |
| Konstam, MA | 2 |
| Liu, T | 1 |
| Song, J | 4 |
| Zuo, R | 1 |
| Sun, L | 1 |
| Zhu, Z | 1 |
| Wang, B | 1 |
| Lu, Z | 1 |
| Pan, Y | 1 |
| Katsiki, N | 1 |
| Rizzo, M | 1 |
| Mikhailidis, DP | 1 |
| Ke, J | 1 |
| Pan, J | 1 |
| Lin, H | 2 |
| Han, Z | 1 |
| Gu, J | 3 |
| Han, Y | 1 |
| Cao, Y | 1 |
| Han, X | 1 |
| Di, H | 1 |
| Yin, Y | 1 |
| Wu, J | 3 |
| Zeng, X | 1 |
| Wei, FF | 1 |
| Chen, X | 2 |
| Cheng, W | 1 |
| Wu, Y | 2 |
| Yu, Z | 1 |
| Huang, J | 2 |
| Zhao, J | 2 |
| He, J | 1 |
| Cauwenberghs, N | 1 |
| Dong, Y | 2 |
| Liu, C | 8 |
| Wahid, A | 1 |
| Wen, J | 1 |
| Yang, Q | 1 |
| Zhang, Z | 1 |
| Zhao, X | 1 |
| Tang, X | 2 |
| Li, Z | 3 |
| Yuan, J | 1 |
| Hu, E | 1 |
| Wei, D | 1 |
| Zhong, J | 1 |
| Xing, LM | 1 |
| He, Y | 2 |
| Feng, J | 3 |
| Zhang, B | 1 |
| Wu, Q | 2 |
| He, D | 1 |
| Zheng, D | 1 |
| Yang, J | 1 |
| Yan, W | 2 |
| Tang, HY | 1 |
| Yang, YQ | 1 |
| He, KL | 1 |
| Sabaka, P | 1 |
| Dukat, A | 2 |
| Gajdosik, J | 1 |
| Caprnda, M | 1 |
| Bendzala, M | 1 |
| Simko, F | 1 |
| Stone, ML | 1 |
| Richardson, MR | 1 |
| Guevara, L | 1 |
| Rand, BG | 1 |
| Churilla, JR | 1 |
| Ruocco, G | 3 |
| Palazzuoli, A | 4 |
| Landolfo, M | 1 |
| Cosentino, E | 2 |
| Kobayashi, Y | 1 |
| Omote, K | 1 |
| Nagai, T | 1 |
| Kamiya, K | 1 |
| Konishi, T | 1 |
| Sato, T | 2 |
| Kato, Y | 1 |
| Komoriyama, H | 1 |
| Tsujinaga, S | 1 |
| Iwano, H | 1 |
| Yamamoto, K | 1 |
| Yoshikawa, T | 2 |
| Saito, Y | 1 |
| Bragagni, A | 1 |
| Afsar, B | 1 |
| Siriopol, D | 1 |
| Dincer, N | 1 |
| Erden, N | 1 |
| Yilmaz, O | 1 |
| Sag, AA | 1 |
| Cherney, D | 1 |
| Rossignol, P | 2 |
| Ortiz, A | 1 |
| Covic, A | 1 |
| Lim, SS | 1 |
| Yang, YL | 1 |
| Chen, SC | 1 |
| Wu, CH | 1 |
| Huang, SS | 1 |
| Chan, WL | 1 |
| Lin, SJ | 1 |
| Chou, CY | 1 |
| Pan, JP | 1 |
| Charng, MJ | 1 |
| Chen, YH | 1 |
| Wu, TC | 1 |
| Lu, TM | 1 |
| Hsu, PF | 3 |
| Huang, PH | 1 |
| Cheng, HM | 4 |
| Huang, CC | 1 |
| Sung, SH | 4 |
| Lin, YJ | 1 |
| Leu, HB | 1 |
| Wu, X | 2 |
| Jian, G | 1 |
| Tang, Y | 1 |
| Cheng, H | 1 |
| Wang, N | 1 |
| Kramer, F | 1 |
| Voss, S | 1 |
| Roessig, L | 1 |
| Igl, BW | 1 |
| Maggioni, AP | 6 |
| Pieske, B | 2 |
| Nakanishi, K | 1 |
| Daimon, M | 1 |
| Yoshida, Y | 1 |
| Ishiwata, J | 1 |
| Sawada, N | 1 |
| Hirokawa, M | 1 |
| Kaneko, H | 2 |
| Nakao, T | 1 |
| Mizuno, Y | 1 |
| Morita, H | 3 |
| Di Tullio, MR | 1 |
| Homma, S | 1 |
| Komuro, I | 2 |
| Carnicelli, AP | 2 |
| Clare, R | 1 |
| Chiswell, K | 1 |
| Lytle, B | 2 |
| Bjursell, M | 2 |
| Perl, S | 2 |
| Andersson, K | 1 |
| Hedman, K | 1 |
| Pagidipati, N | 1 |
| Vemulapalli, S | 1 |
| Roe, MT | 2 |
| Mentz, RJ | 3 |
| Ameri, P | 1 |
| Canepa, M | 1 |
| Luigi Nicolosi, G | 1 |
| Marchioli, R | 2 |
| Latini, R | 2 |
| Tavazzi, L | 3 |
| Sun, JL | 1 |
| Alhanti, B | 2 |
| Pan, JA | 1 |
| Wang, CQ | 2 |
| Zhang, JF | 2 |
| Watanabe, K | 2 |
| Watanabe, T | 2 |
| Otaki, Y | 1 |
| Shishido, T | 2 |
| Murase, T | 2 |
| Nakamura, T | 2 |
| Kato, S | 1 |
| Tamura, H | 1 |
| Nishiyama, S | 1 |
| Takahashi, H | 2 |
| Arimoto, T | 2 |
| Watanabe, M | 1 |
| Yamamoto, H | 1 |
| Nagatomo, Y | 1 |
| Mahara, K | 1 |
| Muiesan, ML | 1 |
| Salvetti, M | 1 |
| Virdis, A | 1 |
| Masi, S | 1 |
| Casiglia, E | 1 |
| Tikhonoff, V | 1 |
| Barbagallo, CM | 1 |
| Bombelli, M | 1 |
| Cicero, AFG | 1 |
| Cirillo, M | 1 |
| Cirillo, P | 1 |
| D'Eliak, L | 1 |
| Ferri, C | 2 |
| Galletti, F | 1 |
| Gesualdo, L | 1 |
| Iaccarino, G | 1 |
| Mallamaci, F | 1 |
| Mazza, A | 1 |
| Nazzaro, P | 1 |
| Palatini, P | 1 |
| Parati, G | 1 |
| Pontremoli, R | 2 |
| Rattazzi, M | 1 |
| Rivasi, G | 1 |
| Tocci, G | 1 |
| Ungar, A | 1 |
| Verdecchia, P | 1 |
| Viazzi, F | 2 |
| Volpe, M | 1 |
| Grassi, G | 1 |
| Guo, CY | 3 |
| Chan, CH | 1 |
| Chou, YC | 1 |
| Niu, W | 1 |
| Yang, H | 2 |
| Lu, C | 1 |
| Selvaraj, S | 1 |
| Pfeffer, MA | 1 |
| Mc Causland, FR | 1 |
| McGrath, MM | 1 |
| Anand, IS | 1 |
| van Veldhuisen, DJ | 2 |
| Kober, L | 1 |
| Janssens, S | 1 |
| Cleland, JGF | 1 |
| Rouleau, JL | 3 |
| Zile, MR | 1 |
| Shi, VC | 2 |
| Lefkowitz, MP | 2 |
| Nguépy Keubo, FR | 1 |
| Mboua, PC | 1 |
| Djifack Tadongfack, T | 1 |
| Fokouong Tchoffo, E | 1 |
| Tasson Tatang, C | 1 |
| Ide Zeuna, J | 1 |
| Noupoue, EM | 1 |
| Tsoplifack, CB | 1 |
| Folefack, GO | 1 |
| Kettani, M | 1 |
| Bandelier, P | 1 |
| Huo, J | 1 |
| Li, H | 4 |
| Yu, D | 2 |
| Arulsamy, N | 1 |
| AlAbbad, S | 1 |
| Sardot, T | 1 |
| Lekashvili, O | 1 |
| Decato, D | 1 |
| Lelj, F | 1 |
| Alexander Ross, JB | 1 |
| Rosenberg, E | 1 |
| Nazir, H | 1 |
| Muthuswamy, N | 1 |
| Louis, C | 1 |
| Jose, S | 1 |
| Prakash, J | 1 |
| Buan, MEM | 1 |
| Flox, C | 1 |
| Chavan, S | 1 |
| Shi, X | 1 |
| Kauranen, P | 1 |
| Kallio, T | 1 |
| Maia, G | 1 |
| Tammeveski, K | 1 |
| Lymperopoulos, N | 1 |
| Carcadea, E | 1 |
| Veziroglu, E | 1 |
| Iranzo, A | 1 |
| M Kannan, A | 1 |
| Arunamata, A | 1 |
| Tacy, TA | 1 |
| Kache, S | 1 |
| Mainwaring, RD | 1 |
| Ma, M | 1 |
| Maeda, K | 1 |
| Punn, R | 1 |
| Noguchi, S | 1 |
| Hahn, S | 3 |
| Iwasa, Y | 3 |
| Ling, J | 2 |
| Voccio, JP | 2 |
| Kim, Y | 3 |
| Bascuñán, J | 2 |
| Chu, Y | 1 |
| Tomita, M | 1 |
| Cazorla, M | 1 |
| Herrera, E | 1 |
| Palomeque, E | 1 |
| Saud, N | 1 |
| Hoplock, LB | 1 |
| Lobchuk, MM | 1 |
| Lemoine, J | 1 |
| Henson, MA | 1 |
| Unsihuay, D | 1 |
| Qiu, J | 1 |
| Swaroop, S | 1 |
| Nagornov, KO | 1 |
| Kozhinov, AN | 1 |
| Tsybin, YO | 1 |
| Kuang, S | 1 |
| Laskin, J | 1 |
| Zin, NNINM | 1 |
| Mohamad, MN | 1 |
| Roslan, K | 1 |
| Abdul Wafi, S | 1 |
| Abdul Moin, NI | 1 |
| Alias, A | 1 |
| Zakaria, Y | 1 |
| Abu-Bakar, N | 1 |
| Naveed, A | 1 |
| Jilani, K | 1 |
| Siddique, AB | 1 |
| Akbar, M | 1 |
| Riaz, M | 1 |
| Mushtaq, Z | 1 |
| Sikandar, M | 1 |
| Ilyas, S | 1 |
| Bibi, I | 1 |
| Asghar, A | 1 |
| Rasool, G | 1 |
| Irfan, M | 1 |
| Li, XY | 1 |
| Zhao, S | 1 |
| Fan, XH | 1 |
| Chen, KP | 1 |
| Hua, W | 1 |
| Liu, ZM | 1 |
| Xue, XD | 1 |
| Zhou, B | 1 |
| Zhang, S | 2 |
| Xing, YL | 1 |
| Chen, MA | 1 |
| Sun, Y | 1 |
| Neradilek, MB | 1 |
| Wu, XT | 1 |
| Zhang, D | 2 |
| Huang, W | 1 |
| Cui, Y | 1 |
| Yang, QQ | 1 |
| Li, HW | 1 |
| Zhao, XQ | 1 |
| Hossein Rashidi, B | 1 |
| Tarafdari, A | 1 |
| Ghazimirsaeed, ST | 1 |
| Shahrokh Tehraninezhad, E | 1 |
| Keikha, F | 1 |
| Eslami, B | 1 |
| Ghazimirsaeed, SM | 1 |
| Jafarabadi, M | 1 |
| Silvani, Y | 1 |
| Lovita, AND | 1 |
| Maharani, A | 1 |
| Wiyasa, IWA | 1 |
| Sujuti, H | 1 |
| Ratnawati, R | 1 |
| Raras, TYM | 1 |
| Lemin, AS | 1 |
| Rahman, MM | 1 |
| Pangarah, CA | 1 |
| Kiyu, A | 1 |
| Zeng, C | 2 |
| Du, H | 1 |
| Lin, D | 1 |
| Jalan, D | 1 |
| Rubagumya, F | 1 |
| Hopman, WM | 1 |
| Vanderpuye, V | 1 |
| Lopes, G | 1 |
| Seruga, B | 1 |
| Booth, CM | 1 |
| Berry, S | 1 |
| Hammad, N | 1 |
| Sajo, EA | 1 |
| Okunade, KS | 1 |
| Olorunfemi, G | 1 |
| Rabiu, KA | 1 |
| Anorlu, RI | 1 |
| Xu, C | 2 |
| Xiang, Y | 1 |
| Xu, X | 1 |
| Zhou, L | 2 |
| Dong, X | 1 |
| Tang, S | 1 |
| Gao, XC | 1 |
| Wei, CH | 1 |
| Zhang, RG | 1 |
| Cai, Q | 1 |
| Tong, F | 1 |
| Dong, JH | 1 |
| Wu, G | 1 |
| Dong, XR | 1 |
| Tao, F | 1 |
| Xiang, W | 1 |
| Zhao, Y | 2 |
| Jin, L | 1 |
| Tao, H | 1 |
| Lei, Y | 1 |
| Gan, H | 1 |
| Chen, L | 3 |
| Shan, A | 1 |
| Zhao, H | 2 |
| Ma, Q | 1 |
| Wang, J | 5 |
| Zhang, E | 1 |
| Li, Y | 7 |
| Xue, F | 1 |
| Deng, L | 1 |
| Liu, L | 2 |
| Yan, Z | 2 |
| Meng, J | 1 |
| Chen, G | 2 |
| Anastassiadou, M | 1 |
| Bernasconi, G | 1 |
| Brancato, A | 1 |
| Carrasco Cabrera, L | 1 |
| Greco, L | 1 |
| Jarrah, S | 1 |
| Kazocina, A | 1 |
| Leuschner, R | 1 |
| Magrans, JO | 1 |
| Miron, I | 1 |
| Nave, S | 1 |
| Pedersen, R | 1 |
| Reich, H | 1 |
| Rojas, A | 1 |
| Sacchi, A | 1 |
| Santos, M | 1 |
| Theobald, A | 1 |
| Vagenende, B | 1 |
| Verani, A | 1 |
| Du, L | 1 |
| Liu, X | 1 |
| Ren, Y | 1 |
| Li, P | 1 |
| Jiao, Q | 1 |
| Meng, P | 1 |
| Wang, F | 2 |
| Wang, YS | 1 |
| Zhou, X | 2 |
| Wang, W | 1 |
| Wang, S | 2 |
| Hou, J | 1 |
| Zhang, A | 1 |
| Lv, B | 1 |
| Gao, C | 1 |
| Pang, D | 1 |
| Lu, K | 1 |
| Ahmad, NH | 1 |
| Wang, L | 4 |
| Zhu, J | 2 |
| Zhang, L | 2 |
| Zhuang, T | 1 |
| Tu, J | 1 |
| Zhao, Z | 1 |
| Qu, Y | 1 |
| Yao, H | 2 |
| Wang, X | 5 |
| Lee, DF | 1 |
| Shen, J | 3 |
| Wen, L | 1 |
| Huang, G | 3 |
| Xie, X | 1 |
| Zhao, Q | 4 |
| Hu, W | 1 |
| Lu, J | 2 |
| Li, M | 1 |
| Li, W | 2 |
| Wu, W | 1 |
| Du, F | 1 |
| Ji, H | 1 |
| Yang, X | 2 |
| Xu, Z | 1 |
| Wan, L | 1 |
| Wen, Q | 1 |
| Cho, CH | 1 |
| Zou, C | 1 |
| Xiao, Z | 1 |
| Liao, J | 1 |
| Su, X | 1 |
| Bi, Z | 1 |
| Su, Q | 1 |
| Wei, Y | 2 |
| Gao, Y | 3 |
| Na, KJ | 1 |
| Choi, H | 1 |
| Oh, HR | 1 |
| Kim, YH | 1 |
| Lee, SB | 1 |
| Jung, YJ | 1 |
| Koh, J | 1 |
| Park, S | 1 |
| Lee, HJ | 1 |
| Jeon, YK | 1 |
| Chung, DH | 1 |
| Paeng, JC | 1 |
| Park, IK | 1 |
| Kang, CH | 1 |
| Cheon, GJ | 1 |
| Kang, KW | 1 |
| Lee, DS | 1 |
| Kim, YT | 1 |
| Pajuelo-Lozano, N | 1 |
| Alcalá, S | 1 |
| Sainz, B | 1 |
| Perona, R | 1 |
| Sanchez-Perez, I | 1 |
| Logotheti, S | 1 |
| Marquardt, S | 1 |
| Gupta, SK | 1 |
| Richter, C | 1 |
| Edelhäuser, BAH | 1 |
| Engelmann, D | 1 |
| Brenmoehl, J | 1 |
| Söhnchen, C | 1 |
| Murr, N | 1 |
| Alpers, M | 1 |
| Singh, KP | 1 |
| Wolkenhauer, O | 1 |
| Heckl, D | 1 |
| Spitschak, A | 1 |
| Pützer, BM | 1 |
| Liao, Y | 1 |
| Cheng, J | 1 |
| Kong, X | 1 |
| Li, S | 2 |
| Zhang, M | 5 |
| Yang, T | 2 |
| Xu, Y | 1 |
| Cao, J | 1 |
| Zheng, Y | 1 |
| Luo, Z | 1 |
| Mei, Z | 1 |
| Yao, Y | 1 |
| Liang, C | 1 |
| Song, Y | 1 |
| Yu, K | 1 |
| Zhu, C | 1 |
| Huang, Z | 1 |
| Qian, J | 1 |
| Ge, J | 1 |
| Hu, J | 2 |
| Wang, H | 2 |
| Mi, Y | 1 |
| Kong, H | 1 |
| Xi, D | 1 |
| Luo, X | 1 |
| Ning, Q | 1 |
| Chang, X | 2 |
| Zhang, T | 2 |
| Wang, Q | 2 |
| Rathore, MG | 1 |
| Reddy, K | 1 |
| Chen, H | 1 |
| Shin, SH | 1 |
| Ma, WY | 1 |
| Bode, AM | 1 |
| Dong, Z | 1 |
| Mu, W | 1 |
| Gao, F | 1 |
| Qi, Y | 1 |
| Lu, H | 1 |
| Zhang, X | 4 |
| Cai, X | 1 |
| Ji, RY | 1 |
| Hou, Y | 3 |
| Tian, J | 2 |
| Shi, Y | 1 |
| Ying, S | 1 |
| Tan, M | 1 |
| Feng, G | 1 |
| Kuang, Y | 1 |
| Chen, D | 1 |
| Wu, D | 3 |
| Zhu, ZQ | 1 |
| Tang, HX | 1 |
| Shi, ZE | 1 |
| Kang, J | 1 |
| Liu, Q | 1 |
| Qi, J | 2 |
| Mu, J | 1 |
| Cong, Z | 1 |
| Fu, D | 1 |
| Celestrin, CP | 1 |
| Rocha, GZ | 1 |
| Stein, AM | 1 |
| Guadagnini, D | 1 |
| Tadelle, RM | 1 |
| Saad, MJA | 1 |
| Oliveira, AG | 1 |
| Bianconi, V | 1 |
| Bronzo, P | 1 |
| Banach, M | 1 |
| Sahebkar, A | 1 |
| Mannarino, MR | 1 |
| Pirro, M | 1 |
| Patsourakos, NG | 1 |
| Kouvari, M | 1 |
| Kotidis, A | 1 |
| Kalantzi, KI | 1 |
| Tsoumani, ME | 1 |
| Anastasiadis, F | 1 |
| Andronikos, P | 1 |
| Aslanidou, T | 1 |
| Efraimidis, P | 1 |
| Georgiopoulos, A | 1 |
| Gerakiou, K | 1 |
| Grigoriadou-Skouta, E | 1 |
| Grigoropoulos, P | 1 |
| Hatzopoulos, D | 1 |
| Kartalis, A | 1 |
| Lyras, A | 1 |
| Markatos, G | 1 |
| Mikrogeorgiou, A | 1 |
| Myroforou, I | 1 |
| Orkopoulos, A | 1 |
| Pavlidis, P | 1 |
| Petras, C | 1 |
| Riga, M | 1 |
| Skouloudi, M | 1 |
| Smyrnioudis, N | 1 |
| Thomaidis, K | 1 |
| Tsikouri, GE | 1 |
| Tsikouris, EI | 1 |
| Zisimos, K | 1 |
| Vavoulis, P | 1 |
| Vitali, MG | 1 |
| Vitsas, G | 1 |
| Vogiatzidis, C | 1 |
| Chantanis, S | 1 |
| Fousas, S | 1 |
| Panagiotakos, DB | 1 |
| Tselepis, AD | 1 |
| Jungen, C | 1 |
| Alken, FA | 1 |
| Eickholt, C | 1 |
| Scherschel, K | 1 |
| Kuklik, P | 1 |
| Klatt, N | 1 |
| Schwarzl, J | 1 |
| Moser, J | 1 |
| Jularic, M | 1 |
| Akbulak, RO | 1 |
| Schaeffer, B | 1 |
| Willems, S | 1 |
| Meyer, C | 1 |
| Nowak, JK | 1 |
| Szczepanik, M | 1 |
| Trypuć, M | 1 |
| Pogorzelski, A | 1 |
| Bobkowski, W | 1 |
| Grytczuk, M | 1 |
| Minarowska, A | 1 |
| Wójciak, R | 1 |
| Walkowiak, J | 1 |
| Lu, Y | 1 |
| Xi, J | 1 |
| Li, C | 1 |
| Chen, W | 2 |
| Hu, X | 1 |
| Zhang, F | 1 |
| Wei, H | 1 |
| Gurzu, S | 1 |
| Jung, I | 1 |
| Sugimura, H | 2 |
| Stefan-van Staden, RI | 1 |
| Yamada, H | 1 |
| Natsume, H | 1 |
| Iwashita, Y | 1 |
| Szodorai, R | 1 |
| Szederjesi, J | 1 |
| Yari, D | 1 |
| Ehsanbakhsh, Z | 1 |
| Validad, MH | 1 |
| Langroudi, FH | 1 |
| Esfandiari, H | 1 |
| Prager, A | 1 |
| Hassanpour, K | 1 |
| Kurup, SP | 1 |
| Mets-Halgrimson, R | 1 |
| Yoon, H | 1 |
| Zeid, JL | 1 |
| Mets, MB | 1 |
| Rahmani, B | 1 |
| Araujo-Castillo, RV | 1 |
| Culquichicón, C | 1 |
| Solis Condor, R | 1 |
| Efendi, F | 1 |
| Sebayang, SK | 1 |
| Astutik, E | 1 |
| Hadisuyatmana, S | 1 |
| Has, EMM | 1 |
| Kuswanto, H | 1 |
| Foroutan, T | 1 |
| Ahmadi, F | 1 |
| Moayer, F | 1 |
| Khalvati, S | 1 |
| Zhang, Q | 2 |
| Lyu, Y | 1 |
| Yu, N | 1 |
| Wen, Z | 2 |
| Hou, H | 1 |
| Zhao, T | 1 |
| Gupta, A | 1 |
| Khosla, N | 1 |
| Govindasamy, V | 1 |
| Saini, A | 1 |
| Annapurna, K | 1 |
| Dhakate, SR | 1 |
| Akkaya, Ö | 1 |
| Chandgude, AL | 1 |
| Dömling, A | 1 |
| Harnett, J | 1 |
| Oakes, K | 1 |
| Carè, J | 1 |
| Leach, M | 1 |
| Brown, D | 1 |
| Cramer, H | 1 |
| Pinder, TA | 1 |
| Steel, A | 1 |
| Anheyer, D | 1 |
| Cantu, J | 1 |
| Valle, J | 1 |
| Flores, K | 1 |
| Gonzalez, D | 1 |
| Valdes, C | 1 |
| Lopez, J | 1 |
| Padilla, V | 1 |
| Alcoutlabi, M | 1 |
| Parsons, J | 1 |
| Núñez, K | 1 |
| Hamed, M | 1 |
| Fort, D | 1 |
| Bruce, D | 1 |
| Thevenot, P | 1 |
| Cohen, A | 1 |
| Weber, P | 1 |
| Menezes, AMB | 1 |
| Gonçalves, H | 1 |
| Perez-Padilla, R | 1 |
| Jarvis, D | 1 |
| de Oliveira, PD | 1 |
| Wehrmeister, FC | 1 |
| Mir, S | 1 |
| Wong, J | 1 |
| Ryan, CM | 1 |
| Bellingham, G | 1 |
| Singh, M | 2 |
| Waseem, R | 1 |
| Eckert, DJ | 1 |
| Chung, F | 1 |
| Hegde, H | 1 |
| Shimpi, N | 1 |
| Panny, A | 1 |
| Glurich, I | 1 |
| Christie, P | 1 |
| Acharya, A | 1 |
| English, KL | 1 |
| Downs, M | 1 |
| Goetchius, E | 1 |
| Buxton, R | 1 |
| Ryder, JW | 1 |
| Ploutz-Snyder, R | 1 |
| Guilliams, M | 1 |
| Scott, JM | 1 |
| Ploutz-Snyder, LL | 1 |
| Martens, C | 1 |
| Goplen, FK | 1 |
| Aasen, T | 1 |
| Gjestad, R | 1 |
| Nordfalk, KF | 1 |
| Nordahl, SHG | 1 |
| Soshi, S | 1 |
| Kubota, M | 1 |
| Marumo, K | 1 |
| Mortensen, NP | 1 |
| Caffaro, MM | 1 |
| Patel, PR | 2 |
| Uddin, MJ | 1 |
| Aravamudhan, S | 1 |
| Sumner, SJ | 1 |
| Fennell, TR | 1 |
| Gal, RL | 1 |
| Cohen, NJ | 1 |
| Kruger, D | 1 |
| Beck, RW | 1 |
| Bergenstal, RM | 1 |
| Calhoun, P | 1 |
| Cushman, T | 1 |
| Haban, A | 1 |
| Hood, K | 1 |
| Johnson, ML | 1 |
| McArthur, T | 1 |
| Olson, BA | 1 |
| Weinstock, RS | 1 |
| Oser, SM | 1 |
| Oser, TK | 1 |
| Bugielski, B | 1 |
| Strayer, H | 1 |
| Aleppo, G | 1 |
| Maruyama, H | 1 |
| Hirayama, K | 1 |
| Yamashita, M | 1 |
| Ohgi, K | 1 |
| Tsujimoto, R | 1 |
| Takayasu, M | 1 |
| Shimohata, H | 1 |
| Kobayashi, M | 1 |
| Buscagan, TM | 1 |
| Rees, DC | 1 |
| Jaborek, JR | 1 |
| Zerby, HN | 1 |
| Wick, MP | 1 |
| Fluharty, FL | 1 |
| Moeller, SJ | 1 |
| Razavi, P | 1 |
| Dickler, MN | 1 |
| Shah, PD | 1 |
| Toy, W | 1 |
| Brown, DN | 1 |
| Won, HH | 1 |
| Li, BT | 1 |
| Shen, R | 1 |
| Vasan, N | 1 |
| Modi, S | 1 |
| Jhaveri, K | 1 |
| Caravella, BA | 1 |
| Patil, S | 1 |
| Selenica, P | 1 |
| Zamora, S | 1 |
| Cowan, AM | 1 |
| Comen, E | 1 |
| Singh, A | 1 |
| Covey, A | 1 |
| Berger, MF | 1 |
| Hudis, CA | 1 |
| Norton, L | 1 |
| Nagy, RJ | 1 |
| Odegaard, JI | 1 |
| Lanman, RB | 1 |
| Solit, DB | 1 |
| Robson, ME | 1 |
| Lacouture, ME | 1 |
| Brogi, E | 1 |
| Reis-Filho, JS | 1 |
| Moynahan, ME | 1 |
| Scaltriti, M | 1 |
| Chandarlapaty, S | 1 |
| Papouskova, K | 1 |
| Moravcova, M | 1 |
| Masrati, G | 1 |
| Ben-Tal, N | 1 |
| Sychrova, H | 1 |
| Zimmermannova, O | 1 |
| Fang, J | 1 |
| Fan, Y | 1 |
| Luo, T | 2 |
| Su, H | 1 |
| Tsetseris, L | 1 |
| Anthopoulos, TD | 1 |
| Liu, SF | 1 |
| Zhao, K | 1 |
| Sacan, O | 1 |
| Turkyilmaz, IB | 1 |
| Bayrak, BB | 1 |
| Mutlu, O | 1 |
| Akev, N | 1 |
| Yanardag, R | 1 |
| Gruber, S | 1 |
| Kamnoedboon, P | 1 |
| Özcan, M | 1 |
| Srinivasan, M | 1 |
| Jo, YH | 1 |
| Oh, HK | 1 |
| Jeong, SY | 1 |
| Lee, BG | 1 |
| Zheng, J | 1 |
| Guan, H | 1 |
| Li, D | 2 |
| Tan, H | 1 |
| Maji, TK | 1 |
| J R, A | 1 |
| Mukherjee, S | 1 |
| Alexander, R | 1 |
| Mondal, A | 1 |
| Das, S | 1 |
| Sharma, RK | 1 |
| Chakraborty, NK | 1 |
| Dasgupta, K | 1 |
| Sharma, AMR | 1 |
| Hawaldar, R | 1 |
| Pandey, M | 1 |
| Naik, A | 1 |
| Majumdar, K | 1 |
| Pal, SK | 1 |
| Adarsh, KV | 1 |
| Ray, SK | 1 |
| Karmakar, D | 1 |
| Ma, Y | 3 |
| Gao, W | 1 |
| Ma, S | 1 |
| Lin, W | 1 |
| Zhou, T | 1 |
| Wu, T | 1 |
| Ye, C | 1 |
| He, X | 1 |
| Jiang, F | 1 |
| Yuan, D | 1 |
| Chen, Q | 1 |
| Hong, M | 1 |
| Chen, K | 1 |
| Razi, SS | 1 |
| Yildiz, EA | 1 |
| Yaglioglu, HG | 1 |
| Donato, MD | 1 |
| Jiang, J | 1 |
| Jamil, MI | 1 |
| Zhan, X | 1 |
| Chen, F | 1 |
| Cheng, D | 1 |
| Wu, CT | 1 |
| Utsunomiya, T | 1 |
| Ichii, T | 1 |
| Fujinami, S | 1 |
| Nakajima, K | 1 |
| Sanchez, DM | 1 |
| Raucci, U | 1 |
| Ferreras, KN | 1 |
| Martínez, TJ | 1 |
| Mordi, NA | 1 |
| Mordi, IR | 1 |
| Singh, JS | 1 |
| McCrimmon, RJ | 1 |
| Struthers, AD | 2 |
| Lang, CC | 1 |
| Wang, XW | 1 |
| Yuan, LJ | 1 |
| Yang, Y | 1 |
| Chen, WF | 1 |
| Luo, R | 1 |
| Yang, K | 1 |
| Amarasiri, SS | 1 |
| Attanayake, AP | 1 |
| Arawwawala, LDAM | 1 |
| Jayatilaka, KAPW | 1 |
| Mudduwa, LKB | 1 |
| Ogunsuyi, O | 2 |
| Akanni, O | 1 |
| Alabi, O | 1 |
| Alimba, C | 1 |
| Adaramoye, O | 1 |
| Cambier, S | 1 |
| Eswara, S | 1 |
| Gutleb, AC | 1 |
| Bakare, A | 1 |
| Gu, Z | 1 |
| Cong, J | 1 |
| Pellegrini, M | 2 |
| Palmieri, S | 1 |
| Ricci, A | 1 |
| Serio, A | 1 |
| Paparella, A | 1 |
| Lo Sterzo, C | 1 |
| Jadeja, SD | 1 |
| Vaishnav, J | 1 |
| Mansuri, MS | 1 |
| Shah, C | 1 |
| Mayatra, JM | 1 |
| Shah, A | 1 |
| Begum, R | 1 |
| Song, H | 2 |
| Lian, Y | 1 |
| Wan, T | 1 |
| Schultz-Lebahn, A | 1 |
| Skipper, MT | 1 |
| Hvas, AM | 1 |
| Larsen, OH | 1 |
| Hijazi, Z | 1 |
| Granger, CB | 1 |
| Hohnloser, SH | 1 |
| Westerbergh, J | 1 |
| Lindbäck, J | 1 |
| Alexander, JH | 1 |
| Keltai, M | 1 |
| Parkhomenko, A | 1 |
| López-Sendón, JL | 1 |
| Lopes, RD | 1 |
| Siegbahn, A | 1 |
| Wallentin, L | 1 |
| El-Tarabany, MS | 1 |
| Saleh, AA | 1 |
| El-Araby, IE | 1 |
| El-Magd, MA | 1 |
| van Ginkel, MPH | 1 |
| Schijven, MP | 1 |
| van Grevenstein, WMU | 1 |
| Schreuder, HWR | 1 |
| Pereira, EDM | 1 |
| da Silva, J | 1 |
| Carvalho, PDS | 1 |
| Grivicich, I | 1 |
| Picada, JN | 1 |
| Salgado Júnior, IB | 1 |
| Vasques, GJ | 1 |
| Pereira, MADS | 1 |
| Reginatto, FH | 1 |
| Ferraz, ABF | 1 |
| Vasilenko, EA | 1 |
| Gorshkova, EN | 1 |
| Astrakhantseva, IV | 1 |
| Drutskaya, MS | 1 |
| Tillib, SV | 1 |
| Nedospasov, SA | 1 |
| Mokhonov, VV | 1 |
| Nam, YW | 1 |
| Cui, M | 1 |
| Orfali, R | 1 |
| Viegas, A | 1 |
| Nguyen, M | 1 |
| Mohammed, EHM | 1 |
| Zoghebi, KA | 1 |
| Rahighi, S | 1 |
| Parang, K | 1 |
| Patterson, KC | 1 |
| Kahanovitch, U | 1 |
| Gonçalves, CM | 1 |
| Hablitz, JJ | 1 |
| Staruschenko, A | 1 |
| Mulkey, DK | 1 |
| Olsen, ML | 1 |
| Gu, L | 1 |
| Cao, X | 1 |
| Mukhtar, A | 1 |
| Wu, K | 1 |
| Zhang, YY | 1 |
| Lu, DZ | 1 |
| Dong, W | 1 |
| Bi, WJ | 1 |
| Feng, XJ | 1 |
| Wen, LM | 1 |
| Sun, H | 1 |
| Qi, MC | 1 |
| Chang, CC | 1 |
| Dinh, TK | 1 |
| Lee, YA | 1 |
| Wang, FN | 1 |
| Sung, YC | 1 |
| Yu, PL | 1 |
| Chiu, SC | 1 |
| Shih, YC | 1 |
| Wu, CY | 1 |
| Huang, YD | 1 |
| Lu, TT | 1 |
| Wan, D | 1 |
| Sakizadeh, J | 1 |
| Cline, JP | 1 |
| Snyder, MA | 1 |
| Kiely, CJ | 1 |
| McIntosh, S | 1 |
| Jiang, X | 1 |
| Cao, JW | 1 |
| Zhao, CK | 1 |
| Yang, R | 1 |
| Zhang, QY | 1 |
| Chen, KJ | 2 |
| He, Z | 1 |
| Chen, B | 1 |
| Du, X | 1 |
| Moore, J | 1 |
| Blank, BR | 1 |
| Eksterowicz, J | 1 |
| Sutimantanapi, D | 1 |
| Yuen, N | 1 |
| Metzger, T | 1 |
| Chan, B | 1 |
| Huang, T | 1 |
| Duong, F | 1 |
| Kong, W | 1 |
| Chang, JH | 1 |
| Sun, J | 1 |
| Zavorotinskaya, T | 1 |
| Ye, Q | 1 |
| Junttila, MR | 1 |
| Ndubaku, C | 1 |
| Friedman, LS | 1 |
| Fantin, VR | 1 |
| Sun, D | 1 |
| Fei, P | 1 |
| Xie, Q | 1 |
| Jiang, Y | 1 |
| Feng, H | 1 |
| Chang, Y | 1 |
| Kang, H | 1 |
| Xing, M | 1 |
| Chen, J | 2 |
| Shao, Z | 1 |
| Yuan, C | 1 |
| Allan, R | 1 |
| Canham, K | 1 |
| Wallace, R | 1 |
| Singh, D | 1 |
| Ward, J | 1 |
| Cooper, A | 1 |
| Newcomb, C | 1 |
| Nammour, S | 1 |
| El Mobadder, M | 1 |
| Maalouf, E | 1 |
| Namour, M | 1 |
| Namour, A | 1 |
| Rey, G | 1 |
| Matamba, P | 1 |
| Matys, J | 1 |
| Zeinoun, T | 1 |
| Grzech-Leśniak, K | 1 |
| Segabinazi Peserico, C | 1 |
| Garozi, L | 1 |
| Zagatto, AM | 1 |
| Machado, FA | 1 |
| Hirth, JM | 1 |
| Dinehart, EE | 1 |
| Lin, YL | 1 |
| Kuo, YF | 1 |
| Nouri, SS | 1 |
| Ritchie, C | 1 |
| Volow, A | 1 |
| Li, B | 2 |
| McSpadden, S | 1 |
| Dearman, K | 1 |
| Kotwal, A | 1 |
| Sudore, RL | 1 |
| Ward, L | 1 |
| Thakur, A | 1 |
| Kondadasula, SV | 1 |
| Ji, K | 1 |
| Schalk, DL | 1 |
| Bliemeister, E | 1 |
| Ung, J | 1 |
| Aboukameel, A | 1 |
| Casarez, E | 1 |
| Sloane, BF | 1 |
| Lum, LG | 1 |
| Xiao, M | 1 |
| Feng, X | 1 |
| Gao, R | 1 |
| Du, B | 1 |
| Brooks, T | 1 |
| Zwirner, J | 1 |
| Hammer, N | 1 |
| Ondruschka, B | 1 |
| Jermy, M | 1 |
| Luengo, A | 1 |
| Marzo, I | 1 |
| Reback, M | 1 |
| Daubit, IM | 1 |
| Fernández-Moreira, V | 1 |
| Metzler-Nolte, N | 1 |
| Gimeno, MC | 1 |
| Tonchev, I | 1 |
| Heberman, D | 1 |
| Peretz, A | 1 |
| Medvedovsky, AT | 1 |
| Gotsman, I | 2 |
| Rashi, Y | 1 |
| Poles, L | 1 |
| Goland, S | 1 |
| Perlman, GY | 1 |
| Danenberg, HD | 1 |
| Beeri, R | 1 |
| Shuvy, M | 1 |
| Fu, Q | 1 |
| Yang, D | 1 |
| Sarapulova, A | 1 |
| Pang, Q | 1 |
| Meng, Y | 1 |
| Wei, L | 1 |
| Ehrenberg, H | 1 |
| Kim, CC | 1 |
| Jeong, SH | 1 |
| Oh, KH | 1 |
| Nam, KT | 1 |
| Sun, JY | 1 |
| Ning, J | 1 |
| Duan, Z | 1 |
| Kershaw, SV | 1 |
| Rogach, AL | 1 |
| Gao, Z | 1 |
| Wang, T | 1 |
| Li, Q | 1 |
| Cao, T | 1 |
| Guo, L | 1 |
| Fu, Y | 1 |
| Seeger, ZL | 1 |
| Izgorodina, EI | 1 |
| Hue, S | 1 |
| Beldi-Ferchiou, A | 1 |
| Bendib, I | 1 |
| Surenaud, M | 1 |
| Fourati, S | 1 |
| Frapard, T | 1 |
| Rivoal, S | 1 |
| Razazi, K | 1 |
| Carteaux, G | 1 |
| Delfau-Larue, MH | 1 |
| Mekontso-Dessap, A | 1 |
| Audureau, E | 1 |
| de Prost, N | 1 |
| Gao, SS | 1 |
| Duangthip, D | 1 |
| Lo, ECM | 1 |
| Chu, CH | 1 |
| Roberts, W | 1 |
| Rosenheck, RA | 1 |
| Miyake, T | 1 |
| Kimoto, E | 1 |
| Luo, L | 1 |
| Mathialagan, S | 1 |
| Horlbogen, LM | 1 |
| Ramanathan, R | 1 |
| Wood, LS | 1 |
| Johnson, JG | 1 |
| Le, VH | 1 |
| Vourvahis, M | 1 |
| Rodrigues, AD | 1 |
| Muto, C | 1 |
| Furihata, K | 1 |
| Sugiyama, Y | 1 |
| Kusuhara, H | 1 |
| Gong, Q | 1 |
| Song, W | 1 |
| Sun, B | 1 |
| Cao, P | 1 |
| Gu, S | 1 |
| Sun, X | 1 |
| Zhou, G | 1 |
| Toma, C | 1 |
| Khandhar, S | 1 |
| Zalewski, AM | 1 |
| D'Auria, SJ | 1 |
| Tu, TM | 1 |
| Jaber, WA | 1 |
| Cho, J | 2 |
| Suwandaratne, NS | 1 |
| Razek, S | 1 |
| Choi, YH | 1 |
| Piper, LFJ | 1 |
| Watson, DF | 1 |
| Banerjee, S | 1 |
| Xie, S | 1 |
| Lindsay, AP | 1 |
| Bates, FS | 1 |
| Lodge, TP | 1 |
| Hao, Y | 1 |
| Chapovetsky, A | 1 |
| Liu, JJ | 1 |
| Welborn, M | 1 |
| Luna, JM | 1 |
| Do, T | 1 |
| Haiges, R | 1 |
| Miller Iii, TF | 1 |
| Marinescu, SC | 1 |
| Lopez, SA | 1 |
| Compter, I | 1 |
| Eekers, DBP | 1 |
| Hoeben, A | 1 |
| Rouschop, KMA | 1 |
| Reymen, B | 1 |
| Ackermans, L | 1 |
| Beckervordersantforth, J | 1 |
| Bauer, NJC | 1 |
| Anten, MM | 1 |
| Wesseling, P | 1 |
| Postma, AA | 1 |
| De Ruysscher, D | 1 |
| Lambin, P | 1 |
| Qiang, L | 1 |
| Yang, S | 1 |
| Cui, YH | 1 |
| He, YY | 1 |
| Kumar, SK | 1 |
| Jacobus, SJ | 1 |
| Cohen, AD | 1 |
| Weiss, M | 1 |
| Callander, N | 1 |
| Singh, AK | 1 |
| Parker, TL | 1 |
| Menter, A | 1 |
| Parsons, B | 1 |
| Kumar, P | 1 |
| Kapoor, P | 1 |
| Rosenberg, A | 1 |
| Zonder, JA | 1 |
| Faber, E | 1 |
| Lonial, S | 1 |
| Anderson, KC | 1 |
| Richardson, PG | 1 |
| Orlowski, RZ | 1 |
| Wagner, LI | 1 |
| Rajkumar, SV | 2 |
| Li, G | 1 |
| Hou, G | 1 |
| Cui, J | 1 |
| Xie, H | 1 |
| Sun, Z | 1 |
| Fang, Z | 1 |
| Dunstand-Guzmán, E | 1 |
| Hallal-Calleros, C | 1 |
| Hernández-Velázquez, VM | 1 |
| Canales-Vargas, EJ | 1 |
| Domínguez-Roldan, R | 1 |
| Pedernera, M | 1 |
| Peña-Chora, G | 1 |
| Flores-Pérez, I | 1 |
| Kim, MJ | 1 |
| Han, C | 1 |
| White, K | 1 |
| Park, HJ | 2 |
| Ding, D | 1 |
| Boyd, K | 1 |
| Rothenberger, C | 1 |
| Bose, U | 1 |
| Carmichael, P | 1 |
| Linser, PJ | 1 |
| Tanokura, M | 1 |
| Salvi, R | 1 |
| Someya, S | 1 |
| Samuni, A | 1 |
| Goldstein, S | 1 |
| Divya, KP | 1 |
| Dharuman, V | 1 |
| Qian, Y | 1 |
| Cheng, Q | 1 |
| Ma, H | 1 |
| Ren, X | 1 |
| Wei, Q | 1 |
| Pan, W | 1 |
| Guo, J | 1 |
| Situ, B | 1 |
| An, T | 1 |
| Zheng, L | 1 |
| Augusto, S | 1 |
| Ratola, N | 1 |
| Tarín-Carrasco, P | 1 |
| Jiménez-Guerrero, P | 1 |
| Turco, M | 1 |
| Schuhmacher, M | 1 |
| Costa, S | 1 |
| Teixeira, JP | 1 |
| Costa, C | 2 |
| Syed, A | 1 |
| Marraiki, N | 1 |
| Al-Rashed, S | 1 |
| Elgorban, AM | 1 |
| Yassin, MT | 1 |
| Chankhanittha, T | 1 |
| Nanan, S | 1 |
| Sorokina, KN | 1 |
| Samoylova, YV | 1 |
| Gromov, NV | 1 |
| Ogorodnikova, OL | 1 |
| Parmon, VN | 1 |
| Ye, J | 1 |
| Liao, W | 1 |
| Zhang, P | 1 |
| Nabi, M | 1 |
| Cai, Y | 1 |
| Li, F | 1 |
| Alsbou, EM | 1 |
| Omari, KW | 1 |
| Adeosun, WA | 1 |
| Asiri, AM | 1 |
| Marwani, HM | 1 |
| Barral, M | 1 |
| Jemal-Turki, A | 1 |
| Beuvon, F | 1 |
| Soyer, P | 1 |
| Camparo, P | 1 |
| Cornud, F | 1 |
| Atwater, BD | 1 |
| Jones, WS | 1 |
| Loring, Z | 1 |
| Friedman, DJ | 1 |
| Namburath, M | 1 |
| Papirio, S | 1 |
| Moscariello, C | 1 |
| Di Costanzo, N | 1 |
| Pirozzi, F | 1 |
| Alappat, BJ | 1 |
| Sreekrishnan, TR | 1 |
| Volpin, F | 1 |
| Woo, YC | 1 |
| Kim, H | 2 |
| Freguia, S | 1 |
| Jeong, N | 1 |
| Choi, JS | 1 |
| Phuntsho, S | 1 |
| Shon, HK | 1 |
| Domínguez-Zambrano, E | 1 |
| Pedraza-Chaverri, J | 1 |
| López-Santos, AL | 1 |
| Medina-Campos, ON | 1 |
| Cruz-Rivera, C | 1 |
| Bueno-Hernández, F | 1 |
| Espinosa-Cuevas, A | 1 |
| Bulavaitė, A | 1 |
| Dalgediene, I | 1 |
| Michailoviene, V | 1 |
| Pleckaityte, M | 1 |
| Sauerbier, P | 1 |
| Köhler, R | 1 |
| Renner, G | 1 |
| Militz, H | 1 |
| Ardahanli, I | 1 |
| Celik, M | 1 |
| Kodama, S | 1 |
| Fujihara, K | 1 |
| Horikawa, C | 1 |
| Yamada, M | 1 |
| Yaguchi, Y | 1 |
| Yamamoto, M | 1 |
| Kitazawa, M | 1 |
| Matsubayashi, Y | 1 |
| Yamada, T | 1 |
| Sone, H | 1 |
| Tedeschi, A | 1 |
| Agostoni, P | 1 |
| Pezzuto, B | 1 |
| Corra', U | 1 |
| Scrutinio, D | 1 |
| La Gioia, R | 1 |
| Raimondo, R | 1 |
| Passantino, A | 1 |
| Piepoli, MF | 2 |
| Sandoval-Plata, G | 1 |
| Nakafero, G | 1 |
| Chakravorty, M | 1 |
| Morgan, K | 1 |
| Abhishek, A | 1 |
| Fujihashi, T | 1 |
| Sakata, Y | 1 |
| Nochioka, K | 1 |
| Miura, M | 1 |
| Abe, R | 1 |
| Kasahara, S | 1 |
| Sato, M | 1 |
| Aoyanagi, H | 1 |
| Yamanaka, S | 1 |
| Hayashi, H | 1 |
| Shiroto, T | 1 |
| Sugimura, K | 1 |
| Takahashi, J | 1 |
| Miyata, S | 1 |
| Shimokawa, H | 1 |
| Wakita, M | 1 |
| Asai, K | 5 |
| Kubota, Y | 1 |
| Koen, M | 1 |
| Shimizu, W | 5 |
| Joseph, J | 1 |
| Giczewska, A | 1 |
| Cheema, AK | 1 |
| Handy, DE | 1 |
| Mann, DL | 2 |
| Loscalzo, J | 1 |
| Givertz, MM | 3 |
| Del Pinto, R | 1 |
| Carubbi, F | 1 |
| Russo, E | 1 |
| Sanikidze, Q | 1 |
| Mamacashvili, I | 1 |
| Petriashvili, S | 1 |
| Chang, Z | 1 |
| Zhou, XH | 1 |
| Wen, X | 1 |
| Ambrosio, G | 2 |
| Leiro, MGC | 1 |
| Lund, LH | 1 |
| Coiro, S | 2 |
| Cardona, A | 1 |
| Ferrari, R | 1 |
| Coats, AJS | 1 |
| Laroche, C | 1 |
| Almenar-Bonet, L | 1 |
| Poder, P | 1 |
| Valero, DB | 1 |
| Frisinghelli, A | 1 |
| Gulab, A | 1 |
| Torres, R | 1 |
| Pelayo, J | 1 |
| Lo, KB | 1 |
| Shahzad, A | 1 |
| Pradhan, S | 1 |
| Rangaswami, J | 1 |
| Seki, H | 1 |
| Itoh, H | 1 |
| Morita, K | 1 |
| Matsuoka, S | 1 |
| Kiriyama, H | 1 |
| Kamon, T | 1 |
| Fujiu, K | 1 |
| Michihata, N | 1 |
| Jo, T | 1 |
| Takeda, N | 1 |
| Yano, Y | 1 |
| Nakamura, S | 1 |
| Yasunaga, H | 1 |
| Liu, CF | 1 |
| Song, KY | 1 |
| Zhou, WN | 1 |
| Wei, YJ | 1 |
| Szygula-Jurkiewicz, B | 1 |
| Szczurek, W | 1 |
| Skrzypek, M | 1 |
| Zakliczyński, M | 2 |
| Siedlecki, Ł | 1 |
| Przybyłowski, P | 1 |
| Zembala, M | 2 |
| Gąsior, M | 1 |
| Chen, YJ | 1 |
| Huang, WM | 2 |
| Wu, CL | 1 |
| Huang, CJ | 1 |
| Yeh, JS | 1 |
| Yu, WC | 2 |
| Chen, CH | 3 |
| Yang, LT | 1 |
| Kado, Y | 1 |
| Nagata, Y | 1 |
| Otani, K | 1 |
| Otsuji, Y | 1 |
| Takeuchi, M | 1 |
| Caussé, E | 1 |
| Fournier, P | 1 |
| Roncalli, J | 1 |
| Salvayre, R | 1 |
| Galinier, M | 1 |
| De Vivo, O | 1 |
| Nuti, R | 2 |
| McCullough, PA | 2 |
| Mogensen, UM | 1 |
| Kristensen, SL | 1 |
| Ramires, F | 1 |
| Prescott, MF | 1 |
| Swedberg, K | 2 |
| Wannamethee, SG | 1 |
| Papacosta, O | 1 |
| Lennon, L | 1 |
| Whincup, PH | 1 |
| Costanzo, MR | 1 |
| Fan, YQ | 1 |
| Zhang, HL | 1 |
| Lucci, D | 1 |
| Gonzini, L | 1 |
| Nicolosi, GL | 1 |
| Tognoni, G | 1 |
| Cosmi, F | 1 |
| Carluccio, E | 1 |
| Biagioli, P | 1 |
| Alunni, G | 1 |
| Murrone, A | 1 |
| D'Antonio, A | 1 |
| Zuchi, C | 1 |
| Mengoni, A | 1 |
| Girerd, N | 2 |
| Marcinkiewicz-Siemion, M | 1 |
| Ciborowski, M | 1 |
| Ptaszynska-Kopczynska, K | 1 |
| Szpakowicz, A | 1 |
| Lisowska, A | 1 |
| Jasiewicz, M | 1 |
| Waszkiewicz, E | 1 |
| Kretowski, A | 1 |
| Musial, WJ | 1 |
| Kaminski, KA | 1 |
| Nodera, M | 1 |
| Suzuki, H | 1 |
| Matsumoto, Y | 1 |
| Kamioka, M | 1 |
| Kaneshiro, T | 1 |
| Ohira, T | 1 |
| Owczarek, AJ | 1 |
| Choręza, P | 1 |
| Arabzada, H | 1 |
| Chudek, J | 1 |
| Wojnicz, R | 1 |
| Takimura, H | 1 |
| Hada, T | 1 |
| Kawano, M | 1 |
| Yabe, T | 1 |
| Takimura, Y | 1 |
| Nishio, S | 1 |
| Nakano, M | 1 |
| Tsukahara, R | 1 |
| Muramatsu, T | 1 |
| Stubnova, V | 1 |
| Os, I | 1 |
| Høieggen, A | 1 |
| Solbu, MD | 1 |
| Grundtvig, M | 1 |
| Westheim, AS | 1 |
| Atar, D | 2 |
| Waldum-Grevbo, B | 1 |
| Okazaki, H | 4 |
| Shirakabe, A | 4 |
| Matsushita, M | 4 |
| Shibata, Y | 2 |
| Sawatani, T | 1 |
| Uchiyama, S | 1 |
| Tani, K | 1 |
| Takayasu, T | 1 |
| Asano, M | 1 |
| Kobayashi, N | 4 |
| Hata, N | 4 |
| Perge, P | 1 |
| Boros, AM | 1 |
| Zima, E | 1 |
| Gellér, L | 1 |
| Merkely, B | 1 |
| Széplaki, G | 1 |
| Zhou, HB | 1 |
| Xu, TY | 1 |
| Liu, SR | 1 |
| Bai, YJ | 1 |
| Huang, XF | 1 |
| Zhan, Q | 1 |
| Zeng, QC | 1 |
| Xu, DL | 2 |
| Qin, J | 1 |
| Deng, X | 1 |
| Luo, G | 1 |
| Zhou, S | 1 |
| Pavlusova, M | 1 |
| Jarkovsky, J | 2 |
| Benesova, K | 1 |
| Vitovec, J | 2 |
| Linhart, A | 2 |
| Widimsky, P | 2 |
| Spinarova, L | 1 |
| Zeman, K | 1 |
| Belohlavek, J | 1 |
| Malek, F | 2 |
| Felsoci, M | 1 |
| Kettner, J | 1 |
| Ostadal, P | 2 |
| Cihalik, C | 1 |
| Spac, J | 1 |
| Al-Hiti, H | 1 |
| Fedorco, M | 2 |
| Fojt, R | 1 |
| Kruger, A | 2 |
| Malek, J | 1 |
| Mikusova, T | 1 |
| Monhart, Z | 1 |
| Bohacova, S | 1 |
| Pohludkova, L | 1 |
| Rohac, F | 1 |
| Vaclavik, J | 1 |
| Vondrakova, D | 2 |
| Vyskocilova, K | 1 |
| Bambuch, M | 1 |
| Dostalova, G | 1 |
| Havranek, S | 1 |
| Svobodová, I | 1 |
| Dusek, L | 1 |
| Spinar, J | 2 |
| Miklik, R | 2 |
| Parenica, J | 2 |
| Stamp, LK | 1 |
| Frampton, C | 1 |
| Drake, J | 1 |
| Doughty, RN | 1 |
| Troughton, RW | 1 |
| Richards, AM | 1 |
| Song, LL | 1 |
| Zhang, XR | 1 |
| Song, YN | 1 |
| Dai, HZ | 1 |
| de Denus, S | 1 |
| Larina, VN | 3 |
| Bart, BIa | 2 |
| Larin, VG | 2 |
| Donskov, AS | 2 |
| Rosenbaum, AN | 1 |
| Duval, S | 1 |
| Adatya, S | 1 |
| Khan, MB | 1 |
| John, R | 1 |
| Eckman, PM | 1 |
| Kannangara, DR | 1 |
| Graham, GG | 1 |
| Williams, KM | 1 |
| Day, RO | 1 |
| Liu, K | 4 |
| Koza, Y | 2 |
| Simsek, Z | 1 |
| Tas, MH | 1 |
| Huang, B | 1 |
| Jing, X | 1 |
| Tekin, G | 2 |
| Tekin, YK | 2 |
| Cosentino, ER | 1 |
| Rinaldi, ER | 1 |
| Cicero, AF | 1 |
| Rinkuniene, D | 1 |
| Bucyte, S | 1 |
| Ceseviciute, K | 1 |
| Abramavicius, S | 1 |
| Baronaite-Dudoniene, K | 1 |
| Laukaitiene, J | 1 |
| Kazakevicius, T | 1 |
| Zabiela, V | 1 |
| Sileikis, V | 1 |
| Puodziukynas, A | 1 |
| Jurkevicius, R | 1 |
| Radovanovic, S | 1 |
| Savic-Radojevic, A | 1 |
| Pekmezovic, T | 1 |
| Markovic, O | 1 |
| Memon, L | 1 |
| Jelic, S | 1 |
| Simic, D | 1 |
| Radic, T | 1 |
| Pljesa-Ercegovac, M | 1 |
| Simic, T | 1 |
| Altay, S | 1 |
| Onat, A | 1 |
| Özpamuk-Karadeniz, F | 1 |
| Karadeniz, Y | 1 |
| Kemaloğlu-Öz, T | 1 |
| Can, G | 1 |
| Karabacak, M | 1 |
| Dogan, A | 1 |
| Tayyar, S | 1 |
| Bas, HA | 1 |
| Greene, SJ | 1 |
| Ambrosy, AP | 1 |
| Subacius, HP | 1 |
| Chioncel, O | 1 |
| Gheorghiade, M | 1 |
| Gazi, E | 1 |
| Temiz, A | 1 |
| Altun, B | 1 |
| Barutçu, A | 1 |
| Bekler, A | 1 |
| Güngör, O | 1 |
| Yener, AU | 1 |
| Kurt, T | 1 |
| Ozcan, S | 1 |
| Gazi, S | 1 |
| Eren, M | 2 |
| Rich, JD | 1 |
| Rich, S | 1 |
| Wojciechowska, C | 1 |
| Romuk, E | 1 |
| Tomasik, A | 1 |
| Skrzep-Poloczek, B | 1 |
| Nowalany-Kozielska, E | 1 |
| Birkner, E | 1 |
| Jacheć, W | 1 |
| Kolomiets, MV | 1 |
| Bil'chenko, AV | 1 |
| Ohuchi, H | 1 |
| Negishi, J | 1 |
| Hayama, Y | 1 |
| Sasaki, O | 1 |
| Taniguchi, Y | 1 |
| Noritake, K | 1 |
| Miyazaki, A | 1 |
| Yamada, O | 1 |
| Meng, H | 1 |
| Liu, G | 2 |
| Zhai, J | 1 |
| Zhen, Y | 3 |
| Zheng, M | 1 |
| Ma, G | 1 |
| Tian, L | 2 |
| Ji, L | 2 |
| Duan, L | 1 |
| Li, L | 1 |
| Tominaga, N | 1 |
| Matsumoto, N | 1 |
| Akashi, YJ | 1 |
| Miyake, F | 1 |
| Kimura, K | 2 |
| Shibagaki, Y | 1 |
| Rywik, TM | 1 |
| Janas, J | 1 |
| Klisiewicz, A | 1 |
| Leszek, P | 1 |
| Sobieszczańska-Małek, M | 1 |
| Kurjata, P | 1 |
| Rozentryt, P | 1 |
| Korewicki, J | 1 |
| Jerzak-Wodzyńska, G | 1 |
| Zieliński, T | 1 |
| Warriner, D | 1 |
| Sheridan, P | 1 |
| Lawford, P | 1 |
| Nogi, S | 1 |
| Fujita, S | 1 |
| Okamoto, Y | 1 |
| Kizawa, S | 1 |
| Ito, T | 1 |
| Sakane, K | 1 |
| Sohmiya, K | 1 |
| Hoshiga, M | 1 |
| Ishizaka, N | 1 |
| Kawabe, M | 1 |
| Sato, A | 1 |
| Hoshi, T | 1 |
| Sakai, S | 1 |
| Hiraya, D | 1 |
| Watabe, H | 1 |
| Kakefuda, Y | 1 |
| Ishibashi, M | 1 |
| Abe, D | 1 |
| Takeyasu, N | 1 |
| Aonuma, K | 1 |
| Jankowska, EA | 2 |
| Springer, J | 2 |
| Lainscak, M | 2 |
| von Lueder, TG | 1 |
| Agewall, S | 1 |
| Lamiral, Z | 1 |
| Pitt, B | 1 |
| Dickstein, K | 1 |
| Lu, DY | 1 |
| Cheng, YL | 1 |
| Xiao, J | 1 |
| Deng, SB | 1 |
| She, Q | 1 |
| Kao, GY | 1 |
| Wang, JS | 1 |
| Beltrami, M | 1 |
| Giordano, N | 1 |
| Zhai, JL | 1 |
| Zhang, JX | 1 |
| Franco, J | 1 |
| Formiga, F | 1 |
| Chivite, D | 1 |
| Cerda, P | 1 |
| Corbella, X | 1 |
| Shinada, T | 3 |
| Yamamoto, Y | 3 |
| Shibuya, J | 3 |
| Shiomura, R | 3 |
| Nishigoori, S | 3 |
| Wu, N | 1 |
| Dai, W | 1 |
| Jiang, L | 1 |
| Ranjith, N | 1 |
| Myeni, NN | 1 |
| Sartorius, B | 1 |
| Mayise, C | 1 |
| Tuven, B | 1 |
| Soysal, P | 1 |
| Unutmaz, G | 1 |
| Kaya, D | 1 |
| Isik, AT | 1 |
| Kushiyama, A | 1 |
| Nakatsu, Y | 1 |
| Matsunaga, Y | 1 |
| Yamamotoya, T | 1 |
| Mori, K | 1 |
| Ueda, K | 1 |
| Sakoda, H | 1 |
| Fujishiro, M | 1 |
| Ono, H | 1 |
| Asano, T | 1 |
| Pakzad, R | 1 |
| Ashrafi-Asgarabad, A | 1 |
| Safiri, S | 1 |
| Otsuka, T | 1 |
| Essex, MN | 1 |
| Hopps, M | 1 |
| Bienen, EJ | 1 |
| Udall, M | 1 |
| Mardekian, J | 1 |
| Makinson, GT | 1 |
| Mehrpooya, M | 1 |
| Larti, F | 1 |
| Nozari, Y | 1 |
| Sattarzadeh-Badkoobeh, R | 1 |
| Zand Parsa, AF | 1 |
| Zebardast, J | 1 |
| Tavoosi, A | 1 |
| Shahbazi, F | 1 |
| Bart, BY | 1 |
| Hare, JM | 5 |
| Mangal, B | 2 |
| Brown, J | 2 |
| Fisher, C | 1 |
| Freudenberger, R | 1 |
| Colucci, WS | 1 |
| Liu, P | 1 |
| Schwarz, RP | 1 |
| Tang, WH | 1 |
| Alcaino, H | 3 |
| Greig, D | 3 |
| Chiong, M | 3 |
| Verdejo, H | 3 |
| Miranda, R | 1 |
| Concepcion, R | 1 |
| Vukasovic, JL | 1 |
| Diaz-Araya, G | 2 |
| Mellado, R | 2 |
| Garcia, L | 3 |
| Salas, D | 1 |
| Gonzalez, L | 1 |
| Godoy, I | 1 |
| Castro, P | 3 |
| Lavandero, S | 3 |
| Gagliardi, AC | 1 |
| Miname, MH | 1 |
| Santos, RD | 1 |
| Sierra, C | 1 |
| Coca, A | 1 |
| Landmesser, U | 2 |
| Pizarro, M | 1 |
| Jindrich, S | 1 |
| Ondrej, L | 1 |
| Viktor, M | 1 |
| Zbynek, P | 1 |
| Tomas, P | 1 |
| Ladislav, D | 1 |
| Jiri, V | 1 |
| Lenka, S | 1 |
| Miroslav, S | 1 |
| von Haehling, S | 5 |
| Szymanowska, K | 1 |
| Piatkowska, A | 1 |
| Nowicka, A | 1 |
| Michalski, M | 1 |
| Dankowski, R | 1 |
| Kandziora, M | 1 |
| Biegalski, W | 1 |
| Wierzchowiecki, M | 1 |
| Poprawski, K | 1 |
| Oh, J | 2 |
| Won, HY | 1 |
| Kang, SM | 2 |
| Ekundayo, OJ | 1 |
| Dell'Italia, LJ | 1 |
| Sanders, PW | 1 |
| Arnett, D | 1 |
| Aban, I | 1 |
| Love, TE | 1 |
| Lloyd-Jones, DM | 1 |
| Bakris, G | 1 |
| Mujib, M | 1 |
| Ahmed, A | 2 |
| Alimonda, AL | 1 |
| Núñez, J | 1 |
| Núñez, E | 1 |
| Husser, O | 1 |
| Sanchis, J | 1 |
| Bodí, V | 1 |
| Miñana, G | 1 |
| Robles, R | 1 |
| Mainar, L | 1 |
| Merlos, P | 1 |
| Darmofal, H | 1 |
| Llácer, A | 1 |
| Kitahara, T | 2 |
| Sasaki, T | 2 |
| Ishino, M | 2 |
| Kubota, I | 3 |
| Kempf, T | 1 |
| Wollert, KC | 1 |
| Holme, I | 2 |
| Aastveit, AH | 2 |
| Hammar, N | 2 |
| Jungner, I | 2 |
| Walldius, G | 2 |
| Trachtenberg, BH | 1 |
| Zhang, YH | 1 |
| Lü, R | 1 |
| Zhao, XY | 1 |
| Kang, LM | 1 |
| Yang, YJ | 1 |
| Arora, S | 1 |
| Aukrust, P | 1 |
| Ueland, T | 1 |
| Broch, K | 1 |
| Simonsen, S | 1 |
| Gude, E | 1 |
| Fiane, AE | 1 |
| Geiran, O | 1 |
| Wergeland, R | 1 |
| Andreassen, AK | 1 |
| Gullestad, L | 1 |
| Gupta, S | 1 |
| McMahan, Z | 1 |
| Patel, PC | 1 |
| Markham, DW | 1 |
| Drazner, MH | 1 |
| Mammen, PP | 1 |
| Reichlin, T | 1 |
| Potocki, M | 1 |
| Breidthardt, T | 1 |
| Noveanu, M | 1 |
| Hartwiger, S | 1 |
| Burri, E | 1 |
| Klima, T | 1 |
| Stelzig, C | 1 |
| Laule, K | 1 |
| Mebazaa, A | 1 |
| Christ, M | 1 |
| Mueller, C | 1 |
| Lizak, MK | 1 |
| Jarosz, A | 1 |
| Krishnan, E | 1 |
| Ogino, K | 1 |
| Kato, M | 1 |
| Furuse, Y | 1 |
| Kinugasa, Y | 1 |
| Ishida, K | 1 |
| Osaki, S | 1 |
| Kinugawa, T | 1 |
| Igawa, O | 1 |
| Shigemasa, C | 1 |
| Hong, N | 1 |
| Hamaguchi, S | 1 |
| Furumoto, T | 1 |
| Tsuchihashi-Makaya, M | 1 |
| Goto, K | 1 |
| Goto, D | 1 |
| Yokota, T | 1 |
| Kinugawa, S | 1 |
| Yokoshiki, H | 1 |
| Takeshita, A | 1 |
| Tsutsui, H | 1 |
| Bode-Böger, SM | 1 |
| Martens-Lobenhoffer, J | 1 |
| Rauchhaus, M | 4 |
| Schefold, JC | 1 |
| Genth-Zotz, S | 2 |
| Karhausen, T | 1 |
| Cicoira, M | 3 |
| Park, HS | 1 |
| Sohn, JH | 1 |
| Shin, HW | 1 |
| Cho, YK | 1 |
| Yoon, HJ | 1 |
| Nam, CW | 1 |
| Hur, SH | 1 |
| Kim, YN | 1 |
| Kim, KB | 1 |
| Desai, RV | 1 |
| Ahmed, MI | 1 |
| Fonarow, GC | 1 |
| Filippatos, GS | 1 |
| White, M | 1 |
| Aban, IB | 1 |
| Aronow, WS | 1 |
| Bilim, O | 1 |
| Baldasseroni, S | 1 |
| Urso, R | 1 |
| Orso, F | 1 |
| Fabbri, G | 1 |
| Marchionni, N | 1 |
| Dorsch, MP | 1 |
| Gillespie, BW | 1 |
| Erickson, SR | 1 |
| Bleske, BE | 1 |
| Weder, AB | 1 |
| Misra, D | 1 |
| Choi, HK | 1 |
| Manzano, L | 1 |
| Babalis, D | 1 |
| Roughton, M | 1 |
| Shibata, M | 1 |
| Ghio, S | 1 |
| Cohen-Solal, A | 1 |
| Coats, AJ | 9 |
| Poole-Wilson, PP | 1 |
| Flather, MD | 1 |
| Brodskiĭ, MS | 1 |
| Quiroga, C | 1 |
| Kaya, MG | 1 |
| Uyarel, H | 1 |
| Akpek, M | 1 |
| Kalay, N | 1 |
| Ergelen, M | 1 |
| Ayhan, E | 1 |
| Isik, T | 1 |
| Cicek, G | 1 |
| Elcik, D | 1 |
| Sahin, O | 1 |
| Cosgun, SM | 1 |
| Oguzhan, A | 1 |
| Gibson, CM | 1 |
| Kozdağ, G | 1 |
| Ertaş, G | 1 |
| Aygün, F | 1 |
| Emre, E | 1 |
| Kirbaş, A | 1 |
| Ural, D | 1 |
| Soran, O | 1 |
| Du, ZY | 1 |
| Shen, A | 1 |
| Su, L | 1 |
| Liang, JQ | 1 |
| Yamada, Y | 1 |
| Okuda, S | 1 |
| Kataoka, M | 1 |
| Tanimoto, A | 1 |
| Tamura, Y | 1 |
| Abe, T | 1 |
| Okamura, T | 1 |
| Fukuda, K | 1 |
| Satoh, T | 1 |
| Kuribayashi, S | 1 |
| Kaufman, M | 1 |
| Guglin, M | 1 |
| Erbay, AR | 1 |
| Turhan, H | 1 |
| Yetkin, E | 1 |
| Coufal, Z | 1 |
| Kuo, CF | 1 |
| See, LC | 1 |
| Yu, KH | 1 |
| Chou, IJ | 1 |
| Chiou, MJ | 1 |
| Luo, SF | 1 |
| Keren, A | 1 |
| Lotan, C | 1 |
| Zwas, DR | 1 |
| Bishu, K | 1 |
| Deswal, A | 1 |
| Chen, HH | 1 |
| LeWinter, MM | 1 |
| Lewis, GD | 1 |
| Semigran, MJ | 1 |
| Borlaug, BA | 1 |
| McNulty, S | 1 |
| Braunwald, E | 1 |
| Redfield, MM | 1 |
| Kapoor, S | 1 |
| Lennie, TA | 1 |
| Moser, DK | 1 |
| Biddle, MJ | 1 |
| Welsh, D | 1 |
| Bruckner, GG | 1 |
| Thomas, DT | 1 |
| Rayens, MK | 1 |
| Bailey, AL | 1 |
| Eisen, A | 1 |
| Benderly, M | 1 |
| Goldbourt, U | 1 |
| Haim, M | 1 |
| Ji, Z | 1 |
| Spieker, LE | 1 |
| Ruschitzka, FT | 1 |
| Lüscher, TF | 1 |
| Noll, G | 1 |
| Olexa, P | 1 |
| Olexová, M | 1 |
| Gonsorcík, J | 1 |
| Tkác, I | 1 |
| Kisel'ová, J | 1 |
| Olejníková, M | 1 |
| Podbregar, M | 1 |
| Voga, G | 1 |
| Kalra, PR | 1 |
| Bolger, AP | 2 |
| Francis, DP | 1 |
| Sharma, R | 3 |
| Ponikowski, PP | 1 |
| Poole-Wilson, PA | 3 |
| Johnson, RJ | 1 |
| Francis, D | 1 |
| Knosalla, C | 1 |
| Davos, CH | 2 |
| Shamim, W | 1 |
| Kemp, M | 1 |
| Segal, R | 1 |
| Osterziel, KJ | 1 |
| Leyva, F | 5 |
| Hetzer, R | 1 |
| Sitnikova, MIu | 1 |
| Shliakhto, EV | 1 |
| WENER, J | 2 |
| SCHUCHER, R | 1 |
| FRIEDMAN, R | 1 |
| Kearney, MT | 1 |
| Nolan, J | 1 |
| Nilsson, SE | 1 |
| Takkinen, S | 1 |
| Tryding, N | 1 |
| Evrin, PE | 1 |
| Berg, S | 1 |
| McClearn, G | 1 |
| Johansson, B | 1 |
| Polidori, MC | 1 |
| Praticó, D | 1 |
| Savino, K | 1 |
| Rokach, J | 1 |
| Stahl, W | 1 |
| Mecocci, P | 1 |
| Kittleson, MM | 2 |
| Reyes, AJ | 3 |
| Ochiai, ME | 1 |
| Barretto, AC | 1 |
| Oliveira, MT | 1 |
| Munhoz, RT | 1 |
| Morgado, PC | 1 |
| Ramires, JA | 1 |
| Kojima, S | 1 |
| Sakamoto, T | 1 |
| Ishihara, M | 1 |
| Miyazaki, S | 1 |
| Yamagishi, M | 1 |
| Tei, C | 1 |
| Hiraoka, H | 1 |
| Sonoda, M | 1 |
| Tsuchihashi, K | 1 |
| Shimoyama, N | 1 |
| Honda, T | 1 |
| Ogata, Y | 1 |
| Matsui, K | 1 |
| Ogawa, H | 1 |
| Calberg, MJ | 1 |
| Kjøller, E | 1 |
| Cengel, A | 1 |
| Türkoğlu, S | 1 |
| Turfan, M | 1 |
| Boyaci, B | 1 |
| Leary, WP | 1 |
| Okuyama, H | 1 |
| Hirono, O | 1 |
| Tsunoda, Y | 1 |
| Nitobe, J | 1 |
| Miyashita, T | 1 |
| Koyama, Y | 1 |
| Ponikowska, B | 1 |
| Majda, J | 1 |
| Zymlinski, R | 1 |
| Trzaska, M | 1 |
| Reczuch, K | 1 |
| Borodulin-Nadzieja, L | 1 |
| Banasiak, W | 1 |
| Sakai, H | 1 |
| Tsutamoto, T | 1 |
| Tsutsui, T | 1 |
| Tanaka, T | 1 |
| Ishikawa, C | 1 |
| Horie, M | 1 |
| Cingolani, HE | 1 |
| Plastino, JA | 1 |
| Escudero, EM | 1 |
| Pérez, NG | 1 |
| Pascual-Figal, DA | 1 |
| Hurtado-Martínez, JA | 1 |
| Redondo, B | 1 |
| Antolinos, MJ | 1 |
| Ruiperez, JA | 1 |
| Valdes, M | 1 |
| St John, ME | 1 |
| Bead, V | 1 |
| Champion, HC | 1 |
| Kasper, EK | 1 |
| Russell, SD | 1 |
| Wittstein, IS | 1 |
| Kielstein, JT | 1 |
| Woywodt, A | 1 |
| Salpeter, SR | 1 |
| Duan, X | 1 |
| Ling, F | 1 |
| Strasak, A | 1 |
| Ruttmann, E | 1 |
| Brant, L | 1 |
| Kelleher, C | 1 |
| Klenk, J | 1 |
| Concin, H | 1 |
| Diem, G | 1 |
| Pfeiffer, K | 1 |
| Ulmer, H | 1 |
| Ellestad, MH | 1 |
| Kumar, S | 1 |
| Dispenzieri, A | 1 |
| Lacy, MQ | 1 |
| Hayman, SR | 1 |
| Leung, N | 1 |
| Zeldenrust, SR | 1 |
| Buadi, FK | 1 |
| Kyle, RA | 1 |
| Gertz, MA | 1 |
| Lippi, G | 1 |
| Montagnana, M | 1 |
| Franchini, M | 1 |
| Favaloro, EJ | 1 |
| Pinelli, M | 2 |
| Bindi, M | 2 |
| Filardo, FP | 1 |
| Moroni, F | 2 |
| Castiglioni, M | 2 |
| Parish, RC | 1 |
| Evans, JD | 1 |
| Kopp, H | 1 |
| Kayser, D | 1 |
| Lundvall, O | 1 |
| Berlind, S | 1 |
| Davidov, M | 1 |
| Kakaviatos, N | 1 |
| Finnerty, FA | 1 |
| Burkhardt, H | 1 |
| Graul, EH | 1 |
| Pfab, R | 1 |
| Schuster, O | 1 |
| Loew, D | 1 |
| Holzgreve, H | 1 |
| de Torrenté, A | 1 |
| Kirsch, JJ | 1 |
| Müller, J | 1 |
| Pitule-Schödel, H | 1 |
| Lorant, P | 1 |
| Kremeier, E | 1 |
| Ladurner, G | 1 |
| Skvarc, A | 1 |
| Ott, E | 1 |
| Lechner, H | 1 |
| Barriales Alvarez, V | 1 |
| Rodríguez Blanco, VM | 1 |
| Barriales Villa, R | 1 |
| Möller Bustinza, I | 1 |
| Batalla Celorio, A | 1 |
| Castellanos Martínez, E | 1 |
| Moris de la Tassa, C | 1 |
| Mayordomo López, J | 1 |
| Decaux, G | 1 |
| Schlesser, M | 1 |
| Coffernils, M | 1 |
| Prospert, F | 1 |
| Namias, B | 1 |
| Brimioulle, S | 1 |
| Soupart, A | 1 |
| Chen, CY | 1 |
| Chen, CS | 1 |
| Anker, S | 1 |
| Swan, JW | 1 |
| Godsland, IF | 2 |
| Wingrove, CS | 1 |
| Chua, TP | 2 |
| Stevenson, JC | 2 |
| Kox, WJ | 2 |
| Gottlieb, S | 1 |
| Teixeira, M | 1 |
| Hellewell, PG | 1 |
| Ohta, H | 1 |
| Satomi, T | 1 |
| Suzuki, J | 1 |
| Ikemoto, F | 1 |
| Nishikibe, M | 1 |
| Constant, J | 1 |
| Paterna, S | 1 |
| Di Pasquale, P | 1 |
| Parrinello, G | 1 |
| Amato, P | 1 |
| Cardinale, A | 1 |
| Follone, G | 1 |
| Giubilato, A | 1 |
| Licata, G | 1 |
| Levchuk, NN | 1 |
| Drozdov, VN | 1 |
| Moiseev, VS | 1 |
| Florea, VG | 1 |
| Schoene, N | 1 |
| Leyva-Leon, F | 1 |
| Pavitt, DV | 1 |
| Reaveley, DA | 1 |
| Schuler, G | 1 |
| Hambrecht, R | 1 |
| Zanolla, L | 1 |
| Rossi, A | 1 |
| Golia, G | 1 |
| Franceschini, L | 1 |
| Brighetti, G | 1 |
| Zeni, P | 1 |
| Zardini, P | 1 |
| Smith, JW | 1 |
| Clements, P | 1 |
| Homeida, M | 1 |
| Roberts, CJ | 1 |
| Dombey, SL | 1 |
| Beg, MA | 1 |
| Ragland, R | 1 |
| Thomas, RD | 1 |
| Newill, A | 1 |
| Morgan, DB | 1 |
| Teodosiev, L | 1 |
| Kosman, ME | 1 |
| Fariello, R | 1 |
| Agabiti-Rosei, E | 1 |
| Alicandri, C | 1 |
| Corea, L | 1 |
| Oldoni, T | 1 |
| Muiesan, G | 2 |
| Carlier, J | 1 |
| Rorive, G | 1 |
| Bovy, P | 1 |
| Levey, BA | 1 |
| Palmer, RF | 1 |
| Niemi, KM | 1 |
| Sar, AV | 1 |
| Huisman, TH | 1 |
| Ianhez, LE | 1 |
| Pessano, B | 1 |
| Davì, S | 1 |
| La Brocca, A | 1 |
| Leone, L | 1 |
| Bakhtiiarov, ZA | 1 |
| Hyams, DE | 1 |
| Darlington, LG | 1 |
| Darrelmann, O | 1 |
| Kreissig, I | 1 |
| Richard, G | 1 |
| Salerno, M | 1 |
| Di Salvo, M | 1 |
| Furnari, R | 1 |
| Vaccaro, F | 1 |
| Licciardi, S | 1 |
| Finocchiaro, S | 1 |
| Wordsworth, BP | 1 |
| Mowat, AG | 1 |
| Puschett, JB | 1 |
| Heffernan, AG | 1 |
| Mannion, RA | 1 |
| Phelps, P | 1 |
| Rubin, IL | 1 |
| Arbeit, SR | 1 |
| Gross, H | 1 |
| Ghani, MF | 1 |
| Parker, BM | 1 |
| Smith, JR | 1 |
| Chien, S | 1 |
| Dellenback, RJ | 1 |
| Usami, S | 1 |
| Burton, DA | 1 |
| Gustavson, PF | 1 |
| Magazinovic, V | 1 |
| Henderson, AR | 1 |
| Kostuk, WJ | 1 |
| Griffiths, JC | 1 |
| Perlman, LV | 1 |
| Kennedy, BW | 1 |
| Hayner, NS | 1 |
| Juul, J | 1 |
| Nielsen, FU | 1 |
| Motolese, M | 1 |
| Petz, E | 1 |
| Todisco, T | 1 |
| Leiter, L | 1 |
| Anderton, JL | 1 |
| Kincaid-Smith, P | 1 |
| Ramirez, EA | 1 |
| Tristani, FE | 1 |
| Rosenberg, G | 1 |
| Cordova, C | 1 |
| Doliopoulos, T | 1 |
| Liaskou, F | 1 |
| Marousis, S | 1 |
| Kuhlbäck, B | 1 |
| Paulus, HE | 1 |
| Coutts, A | 1 |
| Calabro, JJ | 1 |
| Klinenberg, JR | 1 |
| Gresham, GE | 1 |
| Keller, MD | 1 |
| Van Peenen, HJ | 1 |
| Zucchelli, P | 1 |
| Petrella, A | 1 |
| Fusaroli, M | 1 |
| Sasdelli, M | 1 |
| Melica, A | 1 |
| el-Ebrashy, N | 1 |
| el-Danasoury, M | 1 |
| Higazi, AM | 1 |
| Nash, HL | 1 |
| Fitz, AE | 1 |
| Wilson, WR | 1 |
| Kirkendall, WM | 1 |
| Kioschos, JM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Stu[NCT01986881] | Phase 3 | 8,246 participants (Actual) | Interventional | 2013-11-04 | Completed | ||
| A Phase III Randomised, Double-blind Trial to Evaluate Efficacy and Safety of Once Daily Empagliflozin 10 mg Compared to Placebo, in Patients With Chronic Heart Failure With Preserved Ejection Fraction (HFpEF)[NCT03057951] | Phase 3 | 5,988 participants (Actual) | Interventional | 2017-03-02 | Completed | ||
| A Randomized Parallel-group, Placebo-controlled, Double-blind, Multi-center Dose Finding Phase II Trial Exploring the Pharmacodynamic Effects, Safety and Tolerability, and Pharmacokinetics of Four Dose Regimens of the Oral sGC Stimulator BAY1021189 Over 1[NCT01951625] | Phase 2 | 456 participants (Actual) | Interventional | 2013-11-29 | Completed | ||
| A Large Scale Clinical Trial Testing the Effects of n-3 PUFA and Rosuvastatin on Mortality-Morbidity of Patients With Symptomatic Congestive Heart Failure[NCT00336336] | Phase 3 | 6,975 participants (Actual) | Interventional | 2002-08-31 | Completed | ||
| Effects of Allopurinol on Inflammatory Markers and Morphostructural Changes Evidenced by Musculoskeletal Ultrasound in Individuals With Asymptomatic Hyperuricemia. A Proof of Concept[NCT04012294] | Phase 3 | 200 participants (Anticipated) | Interventional | 2019-08-30 | Recruiting | ||
| A Phase II-III Prospective, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Oxypurinol Added to Standard Therapy in Patients With NYHA Class III-IV Congestive Heart Failure[NCT00063687] | Phase 2/Phase 3 | 400 participants | Interventional | 2003-03-31 | Completed | ||
| Serum Uric Acid Levels and Initial Presentation of Cardiovascular Diseases: a CALIBER Study[NCT03425305] | 180,000 participants (Actual) | Observational | 1998-01-31 | Active, not recruiting | |||
| Hyperuricemia and the Effects of the Uricosuric Agents Benzbromarone in Patients With Chronic Heart Failure[NCT00422318] | Phase 4 | 0 participants | Interventional | 2004-01-31 | Completed | ||
| Allopurinol in the Treatment of Patients With Diabetes Mellitus and Multivessel Coronary Artery Disease Treated by Either PCI or CABG: Pilot Study[NCT03700645] | Phase 4 | 100 participants (Anticipated) | Interventional | 2018-12-01 | Not yet recruiting | ||
| Prednisone Versus Allopurinol for Symptomatic Heart Failure Patients With Hyperuricemia[NCT00919243] | Phase 4 | 40 participants (Anticipated) | Interventional | 2009-02-28 | Completed | ||
| Long-term Prednisone Use in Patients With Advanced Heart Failure (ACCF/AHA Stage D) and Hyperuricemia[NCT02282683] | Phase 2/Phase 3 | 90 participants (Anticipated) | Interventional | 2013-12-31 | Recruiting | ||
| Study Protocol for a Prospective Observational Study Investigating the Role of Luminal Pressure on Arteriovenous Fistula Maturation[NCT04017806] | 60 participants (Anticipated) | Observational | 2018-09-19 | Recruiting | |||
| Monocyte Phenotypic Changes in Heart Failure[NCT02997462] | 60 participants (Anticipated) | Observational | 2011-11-30 | Recruiting | |||
| Hypertonic Saline With Furosemide and a Normosodic Diet for the Treatment of Decompensated Congestive Heart Failure With Prerenal Physiology[NCT00575484] | Phase 2 | 11 participants (Actual) | Interventional | 2007-11-30 | Terminated | ||
| HSS (Hypertonic Saline Solution) Plus High Dose Furosemide vs High Dose Furosemide in Nephrotic Syndrome - a Randomized Trial[NCT03750136] | 30 participants (Anticipated) | Interventional | 2018-12-15 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
All events (first and recurrent) of the composite of CV death and HHF were assessed using an Andersen-Gill model. Person-years were calculated as the sum of time from randomization to end of follow-up. The on-study approach included events that occurred between the randomization date and the on-study censor date. (NCT01986881)
Timeframe: Up to approximately 6 years
| Intervention | Events per 100 Person-years (Number) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | 2.92 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | 2.71 |
| Placebo (Overall Cardiovascular Study) | 3.42 |
| All Ertugliflozin (Overall Cardiovascular Study) | 2.82 |
All events (first and recurrent) of the composite of MACE (3-point major adverse cardiovascular events: cardiovascular (CV) death (including fatal stroke and fatal myocardial infarction (MI)), non-fatal MI, and non-fatal stroke) were assessed using Andersen-Gill model. The on-study approach included events that occurred between the randomization date and the on-study censor date. (NCT01986881)
Timeframe: Up to approximately 6 years
| Intervention | Events per 100 Person-years (Number) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | 4.35 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | 4.91 |
| Placebo (Overall Cardiovascular Study) | 4.59 |
| All Ertugliflozin (Overall Cardiovascular Study) | 4.63 |
A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. This baseline reflects the Week 0 A1C. (NCT01986881)
Timeframe: Baseline
| Intervention | A1C Percentage (Mean) |
|---|---|
| Ertugliflozin 5 mg (Insulin +/- Metformin Glycemic Sub-study) | 8.45 |
| Ertugliflozin 15 mg (Insulin +/- Metformin Glycemic Sub-study) | 8.38 |
| Placebo (Ins+/-Met Sub-study) | 8.39 |
A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. This baseline reflects Week 0 A1C. (NCT01986881)
Timeframe: Baseline
| Intervention | A1C Percentage (Mean) |
|---|---|
| Ertugliflozin 5 mg (Metformin With Sulfonylurea Glycemic Sub-study) | 8.39 |
| Ertugliflozin 15 mg (Metformin With Sulfonylurea Glycemic Sub-study) | 8.30 |
| Placebo (Metformin With Sulfonylurea Glycemic Sub-study) | 8.27 |
A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. This baseline reflects the Week 0 A1C. (NCT01986881)
Timeframe: Baseline
| Intervention | A1C Percentage (Mean) |
|---|---|
| Ertugliflozin 5 mg (Sulfonylurea Monotherapy Glycemic Sub-Study) | 8.27 |
| Ertugliflozin 15 mg (Sulfonylurea Monotherapy Glycemic Sub-Study) | 8.39 |
| Placebo (Sulfonylurea Monotherapy Glycemic Sub-Study) | 8.21 |
Baseline reflects Week 0 insulin dose. (NCT01986881)
Timeframe: Baseline
| Intervention | Unit/day (Mean) |
|---|---|
| Ertugliflozin 5 mg (Insulin +/- Metformin Glycemic Sub-study) | 70.76 |
| Ertugliflozin 15 mg (Insulin +/- Metformin Glycemic Sub-study) | 67.29 |
| Placebo (Insulin +/- Metformin Glycemic Sub-study) | 73.20 |
Baseline reflects Week 0 insulin dose. (NCT01986881)
Timeframe: Baseline
| Intervention | Units/Day (Mean) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | 63.82 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | 62.15 |
| Placebo (Overall Cardiovascular Study) | 65.74 |
Baseline reflects Week 0 serum creatinine. (NCT01986881)
Timeframe: Baseline
| Intervention | mg/dL (Mean) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | 0.992 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | 0.985 |
| Placebo (Overall Cardiovascular Study) | 0.991 |
| All Ertugliflozin (Overall Cardiovascular Study) | 0.998 |
Baseline reflects Week 0 albumin/creatinine ratio. (NCT01986881)
Timeframe: Baseline
| Intervention | mg/g (Median) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | 18.00 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | 19.00 |
| Placebo (Overall Cardiovascular Study) | 19.00 |
"This change from baseline reflects the Week 18 insulin dose minus the Week 0 insulin dose. A negative number indicates a decrease in insulin dose. Participants who met glycemic rescue criteria received glycemic rescue medication. Including rescue, included data following the initiation of rescue therapy." (NCT01986881)
Timeframe: Baseline and Week 18
| Intervention | Unit/day (Mean) |
|---|---|
| Ertugliflozin 5 mg (Insulin +/- Metformin Glycemic Sub-study) | -0.71 |
| Ertugliflozin 15 mg (Insulin +/- Metformin Glycemic Sub-study) | -2.14 |
| Placebo (Insulin +/- Metformin Glycemic Sub-study) | -0.29 |
A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. This change from baseline reflects the Month 24 A1C minus the Week 0 A1C. A negative number indicates a reduction in A1C level. Participants who met glycemic rescue criteria received glycemic rescue medication. (NCT01986881)
Timeframe: Baseline and Month 24
| Intervention | A1C Percentage (Least Squares Mean) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | -0.48 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | -0.46 |
| Placebo (Overall Cardiovascular Study) | -0.08 |
A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. This change from baseline reflects the Month 36 A1C minus the Week 0 A1C. A negative number indicates a reduction in A1C level. Participants who met glycemic rescue criteria received glycemic rescue medication. (NCT01986881)
Timeframe: Baseline and Month 36
| Intervention | A1C Percentage (Mean) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | -0.42 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | -0.38 |
| Placebo (Overall Cardiovascular Study) | -0.04 |
A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. This change from baseline reflects the Month 48 A1C minus the Week 0 A1C. A negative number indicates a reduction in A1C level. Participants who met glycemic rescue criteria received glycemic rescue medication. (NCT01986881)
Timeframe: Baseline and Month 48
| Intervention | A1C Percentage (Least Squares Mean) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | -0.22 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | -0.17 |
| Placebo (Overall Cardiovascular Study) | 0.14 |
A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. This change from baseline reflects the Month 60 A1C minus the Week 0 A1C. A negative number indicates a reduction in A1C level. Participants who met glycemic rescue criteria received glycemic rescue medication. (NCT01986881)
Timeframe: Baseline and Month 60
| Intervention | A1C Percentage (Mean) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | -0.25 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | -0.28 |
| Placebo (Overall Cardiovascular Study) | -0.10 |
A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. This change from baseline reflects the Month 72 A1C minus the Week 0 A1C. A negative number indicates a reduction in A1C level. Participants who met glycemic rescue criteria received glycemic rescue medication. (NCT01986881)
Timeframe: Baseline and Month 72
| Intervention | A1C Percentage (Mean) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | -0.35 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | -0.13 |
| Placebo (Overall Cardiovascular Study) | 0.24 |
A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. This change from baseline reflects the Week 52 A1C minus the Week 0 A1C. A negative number indicates a reduction in A1C level. Participants who met glycemic rescue criteria received glycemic rescue medication. (NCT01986881)
Timeframe: Baseline and Week 52
| Intervention | A1C Percentage (Least Squares Mean) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | -0.69 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | -0.67 |
| Placebo (Overall Cardiovascular Study) | -0.19 |
This change from baseline reflects the Month 24 body weight minus the Week 0 body weight. A negative number indicates a reduction in body weight. Participants who met glycemic rescue criteria received glycemic rescue medication. (NCT01986881)
Timeframe: Baseline and Month 24
| Intervention | Kilograms (Least Squares Mean) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | -2.75 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | -3.17 |
| Placebo (Overall Cardiovascular Study) | -0.65 |
This change from baseline reflects the Month 36 body weight minus the Week 0 body weight. A negative number indicates a reduction in body weight. Participants who met glycemic rescue criteria received glycemic rescue medication. (NCT01986881)
Timeframe: Baseline and Month 36
| Intervention | Kilograms (Mean) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | -3.03 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | -3.41 |
| Placebo (Overall Cardiovascular Study) | -0.98 |
This change from baseline reflects the Month 48 body weight minus the Week 0 body weight. A negative number indicates a reduction in body weight. Participants who met glycemic rescue criteria received glycemic rescue medication. (NCT01986881)
Timeframe: Baseline and Month 48
| Intervention | Kilograms (Least Squares Mean) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | -3.39 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | -3.83 |
| Placebo (Overall Cardiovascular Study) | -1.29 |
This change from baseline reflects the Month 60 body weight minus the Week 0 body weight. A negative number indicates a reduction in body weight. Participants who met glycemic rescue criteria received glycemic rescue medication. (NCT01986881)
Timeframe: Baseline and Month 60
| Intervention | Kilograms (Mean) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | -3.66 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | -4.58 |
| Placebo (Overall Cardiovascular Study) | -1.21 |
This change from baseline reflects the Month 72 body weight minus the Week 0 body weight. A negative number indicates a reduction in body weight. Participants who met glycemic rescue criteria received glycemic rescue medication. (NCT01986881)
Timeframe: Baseline and Month 72
| Intervention | Kilograms (Mean) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | -4.18 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | -7.37 |
| Placebo (Overall Cardiovascular Study) | -0.98 |
"This change from baseline reflects the Week 18 body weight minus the Week 0 body weight. Participants who met glycemic rescue criteria received glycemic rescue medication. Excluding Rescue excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy." (NCT01986881)
Timeframe: Baseline and Week 18
| Intervention | Kilograms (Least Squares Mean) |
|---|---|
| Ertugliflozin 5 mg (Insulin +/- Metformin Glycemic Sub-study) | -1.87 |
| Ertugliflozin 15 mg (Insulin +/- Metformin Glycemic Sub-study) | -2.13 |
| Placebo (Insulin +/- Metformin Glycemic Sub-study) | -0.25 |
"This change from baseline reflects the Week 18 body weight minus the Week 0 body weight. A negative number indicates a reduction in body weight. Participants who met glycemic rescue criteria received glycemic rescue medication. Excluding Rescue excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy." (NCT01986881)
Timeframe: Baseline and Week 18
| Intervention | Kilograms (Least Squares Mean) |
|---|---|
| Ertugliflozin 5 mg (Metformin With Sulfonylurea Glycemic Sub-study) | -2.04 |
| Ertugliflozin 15 mg (Metformin With Sulfonylurea Glycemic Sub-study) | -2.41 |
| Placebo (Metformin With Sulfonylurea Glycemic Sub-study) | -0.47 |
"This change from baseline reflects the Week 18 body weight minus the Week 0 body weight. A negative number indicates a reduction in body weight. Participants who met glycemic rescue criteria received glycemic rescue medication. Excluding Rescue excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy." (NCT01986881)
Timeframe: Baseline and Week 18
| Intervention | Kilograms (Least Squares Mean) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | -2.03 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | -2.32 |
| Placebo (Overall Cardiovascular Study) | -0.40 |
"This change from baseline reflects the Week 18 body weight minus the Week 0 body weight. A negative number indicates a reduction in body weight. Participants who met glycemic rescue criteria received glycemic rescue medication. Excluding Rescue excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy." (NCT01986881)
Timeframe: Baseline and Week 18
| Intervention | Kilograms (Least Squares Mean) |
|---|---|
| Ertugliflozin 5 mg (Sulfonylurea Monotherapy Glycemic Sub-study) | -1.75 |
| Ertugliflozin 15 mg (Sulfonylurea Monotherapy Glycemic Sub-study) | -1.20 |
| Placebo (Sulfonylurea Monotherapy Glycemic Sub-study) | -0.68 |
This change from baseline reflects the Week 52 body weight minus the Week 0 body weight. A negative number indicates a reduction in body weight. Participants who met glycemic rescue criteria received glycemic rescue medication. (NCT01986881)
Timeframe: Baseline and Week 52
| Intervention | Kilograms (Least Squares Mean) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | -2.46 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | -2.84 |
| Placebo (Overall Cardiovascular Study) | -0.39 |
This change from baseline reflects the Month 24 eGFR minus the Week 0 eGFR. A negative number indicates a reduction in the eGFR level. (NCT01986881)
Timeframe: Baseline and Month 24
| Intervention | mL/min/1.73 m^2 (Mean) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | -1.48 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | -2.35 |
| Placebo (Overall Cardiovascular Study) | -2.60 |
This change from baseline reflects the Month 36 eGFR minus the Week 0 eGFR. A negative number indicates a reduction in the eGFR level. (NCT01986881)
Timeframe: Baseline and Month 36
| Intervention | mL/min/1.73 m^2 (Mean) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | -2.4 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | -2.3 |
| Placebo (Overall Cardiovascular Study) | -3.8 |
This change from baseline reflects the Month 48 eGFR minus the Week 0 eGFR. A negative number indicates a reduction in eGFR level. (NCT01986881)
Timeframe: Baseline and Month 48
| Intervention | mL/min/1.73 m^2 (Least Squares Mean) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | -2.75 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | -2.93 |
| Placebo (Overall Cardiovascular Study) | -4.41 |
This change from baseline reflects the Month 60 eGFR minus the Week 0 eGFR. A negative number indicates a reduction in the eGFR level. (NCT01986881)
Timeframe: Baseline and Month 60
| Intervention | mL/min/1.73 m^2 (Mean) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | -2.4 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | -2.9 |
| Placebo (Overall Cardiovascular Study) | -6.8 |
This change from baseline reflects the Month 72 eGFR minus the Week 0 eGFR. A negative number indicates a reduction in the eGFR level. (NCT01986881)
Timeframe: Baseline and Month 72
| Intervention | mL/min/1.73 m^2 (Mean) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | 3.7 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | 0.2 |
| Placebo (Overall Cardiovascular Study) | -1.8 |
This change from baseline reflects the Week 18 eGFR minus the Week 0 eGFR. A negative number indicates a reduction in the eGFR level. (NCT01986881)
Timeframe: Baseline and Week 18
| Intervention | mL/min/1.73 m^2 (Least Squares Mean) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | -1.22 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | -1.81 |
| Placebo (Overall Cardiovascular Study) | -0.03 |
This change from baseline reflects the Week 52 eGFR minus the Week 0 eGFR. A negative number indicates a reduction in eGFR level. (NCT01986881)
Timeframe: Baseline and Week 52
| Intervention | mL/min/1.73 m^2 (Least Squares Mean) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | -0.51 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | -1.18 |
| Placebo (Overall Cardiovascular Study) | -0.30 |
FPG was analyzed after an overnight fast. This change from baseline reflects the Month 24 FPG minus the Week 0 FPG. A negative number indicates a reduction in FPG. Participants who met glycemic rescue criteria received glycemic rescue medication. (NCT01986881)
Timeframe: Baseline and Month 24
| Intervention | mg/dL (Mean) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | -22.09 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | -24.31 |
| Placebo (Overall Cardiovascular Study) | -4.39 |
FPG was analyzed after an overnight fast. This change from baseline reflects the Month 36 FPG minus the Week 0 FPG. A negative number indicates a reduction in FPG. Participants who met glycemic rescue criteria received glycemic rescue medication. (NCT01986881)
Timeframe: Baseline and Month 36
| Intervention | mg/dL (Mean) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | -19.39 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | -22.59 |
| Placebo (Overall Cardiovascular Study) | -3.63 |
FPG was analyzed after an overnight fast. This change from baseline reflects the Month 48 FPG minus the Week 0 FPG. A negative number indicates a reduction in FPG. Participants who met glycemic rescue criteria received glycemic rescue medication. (NCT01986881)
Timeframe: Baseline and Month 48
| Intervention | mg/dL (Mean) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | -15.28 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | -16.16 |
| Placebo (Overall Cardiovascular Study) | 3.59 |
FPG was analyzed after an overnight fast. This change from baseline reflects the Month 60 FPG minus the Week 0 FPG. A negative number indicates a reduction in FPG. Participants who met glycemic rescue criteria received glycemic rescue medication. (NCT01986881)
Timeframe: Baseline and Month 60
| Intervention | mg/dL (Mean) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | -13.87 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | -11.15 |
| Placebo (Overall Cardiovascular Study) | -4.69 |
FPG was analyzed after an overnight fast. This change from baseline reflects the Month 72 FPG minus the Week 0 FPG. A negative number indicates a reduction in FPG. Participants who met glycemic rescue criteria received glycemic rescue medication. (NCT01986881)
Timeframe: Baseline and Month 72
| Intervention | mg/dL (Mean) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | -2.46 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | -84.83 |
| Placebo (Overall Cardiovascular Study) | 14.56 |
"FPG was analyzed after an overnight fast. This change from baseline reflects the Week 18 FPG minus the Week 0 FPG. A negative number indicates a reduction in the FPG. Participants who met glycemic rescue criteria received glycemic rescue medication. Excluding Rescue excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy." (NCT01986881)
Timeframe: Baseline and Week 18
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Ertugliflozin 5 mg (Insulin +/- Metformin Glycemic Sub-study) | -26.98 |
| Ertugliflozin 15 mg (Insulin +/- Metformin Glycemic Sub-study) | -33.15 |
| Placebo (Insulin +/- Metformin Glycemic Sub-study) | -7.74 |
"FPG was analyzed after an overnight fast. This change from baseline reflects the Week 18 FPG minus the Week 0 FPG. A negative number indicates a reduction in FPG. Participants who met glycemic rescue criteria received glycemic rescue medication. Excluding Rescue excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy." (NCT01986881)
Timeframe: Baseline and Week 18
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Ertugliflozin 5 mg (Metformin With Sulfonylurea Glycemic Sub-study) | -35.28 |
| Ertugliflozin 15 mg (Metformin With Sulfonylurea Glycemic Sub-study) | -36.18 |
| Placebo (Metformin With Sulfonylurea Glycemic Sub-study) | -4.81 |
"FPG was analyzed after an overnight fast. This change from baseline reflects the Week 18 FPG minus the Week 0 FPG. A negative number indicates a reduction in FPG. Participants who met glycemic rescue criteria received glycemic rescue medication. Excluding rescue, excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy." (NCT01986881)
Timeframe: Baseline and Week 18
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | -32.18 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | -34.64 |
| Placebo (Overall Cardiovascular Study) | -17.08 |
"FPG was analyzed after an overnight fast. This change from baseline reflects the Week 18 FPG minus the Week 0 FPG. A negative number indicates a reduction in FPG. Participants who met glycemic rescue criteria received glycemic rescue medication. Excluding Rescue excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy." (NCT01986881)
Timeframe: Baseline and Week 18
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Ertugliflozin 5 mg (Sulfonylurea Monotherapy Glycemic Sub-study) | -28.28 |
| Ertugliflozin 15 mg (Sulfonylurea Monotherapy Glycemic Sub-study) | -26.97 |
| Placebo (Sulfonylurea Monotherapy Glycemic Sub-study) | -14.76 |
FPG was analyzed after an overnight fast. This change from baseline reflects the Week 52 FPG minus the Week 0 FPG. A negative number indicates a reduction in FPG. Participants who met glycemic rescue criteria received glycemic rescue medication. (NCT01986881)
Timeframe: Baseline and Week 52
| Intervention | mg/dL (Mean) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | -28.63 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | -28.97 |
| Placebo (Overall Cardiovascular Study) | -8.76 |
"A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. This change from baseline reflects the Week 18 A1C minus the Week 0 A1C. A negative number indicates a reduction in A1C level. Participants who met glycemic rescue criteria received glycemic rescue medication. Excluding Rescue excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy." (NCT01986881)
Timeframe: Baseline and Week 18
| Intervention | A1C Percentage (Least Squares Mean) |
|---|---|
| Ertugliflozin 5 mg (Insulin +/- Metformin Glycemic Sub-study) | -0.77 |
| Ertugliflozin 15 mg (Insulin +/- Metformin Glycemic Sub-study) | -0.84 |
| Placebo (Ins+/-Met Sub-study) | -0.19 |
"A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. This change from baseline reflects the Week 18 A1C minus the Week 0 A1C. A negative number indicates a reduction in A1C level. Participants who met glycemic rescue criteria received glycemic rescue medication. Excluding Rescue excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy." (NCT01986881)
Timeframe: Baseline and Week 18
| Intervention | A1C Percentage (Least Squares Mean) |
|---|---|
| Ertugliflozin 5 mg (Metformin With Sulfonylurea Glycemic Sub-study) | -0.89 |
| Ertugliflozin 15 mg (Metformin With Sulfonylurea Glycemic Sub-study) | -0.98 |
| Placebo (Metformin With Sulfonylurea Glycemic Sub-study) | -0.23 |
"A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. This change from baseline reflects the Week 18 A1C minus the Week 0 A1C. A negative number indicates a reduction in A1C level. Participants who met glycemic rescue criteria received glycemic rescue medication. Excluding Rescue excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy." (NCT01986881)
Timeframe: Baseline and Week 18
| Intervention | A1C Percentage (Least Squares Mean) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | -0.70 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | -0.72 |
| Placebo (Overall Cardiovascular Study) | -0.22 |
"A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. This change from baseline reflects the Week 18 A1C minus the Week 0 A1C. A negative number indicates a reduction in A1C level. Participants who met glycemic rescue criteria received glycemic rescue medication. Excluding Rescue excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy." (NCT01986881)
Timeframe: Baseline and Week 18
| Intervention | A1C Percentage (Least Squares Mean) |
|---|---|
| Ertugliflozin 5 mg (Sulfonylurea Monotherapy Glycemic Sub-Study) | -0.91 |
| Ertugliflozin 15 mg (Sulfonylurea Monotherapy Glycemic Sub-Study) | -0.78 |
| Placebo (Sulfonylurea Monotherapy Glycemic Sub-Study) | -0.56 |
This change from baseline reflects the Month 24 insulin dose minus the Week 0 insulin dose. A negative number indicates a reduction in the insulin dose. (NCT01986881)
Timeframe: Baseline and Month 24
| Intervention | Units/Day (Mean) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | 0.45 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | -1.58 |
| Placebo (Overall Cardiovascular Study) | 6.16 |
This change from baseline reflects the Month 36 insulin dose minus the Week 0 insulin dose. A negative number indicates a reduction in the insulin dose. (NCT01986881)
Timeframe: Baseline and Month 36
| Intervention | Units/Day (Mean) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | 1.64 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | -1.92 |
| Placebo (Overall Cardiovascular Study) | 7.99 |
This change from baseline reflects the Month 48 insulin dose minus the Week 0 insulin dose. A negative number indicates a reduction in the insulin dose. (NCT01986881)
Timeframe: Baseline and Month 48
| Intervention | Units/Day (Mean) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | 2.96 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | -1.87 |
| Placebo (Overall Cardiovascular Study) | 7.28 |
This change from baseline reflects the Month 60 insulin dose minus the Week 0 insulin dose. A negative number indicates a reduction in the insulin dose. (NCT01986881)
Timeframe: Baseline and Month 60
| Intervention | Units/Day (Mean) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | -2.47 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | -1.77 |
| Placebo (Overall Cardiovascular Study) | 9.42 |
This change from baseline reflects the Week 18 insulin dose minus the Week 0 insulin dose. A negative number indicates a reduction in the insulin dose. (NCT01986881)
Timeframe: Baseline and Week 18
| Intervention | Units/Day (Mean) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | 1.05 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | 0.81 |
| Placebo (Overall Cardiovascular Study) | 3.71 |
This change from baseline reflects the Week 52 insulin dose minus the Week 0 insulin dose. A negative number indicates a reduction in the insulin dose. (NCT01986881)
Timeframe: Baseline and Week 52
| Intervention | Units/Day (Mean) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | 0.84 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | -1.69 |
| Placebo (Overall Cardiovascular Study) | 5.57 |
This change from baseline reflects the Month 24 serum creatinine minus the Week 0 serum creatinine. Participants who met glycemic rescue criteria received glycemic rescue medication. (NCT01986881)
Timeframe: Baseline and Month 24
| Intervention | mg/dL (Mean) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | 0.024 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | 0.035 |
| Placebo (Overall Cardiovascular Study) | 0.034 |
This change from baseline reflects the Month 36 serum creatinine minus the Week 0 serum creatinine. Participants who met glycemic rescue criteria received glycemic rescue medication. (NCT01986881)
Timeframe: Baseline and Month 36
| Intervention | mg/dL (Mean) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | 0.037 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | 0.035 |
| Placebo (Overall Cardiovascular Study) | 0.049 |
This change from baseline reflects the Month 48 serum creatinine minus the Week 0 serum creatinine. Participants who met glycemic rescue criteria received glycemic rescue medication. (NCT01986881)
Timeframe: Baseline and Month 48
| Intervention | mg/dL (Mean) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | 0.032 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | 0.036 |
| Placebo (Overall Cardiovascular Study) | 0.059 |
This change from baseline reflects the Month 60 serum creatinine minus the Week 0 serum creatinine. Participants who met glycemic rescue criteria received glycemic rescue medication. (NCT01986881)
Timeframe: Baseline and Month 60
| Intervention | mg/dL (Mean) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | 0.027 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | 0.042 |
| Placebo (Overall Cardiovascular Study) | 0.098 |
This change from baseline reflects the Month 72 serum creatinine minus the Week 0 serum creatinine. Participants who met glycemic rescue criteria received glycemic rescue medication. (NCT01986881)
Timeframe: Baseline and Month 72
| Intervention | mg/dL (Mean) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | -0.034 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | 0.001 |
| Placebo (Overall Cardiovascular Study) | -0.013 |
This change from baseline reflects the Week 18 serum creatinine minus the Week 0 serum creatinine. Participants who met glycemic rescue criteria received glycemic rescue medication. (NCT01986881)
Timeframe: Baseline and Week 18
| Intervention | mg/dL (Mean) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | 0.022 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | 0.032 |
| Placebo (Overall Cardiovascular Study) | -0.002 |
This change from baseline reflects the Week 52 serum creatinine minus the Week 0 serum creatinine. Participants who met glycemic rescue criteria received glycemic rescue medication. (NCT01986881)
Timeframe: Baseline and Week 52
| Intervention | mg/dL (Mean) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | 0.013 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | 0.023 |
| Placebo (Overall Cardiovascular Study) | 0.004 |
"This change from baseline reflects the Week 18 DBP minus the Week 0 DBP. A negative number indicates a reduction in DBP. Participants who met glycemic rescue criteria received glycemic rescue medication. Excluding Rescue excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy." (NCT01986881)
Timeframe: Baseline and Week 18
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Ertugliflozin 5 mg (Metformin With Sulfonylurea Glycemic Sub-study) | -0.30 |
| Ertugliflozin 15 mg (Metformin With Sulfonylurea Glycemic Sub-study) | -0.92 |
| Placebo (Metformin With Sulfonylurea Glycemic Sub-study) | -0.24 |
"This change from baseline reflects the Week 18 DBP minus the Week 0 DBP. A negative number indicates a reduction in DBP. Participants who met glycemic rescue criteria received glycemic rescue medication. Excluding Rescue excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy." (NCT01986881)
Timeframe: Baseline and Week 18
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Ertugliflozin 5 mg (Sulfonylurea Monotherapy Glycemic Sub-study) | -1.18 |
| Ertugliflozin 15 mg (Sulfonylurea Monotherapy Glycemic Sub-study) | -0.93 |
| Placebo (Sulfonylurea Monotherapy Glycemic Sub-study) | -2.91 |
This change from baseline reflects the Month 24 DBP minus the Week 0 DBP. A negative number indicates a reduction in DBP. Participants who met glycemic rescue criteria received glycemic rescue medication. (NCT01986881)
Timeframe: Baseline and Month 24
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | -0.94 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | -0.90 |
| Placebo (Overall Cardiovascular Study) | -0.23 |
This change from baseline reflects the Month 36 DBP minus the Week 0 DBP. A negative number indicates a reduction in DBP. Participants who met glycemic rescue criteria received glycemic rescue medication. (NCT01986881)
Timeframe: Baseline and Month 36
| Intervention | mmHg (Mean) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | -1.27 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | -0.92 |
| Placebo (Overall Cardiovascular Study) | -0.22 |
This change from baseline reflects the Month 48 DBP minus the Week 0 DBP. A negative number indicates a reduction in DBP. Participants who met glycemic rescue criteria received glycemic rescue medication. (NCT01986881)
Timeframe: Baseline and Month 48
| Intervention | mmHg (Mean) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | -1.45 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | -1.42 |
| Placebo (Overall Cardiovascular Study) | -0.64 |
This change from baseline reflects the Month 60 DBP minus the Week 0 DBP. A negative number indicates a reduction in DBP. Participants who met glycemic rescue criteria received glycemic rescue medication. (NCT01986881)
Timeframe: Baseline and Month 60
| Intervention | mmHg (Mean) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | -1.82 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | -1.43 |
| Placebo (Overall Cardiovascular Study) | -1.26 |
This change from baseline reflects the Month 72 DBP minus the Week 0 DBP. A negative number indicates a reduction in DBP. Participants who met glycemic rescue criteria received glycemic rescue medication. (NCT01986881)
Timeframe: Baseline and Month 72
| Intervention | mmHg (Mean) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | -2.18 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | 1.86 |
| Placebo (Overall Cardiovascular Study) | 7.29 |
"This change from baseline reflects the Week 18 DBP minus the Week 0 BBP. A negative number indicates a reduction in DBP. Participants who met glycemic rescue criteria received glycemic rescue medication. Excluding Rescue excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy." (NCT01986881)
Timeframe: Baseline and Week 18
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Ertugliflozin 5 mg (Insulin +/- Metformin Glycemic Sub-study) | -0.86 |
| Ertugliflozin 15 mg (Insulin +/- Metformin Glycemic Sub-study) | -0.64 |
| Placebo (Insulin +/- Metformin Glycemic Sub-study) | -0.26 |
"This change from baseline reflects the Week 18 DBP minus the Week 0 DBP. A negative number indicates a reduction in DBP. Participants who met glycemic rescue criteria received glycemic rescue medication. Excluding rescue, excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy." (NCT01986881)
Timeframe: Baseline and Week 18
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | -0.99 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | -1.08 |
| Placebo (Overall Cardiovascular Study) | -0.12 |
This change from baseline reflects the Week 52 DBP minus the Week 0 DBP. A negative number indicates a reduction in DBP. Participants who met glycemic rescue criteria received glycemic rescue medication. (NCT01986881)
Timeframe: Baseline and Week 52
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | -0.97 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | -0.95 |
| Placebo (Overall Cardiovascular Study) | -0.15 |
This change from baseline reflects the Month 24 SBP minus the Week 0 SBP. A negative number indicates a reduction in SBP. Participants who met glycemic rescue criteria received glycemic rescue medication. (NCT01986881)
Timeframe: Baseline and Month 24
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | -1.80 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | -1.82 |
| Placebo (Overall Cardiovascular Study) | 0.90 |
This change from baseline reflects the Month 36 SBP minus the Week 0 SBP. A negative number indicates a reduction in SBP. Participants who met glycemic rescue criteria received glycemic rescue medication. (NCT01986881)
Timeframe: Baseline and Month 36
| Intervention | mmHg (Mean) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | -1.55 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | -1.21 |
| Placebo (Overall Cardiovascular Study) | 0.84 |
This change from baseline reflects the Month 48 SBP minus the Week 0 SBP. A negative number indicates a reduction in SBP. Participants who met glycemic rescue criteria received glycemic rescue medication. (NCT01986881)
Timeframe: Baseline and Month 48
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | -2.07 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | -2.26 |
| Placebo (Overall Cardiovascular Study) | 0.53 |
This change from baseline reflects the Month 60 SBP minus the Week 0 SBP. A negative number indicates a reduction in SBP. Participants who met glycemic rescue criteria received glycemic rescue medication. (NCT01986881)
Timeframe: Baseline and Month 60
| Intervention | mmHg (Mean) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | -2.18 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | -1.87 |
| Placebo (Overall Cardiovascular Study) | 0.62 |
This change from baseline reflects the Month 72 SBP minus the Week 0 SBP. A negative number indicates a reduction in SBP. Participants who met glycemic rescue criteria received glycemic rescue medication. (NCT01986881)
Timeframe: Baseline and Month 72
| Intervention | mmHg (Mean) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | 1.28 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | -3.46 |
| Placebo (Overall Cardiovascular Study) | 2.72 |
"This change from baseline reflects the Week 18 SBP minus the Week 0 SBP. A negative number indicates a reduction in SBP. Participants who met glycemic rescue criteria received glycemic rescue medication. Excluding Rescue excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy." (NCT01986881)
Timeframe: Baseline and Week 18
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Ertugliflozin 5 mg (Insulin +/- Metformin Glycemic Sub-study) | -2.67 |
| Ertugliflozin 15 mg (Insulin +/- Metformin Glycemic Sub-study) | -2.12 |
| Placebo (Insulin +/- Metformin Glycemic Sub-study) | 0.20 |
"This change from baseline reflects the Week 18 SBP minus the Week 0 SBP. A negative number indicates a reduction in SBP. Participants who met glycemic rescue criteria received glycemic rescue medication. Excluding Rescue excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy." (NCT01986881)
Timeframe: Baseline and Week 18
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Ertugliflozin 5 mg (Metformin With Sulfonylurea Glycemic Sub-study) | -2.26 |
| Ertugliflozin 15 mg (Metformin With Sulfonylurea Glycemic Sub-study) | -1.54 |
| Placebo (Metformin With Sulfonylurea Glycemic Sub-study) | -0.70 |
"This change from baseline reflects the Week 18 SBP minus the Week 0 SBP. A negative number indicates a reduction in SBP. Participants who met glycemic rescue criteria received glycemic rescue medication. Excluding rescue, excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy." (NCT01986881)
Timeframe: Baseline and Week 18
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | -2.51 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | -2.75 |
| Placebo (Overall Cardiovascular Study) | 0.03 |
"This change from baseline reflects the Week 18 SBP minus the Week 0 SBP. A negative number indicates a reduction in SBP. Participants who met glycemic rescue criteria received glycemic rescue medication. Excluding Rescue excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy." (NCT01986881)
Timeframe: Baseline and Week 18
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Ertugliflozin 5 mg (Sulfonylurea Monotherapy Glycemic Sub-study) | -0.72 |
| Ertugliflozin 15 mg (Sulfonylurea Monotherapy Glycemic Sub-study) | -0.80 |
| Placebo (Sulfonylurea Monotherapy Glycemic Sub-study) | -3.53 |
This change from baseline reflects the Week 52 sitting SBP minus the Week 0 SBP. A negative number indicates a reduction in SBP. Participants who met glycemic rescue criteria received glycemic rescue medication. (NCT01986881)
Timeframe: Baseline and Week 52
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | -1.84 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | -2.41 |
| Placebo (Overall Cardiovascular Study) | 0.75 |
This percent change relative to baseline reflects the Month 24 albumin/creatinine ratio minus the Week 0 albumin/creatinine ratio. This difference was divided by the baseline to obtain the percent change. A negative number indicates a reduction in urinary albumin/creatinine ratio. Participants who met glycemic rescue criteria received glycemic rescue medication. (NCT01986881)
Timeframe: Baseline and Month 24
| Intervention | Percent Change (Median) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | -0.73 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | 1.06 |
| Placebo (Overall Cardiovascular Study) | 17.14 |
This percent change relative to baseline reflects the Month 36 albumin/creatinine ratio minus the Week 0 albumin/creatinine ratio. This difference was divided by the baseline to obtain the percent change. A negative number indicates a reduction in urinary albumin/creatinine ratio. Participants who met glycemic rescue criteria received glycemic rescue medication. (NCT01986881)
Timeframe: Baseline and Month 36
| Intervention | Percent Change (Median) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | 13.33 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | 3.33 |
| Placebo (Overall Cardiovascular Study) | 27.03 |
This percent change relative to baseline reflects the Month 48 albumin/creatinine ratio minus the Week 0 albumin/creatinine ratio. This difference was divided by the baseline to obtain the percent change. A negative number indicates a reduction in albumin/creatinine ratio. Participants who met glycemic rescue criteria received glycemic rescue medication. (NCT01986881)
Timeframe: Baseline and Month 48
| Intervention | Percent Change (Median) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | 33.33 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | 21.25 |
| Placebo (Overall Cardiovascular Study) | 50.00 |
This percent change relative to baseline reflects the Month 60 albumin/creatinine ratio minus the Week 0 albumin/creatinine ratio. This difference was divided by the baseline to obtain the percent change. A negative number indicates a reduction in albumin/creatinine ratio. Participants who met glycemic rescue criteria received glycemic rescue medication. (NCT01986881)
Timeframe: Baseline and Month 60
| Intervention | Percent Change (Median) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | 30.99 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | 20.00 |
| Placebo (Overall Cardiovascular Study) | 48.53 |
This percent change relative to baseline reflects the Week 18 albumin/creatinine ratio minus the Week 0 albumin/creatinine ratio. This difference was divided by the baseline to obtain the percent change. A negative number indicates a reduction in the urinary albumin/creatinine ratio. Participants who met glycemic rescue criteria received glycemic rescue medication. (NCT01986881)
Timeframe: Baseline and Week 18
| Intervention | Percent Change (Median) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | -13.40 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | -14.71 |
| Placebo (Overall Cardiovascular Study) | 0.00 |
This percent change relative to baseline reflects the Week 52 albumin/creatinine ratio minus the Week 0 albumin/creatinine ratio. This difference was divided by the baseline to obtain the percent change. A negative number indicates a reduction in the albumin/creatinine ratio. Participants who met glycemic rescue criteria received glycemic rescue medication. (NCT01986881)
Timeframe: Baseline and Week 52
| Intervention | Percent Change (Median) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | -2.53 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | -6.82 |
| Placebo (Overall Cardiovascular Study) | 5.41 |
An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. (NCT01986881)
Timeframe: Up to 18 weeks
| Intervention | Percentage of Participants (Number) |
|---|---|
| Ertugliflozin 5 mg (Insulin +/- Metformin Glycemic Sub-study) | 2.9 |
| Ertugliflozin 15 mg (Insulin +/- Metformin Glycemic Sub-study) | 3.8 |
| Placebo (Insulin +/- Metformin Glycemic Sub-study) | 3.7 |
An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. (NCT01986881)
Timeframe: Up to 18 weeks
| Intervention | Percentage of Participants (Number) |
|---|---|
| Ertugliflozin 5 mg (Metformin With Sulfonylurea Glycemic Sub-study) | 0 |
| Ertugliflozin 15 mg (Metformin With Sulfonylurea Glycemic Sub-study) | 2.7 |
| Placebo (Metformin With Sulfonylurea Glycemic Sub-study) | 1.7 |
An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. (NCT01986881)
Timeframe: Up to approximately 6 years
| Intervention | Percentage of Participants (Number) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | 7.5 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | 7.3 |
| Placebo (Overall Cardiovascular Study) | 6.8 |
An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. (NCT01986881)
Timeframe: Up to 18 weeks
| Intervention | Percentage of Participants (Number) |
|---|---|
| Ertugliflozin 5 mg (Sulfonylurea Monotherapy Glycemic Sub-study) | 3.6 |
| Ertugliflozin 15 mg (Sulfonylurea Monotherapy Glycemic Sub-study) | 1.9 |
| Placebo (Sulfonylurea Monotherapy Glycemic Sub-study) | 2.1 |
An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. (NCT01986881)
Timeframe: Up to 18 weeks
| Intervention | Percentage of Participants (Number) |
|---|---|
| Ertugliflozin 5 mg (Insulin +/- Metformin Glycemic Sub-study) | 59.2 |
| Ertugliflozin 15 mg (Insulin +/- Metformin Glycemic Sub-study) | 62.4 |
| Placebo (Insulin +/- Metformin Glycemic Sub-study) | 61.1 |
An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. (NCT01986881)
Timeframe: Up to 18 weeks
| Intervention | Percentage of Participants (Number) |
|---|---|
| Ertugliflozin 5 mg (Metformin With Sulfonylurea Glycemic Sub-study) | 48.0 |
| Ertugliflozin 15 mg (Metformin With Sulfonylurea Glycemic Sub-study) | 54.9 |
| Placebo (Metformin With Sulfonylurea Glycemic Sub-study) | 47.0 |
An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. (NCT01986881)
Timeframe: Up to approximately 6 years
| Intervention | Percentage of Participants (Number) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | 85.8 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | 84.6 |
| Placebo (Overall Cardiovascular Study) | 85.6 |
An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. (NCT01986881)
Timeframe: Up to 18 weeks
| Intervention | Percentage of Participants (Number) |
|---|---|
| Ertugliflozin 5 mg (Sulfonylurea Monotherapy Glycemic Sub-study) | 47.3 |
| Ertugliflozin 15 mg (Sulfonylurea Monotherapy Glycemic Sub-study) | 25.9 |
| Placebo (Sulfonylurea Monotherapy Glycemic Sub-study) | 45.8 |
A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication. (NCT01986881)
Timeframe: Month 24
| Intervention | Percentage of Participants (Number) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | 9.2 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | 8.6 |
| Placebo (Overall Cardiovascular Study) | 5.8 |
A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication. (NCT01986881)
Timeframe: Month 36
| Intervention | Percentage of Participants (Number) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | 7.9 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | 8.0 |
| Placebo (Overall Cardiovascular Study) | 5.8 |
A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication. (NCT01986881)
Timeframe: Month 48
| Intervention | Percentage of Participants (Number) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | 8.1 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | 9.1 |
| Placebo (Overall Cardiovascular Study) | 7.5 |
A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication. (NCT01986881)
Timeframe: Month 60
| Intervention | Percentage of Participants (Number) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | 5.3 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | 9.5 |
| Placebo (Overall Cardiovascular Study) | 6.5 |
A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication. (NCT01986881)
Timeframe: Week 18
| Intervention | Percentage of Participants (Number) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | 9.0 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | 8.8 |
| Placebo (Overall Cardiovascular Study) | 4.7 |
A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication. (NCT01986881)
Timeframe: Week 52
| Intervention | Percentage of Participants (Number) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | 9.4 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | 10.9 |
| Placebo (Overall Cardiovascular Study) | 6.1 |
A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication. (NCT01986881)
Timeframe: Month 24
| Intervention | Percentage of Participants (Number) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | 23.9 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | 23.8 |
| Placebo (Overall Cardiovascular Study) | 16.6 |
A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication. (NCT01986881)
Timeframe: Month 36
| Intervention | Percentage of Participants (Number) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | 23.1 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | 22.7 |
| Placebo (Overall Cardiovascular Study) | 16.9 |
A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication. (NCT01986881)
Timeframe: Month 48
| Intervention | Percentage of Participants (Number) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | 24.9 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | 22.7 |
| Placebo (Overall Cardiovascular Study) | 18.2 |
A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication. (NCT01986881)
Timeframe: Month 60
| Intervention | Percentage of Participants (Number) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | 18.6 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | 20.0 |
| Placebo (Overall Cardiovascular Study) | 16.5 |
"A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication. Excluding Rescue excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy." (NCT01986881)
Timeframe: Week 18
| Intervention | Percentage of Participants (Number) |
|---|---|
| Ertugliflozin 5 mg (Insulin +/- Metformin Glycemic Sub-study) | 20.7 |
| Ertugliflozin 15 mg (Insulin +/- Metformin Glycemic Sub-study) | 21.1 |
| Placebo (Insulin +/- Metformin Glycemic Sub-study) | 10.7 |
"A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication. Excluding Rescue excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy." (NCT01986881)
Timeframe: Week 18
| Intervention | Percentage of Participants (Number) |
|---|---|
| Ertugliflozin 5 mg (Metformin With Sulfonylurea Glycemic Sub-study) | 37.0 |
| Ertugliflozin 15 mg (Metformin With Sulfonylurea Glycemic Sub-study) | 32.7 |
| Placebo (Metformin With Sulfonylurea Glycemic Sub-study) | 12.8 |
"A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication. Excluding Rescue excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy." (NCT01986881)
Timeframe: Week 18
| Intervention | Percentage of Participants (Number) |
|---|---|
| Ertugliflozin 5 mg (Sulfonylurea Monotherapy Glycemic Sub-study) | 32.7 |
| Ertugliflozin 15 mg (Sulfonylurea Monotherapy Glycemic Sub-study) | 27.8 |
| Placebo (Sulfonylurea Monotherapy Glycemic Sub-study) | 25.0 |
A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication. (NCT01986881)
Timeframe: Week 18
| Intervention | Percentage of Participants (Number) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | 28.4 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | 28.2 |
| Placebo (Overall Cardiovascular Study) | 15.5 |
A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication. (NCT01986881)
Timeframe: Week 52
| Intervention | Percentage of Participants (Number) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | 28.3 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | 29.0 |
| Placebo (Overall Cardiovascular Study) | 17.4 |
Time to First Occurrence of Fatal or Non-fatal Myocardial Infarction. The on-study approach included confirmed events that occurred between the randomization date and the on-study censor date. Person-years was calculated as the sum of participants' time to first event or time to censoring (the earliest of participants' end of study date, death date, or last contact date). (NCT01986881)
Timeframe: Up to approximately 6 years
| Intervention | Events per 100 Person-years (Number) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | 1.55 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | 2.00 |
| Placebo (Overall Cardiovascular Study) | 1.70 |
| All Ertugliflozin (Overall Cardiovascular Study) | 1.77 |
Time to the first occurrence of fatal and no-fatal stroke. The on-study approach included confirmed events that occurred between the randomization date and the on-study censor date. Person-years was calculated as the sum of participants' time to first event or time to censoring (the earliest of participants' end of study date, death date, or last contact date). The on-study approach included events that occurred between the randomization date and the on-study censor date. (NCT01986881)
Timeframe: Up to approximately 6 years
| Intervention | Events per 100 Person-years (Number) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | 0.92 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | 1.04 |
| Placebo (Overall Cardiovascular Study) | 0.93 |
| All Ertugliflozin (Overall Cardiovascular Study) | 0.98 |
Time to the first occurrence of heart failure requiring hospitalization (adjudicated). The on-study approach included confirmed events that occurred between the randomization date and the on-study censor date. Person-years was calculated as the sum of participants' time to first event or time to censoring (the earliest of participants' end of study date, death date, or last contact date). The on-study approach included events that occurred between the randomization date and the on-study censor date. (NCT01986881)
Timeframe: Up to approximately 6 years
| Intervention | Events per 100 Person-years (Number) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | 0.75 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | 0.72 |
| Placebo (Overall Cardiovascular Study) | 1.05 |
| All Ertugliflozin (Overall Cardiovascular Study) | 0.73 |
Time to the first occurrence of any of the following adjudicated components of the primary composite endpoint (3-point major adverse cardiovascular events (MACE)): cardiovascular (CV) death (including fatal stroke and fatal myocardial infarction (MI)), non-fatal MI, and non-fatal stroke. The on-treatment approach included confirmed events that occurred between the date of first dose of study medication and the on-treatment censor date. Person-years was calculated as the sum of participants' time to first event or time to censoring (the earliest of participants' end of study date, death date, last contact date, or 365 days after the last dose). (NCT01986881)
Timeframe: Up to approximately 6 years
| Intervention | Events per 100 Person-years (Number) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | 3.64 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | 4.16 |
| Placebo (Overall Cardiovascular Study) | 4.01 |
| All Ertugliflozin (Overall Cardiovascular Study) | 3.90 |
Time to the first occurrence of any of the following adjudicated components 4-point MACE: cardiovascular death (including fatal stroke and fatal myocardial infarction), non-fatal myocardial infarction, non-fatal stroke, and hospitalization for unstable angina pectoris. The on-study approach included confirmed events that occurred between the randomization date and the on-study censor date. Person-years was calculated as the sum of participants' time to first event or time to censoring (the earliest of participants' end of study date, death date, or last contact date). The on-study approach included events that occurred between the randomization date and the on-study censor date. (NCT01986881)
Timeframe: Up to approximately 6 years
| Intervention | Events per 100 Person-years (Number) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | 4.42 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | 4.67 |
| Placebo (Overall Cardiovascular Study) | 4.92 |
| All Ertugliflozin (Overall Cardiovascular Study) | 4.54 |
Renal composite endpoint was defined as a composite of renal death, renal dialysis/transplant, or doubling of serum creatinine from baseline. The on-study approach included events that occurred between the randomization date and the on-study censor date. Person-years was calculated as the sum of participants' time to first event or time to censoring (the earliest of participants' end of study date, death date, or last contact date). The on-study approach included events that occurred between the randomization date and the on-study censor date. (NCT01986881)
Timeframe: Up to approximately 6 years
| Intervention | Events per 100 Person-years (Number) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | 0.87 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | 0.98 |
| Placebo (Overall Cardiovascular Study) | 1.15 |
| All Ertugliflozin (Overall Cardiovascular Study) | 0.93 |
Participants who were not on insulin therapy at the start of study medication. (NCT01986881)
Timeframe: Up to approximately 6 years
| Intervention | Days (Median) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | 602 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | 650 |
| Placebo (Overall Cardiovascular Study) | 482 |
Time to the occurrence of any of the following adjudicated components of cardiovascular (CV) death (including fatal stroke and fatal myocardial infarction (MI)) or hospitalization for heart failure. The on-study approach included confirmed events that occurred between the randomization date and the on-study censor date. Person-years was calculated as the sum of participants' time to event or time to censoring (the earliest of participants' end of study date, death date, or last contact date). (NCT01986881)
Timeframe: Up to approximately 6 years
| Intervention | Events per 100 Person-years (Number) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | 2.36 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | 2.33 |
| Placebo (Overall Cardiovascular Study) | 2.66 |
| All Ertugliflozin (Overall Cardiovascular Study) | 2.34 |
Time to the occurrence of cardiovascular (CV) death (including fatal stroke and fatal myocardial infarction (MI)). The on-study approach included confirmed events that occurred between the randomization date and the on-study censor date. Person-years was calculated as the sum of participants' time to CV death or time to censoring (the earliest of participants' end of study date or date last known to be alive). (NCT01986881)
Timeframe: Up to approximately 6 years
| Intervention | Events per 100 Person-years (Number) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | 1.77 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | 1.74 |
| Placebo (Overall Cardiovascular Study) | 1.90 |
| All Ertugliflozin (Overall Cardiovascular Study) | 1.76 |
Time to the occurrence of death from any cause. The on-study approach included confirmed events that occurred between the randomization date and the on-study censor date. Person-years was calculated as the sum of participants' time to event or time to censoring (the earliest of participants' end of study date, death date, last contact date, or date last known to be alive. The on-study approach included events that occurred between the randomization date and the on-study censor date. (NCT01986881)
Timeframe: Up to approximately 6 years
| Intervention | Events per 100 Person-years (Number) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | 2.42 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | 2.46 |
| Placebo (Overall Cardiovascular Study) | 2.62 |
| All Ertugliflozin (Overall Cardiovascular Study) | 2.44 |
Participants who met glycemic rescue criteria received open-label sitagliptin glycemic rescue medication. (NCT01986881)
Timeframe: Up to 18 weeks
| Intervention | Days (Median) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | 59.0 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | 51.0 |
| Placebo (Overall Cardiovascular Study) | 74.0 |
Albuminuria progression and regression were assessed relative to the baseline albuminuria category. Progression was defined as either a change from having normal albuminuria at baseline to micro-albuminuria at the respective visit, or micro-albuminuria at baseline to macro-albuminuria at the respective visit, or normal albuminuria at baseline to macro-albuminuria at the respective visit. Regression was defined as either a change from having micro-albuminuria at baseline to normal albuminuria at the respective visit, or macro-albuminuria at baseline to micro-albuminuria at the respective visit, or macro-albuminuria at baseline to normal albuminuria at the respective visit. Normal albuminuria: urine albumin to urinary creatinine ratio (UACR) <30 (mg/g); Micro-albuminuria: UACR ≥30 and ≤300 (mg/g); Macro-albuminuria: UACR>300 (mg/g). (NCT01986881)
Timeframe: Month 24
| Intervention | Percentage of Participants (Number) | |
|---|---|---|
| Percentage of Participants with albuminuria progression | Percentage of Participants with albuminuria regression | |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | 11.0 | 13.8 |
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | 12.1 | 14.3 |
| Placebo (Overall Cardiovascular Study) | 16.9 | 9.9 |
Albuminuria progression and regression were assessed relative to the baseline albuminuria category. Progression was defined as either a change from having normal albuminuria at baseline to micro-albuminuria at the respective visit, or micro-albuminuria at baseline to macro-albuminuria at the respective visit, or normal albuminuria at baseline to macro-albuminuria at the respective visit. Regression was defined as either a change from having micro-albuminuria at baseline to normal albuminuria at the respective visit, or macro-albuminuria at baseline to micro-albuminuria at the respective visit, or macro-albuminuria at baseline to normal albuminuria at the respective visit. Normal albuminuria: urine albumin to urinary creatinine ratio (UACR) <30 (mg/g); Micro-albuminuria: UACR ≥30 and ≤300 (mg/g); Macro-albuminuria: UACR>300 (mg/g). (NCT01986881)
Timeframe: Month 36
| Intervention | Percentage of Participants (Number) | |
|---|---|---|
| Participants with albuminuria progression | Participants with albuminuria regression | |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | 12.5 | 14.3 |
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | 14.6 | 13.8 |
| Placebo (Overall Cardiovascular Study) | 18.1 | 11.0 |
Albuminuria progression and regression were assessed relative to the baseline albuminuria category. Progression was defined as either a change from having normal albuminuria at baseline to micro-albuminuria at the respective visit, or micro-albuminuria at baseline to macro-albuminuria at the respective visit, or normal albuminuria at baseline to macro-albuminuria at the respective visit. Regression was defined as either a change from having micro-albuminuria at baseline to normal albuminuria at the respective visit, or macro-albuminuria at baseline to micro-albuminuria at the respective visit, or macro-albuminuria at baseline and normal albuminuria at the respective visit. Normal albuminuria: urine albumin to urinary creatinine ratio (UACR) <30 (mg/g); Micro-albuminuria: UACR ≥30 and ≤300 (mg/g); Macro-albuminuria: UACR>300 (mg/g). (NCT01986881)
Timeframe: Month 48
| Intervention | Percentage of Participants (Number) | |
|---|---|---|
| Percentage of Participants with albuminuria progression | Percentage of Participants with albuminuria regression | |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | 14.9 | 12.2 |
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | 19.5 | 11.6 |
| Placebo (Overall Cardiovascular Study) | 21.5 | 9.9 |
Albuminuria progression and regression were assessed relative to the baseline albuminuria category. Progression was defined as either a change from having normal albuminuria at baseline to micro albuminuria at the respective visit, or micro-albuminuria at baseline to macro-albuminuria at the respective visit, or normal albuminuria at baseline to macro-albuminuria at the respective visit. Regression was defined as either a change from having micro-albuminuria at baseline to normal albuminuria at the respective visit, or macro-albuminuria at baseline to micro-albuminuria at the respective visit, or macro-albuminuria at baseline to normal albuminuria at the respective visit. Normal albuminuria: urine albumin to urinary creatinine ratio (UACR) <30 (mg/g); Micro-albuminuria: UACR ≥30 and ≤300 (mg/g); Macro-albuminuria: UACR>300 (mg/g). (NCT01986881)
Timeframe: Month 60
| Intervention | Percentage of Participants (Number) | |
|---|---|---|
| Percentage of Participants with albuminuria progression | Percentage of Participants with albuminuria regression | |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | 14.7 | 14.8 |
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | 18.6 | 11.3 |
| Placebo (Overall Cardiovascular Study) | 22.1 | 10.5 |
Albuminuria progression and regression were assessed relative to the baseline albuminuria category. Progression was defined as either a change from having normal-albuminuria at baseline to micro-albuminuria at the respective visit, or micro-albuminuria at baseline to macro-albuminuria at the respective visit, or normal albuminuria at baseline to macro-albuminuria at the respective visit. Regression was defined as either a change from having micro-albuminuria at baseline to normal albuminuria at the respective visit, or macro-albuminuria at baseline to micro-albuminuria at the respective visit, or macro-albuminuria at baseline to normal albuminuria at the respective visit. Normal albuminuria: urine albumin to urinary creatinine ratio (UACR) <30 (mg/g); Micro-albuminuria: UACR ≥30 and ≤300 (mg/g); Macro-albuminuria: UACR>300 (mg/g). (NCT01986881)
Timeframe: Week 18
| Intervention | Percentage of Participants (Number) | |
|---|---|---|
| Percentage of Participants with albuminuria progression | Percentage of Participants with albuminuria regression | |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | 7.7 | 14.7 |
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | 7.6 | 14.9 |
| Placebo (Overall Cardiovascular Study) | 10.8 | 10.7 |
Albuminuria progression and regression were assessed relative to the baseline albuminuria category. Progression was defined as either a change from having normal albuminuria at baseline to micro-albuminuria at the respective visit, or micro-albuminuria at baseline to macro-albuminuria at the respective visit, or normal albuminuria at baseline to macro-albuminuria at the respective visit. Regression was defined as either a change from having micro-albuminuria at baseline to normal albuminuria at the respective visit, or macro-albuminuria at baseline to micro-albuminuria at the respective visit, or macro-albuminuria at baseline to normal albuminuria at the respective visit. Normal albuminuria: urine albumin to urinary creatinine ratio (UACR) <30 (mg/g); Micro-albuminuria: UACR ≥30 and ≤300 (mg/g); Macro-albuminuria: UACR>300 (mg/g). (NCT01986881)
Timeframe: Week 52
| Intervention | Percentage of Participants (Number) | |
|---|---|---|
| Percentage of Participants with albuminuria progression | Percentage of Participants with albuminuria regression | |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | 10.2 | 14.8 |
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | 9.5 | 14.6 |
| Placebo (Overall Cardiovascular Study) | 12.9 | 10.2 |
"The KCCQ is a 23-item self-administered questionnaire designed to evaluate physical limitations, symptoms (frequency, severity, and changes over time), social limitations, self-efficacy, and quality of life in patients with Heart Failure. The KCCQ-clinical summary score comprises the following domains: Symptom frequency, symptom burden and physical limitation. The score is calculated by summing domain responses and then transforming scores to a 0-100 unit scale with higher scores indicating better health status.~For patients who died, a worst score (score of 0) was imputed for the score at all subsequent scheduled visits after the date of death where the score would have been assessed.~Change from baseline in KCCQ-score at week 52 was modeled using a MMRM with visit (week 12, 32 and 52) as repeated measures, adjusted mean (standard error) at week 52 is reported." (NCT03057951)
Timeframe: At baseline and at week 12, week 32 and week 52.
| Intervention | Score on a scale (Least Squares Mean) |
|---|---|
| Placebo | 3.18 |
| 10 mg Empagliflozin | 4.51 |
"Glomerular filtration rate estimated by the chronic kidney disease epidemiology collaboration formula with serum creatinine measurement (eGFR(CKD-EPI)cr) slope of change from baseline.~Available on-treatment change-from-baseline data were used. The slope represents the long term effect of eGFR change from baseline and provides the yearly rate of decline.~Timepoints after baseline were included in calculation of slope of change from baseline.~The slope per patient was calculated using a random coefficient model with terms for treatment, region, baseline status of diabetes, age, sex, left ventricular ejection fraction (LVEF) and glomerular filtration rate estimated by the chronic kidney disease epidemiology collaboration formula (eGFR (CKD-EPI)cr) at baseline and in addition the factors time, treatment-by-time interaction, and baseline eGFR (CKD-EPI)cr-by-time interaction." (NCT03057951)
Timeframe: At baseline, week 4, 12, 32, 52, 76, 100, 124, 148, 172 and week 196, up to 1043 days.
| Intervention | mL/min/ 1.73 meters squared/year (Mean) |
|---|---|
| Placebo | -2.616 |
| 10 mg Empagliflozin | -1.253 |
Reported is the total number of adjudicated HHF events (first and recurrent) which occurred. (NCT03057951)
Timeframe: From randomization until completion of the planned treatment phase, up to 1403 days.
| Intervention | HHF events (Number) |
|---|---|
| Placebo | 541 |
| 10 mg Empagliflozin | 407 |
Occurrence of all-cause hospitalisation (first and recurrent). Total number of all cause hospitalisations is reported. (NCT03057951)
Timeframe: From randomization until completion of the planned treatment phase, up to 1403 days.
| Intervention | Events of all-cause hospitialisations (Number) |
|---|---|
| Placebo | 2769 |
| 10 mg Empagliflozin | 2566 |
"Time to adjudicated CV death. The incidence rate per 100 patient years (pt-yrs) is presented and calculated as followed:~Incidence rate per 100 pt-yrs = 100 * number of patients with event / time at risk [years].~Time at risk [years] = Sum of time at risk [days] over all patients in a treatment group / 365.25.~Patients without a specific endpoint event were censored at the last date the patient was known to be free of the event or at the end of the planned treatment period, whichever was earlier." (NCT03057951)
Timeframe: From randomization until completion of the planned treatment phase, up to 1403 days.
| Intervention | Patients with event /100 pt-yrs at risk (Number) |
|---|---|
| Placebo | 3.81 |
| 10 mg Empagliflozin | 3.42 |
"Time to all-cause mortality. The incidence rate per 100 patient years (pt-yrs) is presented and calculated as followed:~Incidence rate per 100 pt-yrs = 100 * number of patients with event / time at risk [years].~Time at risk [years] = Sum of time at risk [days] over all patients in a treatment group / 365.25.~Patients without a specific endpoint event were censored at the last date the patient was known to be free of the event or at the end of the planned treatment period, whichever was earlier." (NCT03057951)
Timeframe: From randomization until completion of the planned treatment phase, up to 1403 days.
| Intervention | Patients with event /100 pt-yrs at risk (Number) |
|---|---|
| Placebo | 6.67 |
| 10 mg Empagliflozin | 6.60 |
"Time to first adjudicated HHF. The incidence rate per 100 patient years (pt-yrs) is presented and calculated as followed:~Incidence rate per 100 pt-yrs = 100 * number of patients with event / time at risk [years].~Time at risk [years] = Sum of time at risk [days] over all patients in a treatment group / 365.25.~Patients without a specific endpoint event were censored at the last date the patient was known to be free of the event or at the end of the planned treatment period, whichever was earlier." (NCT03057951)
Timeframe: From randomization until completion of the planned treatment phase, up to 1403 days.
| Intervention | Patients with event /100 pt-yrs at risk (Number) |
|---|---|
| Placebo | 5.97 |
| 10 mg Empagliflozin | 4.28 |
"Failure with preserved Ejection Fraction (HFpEF). The incidence rate per 100 patient years (pt-yrs) is presented and calculated as followed:~Incidence rate per 100 pt-yrs = 100 * number of patients with event / time at risk [years].~Time at risk [years] = Sum of time at risk [days] over all patients in a treatment group / 365.25.~Patients without a specific endpoint event were censored at the last date the patient was known to be free of the event or at the end of the planned treatment period, whichever was earlier." (NCT03057951)
Timeframe: From randomization until completion of the planned treatment phase, up to 1403 days.
| Intervention | Patients with event/100 pt-yrs at risk (Number) |
|---|---|
| Placebo | 8.67 |
| 10 mg Empagliflozin | 6.86 |
"Time to onset of DM (defined as HbA1c ≥6.5% or as diagnosed by the investigator) in patients with pre-DM.~Pre-DM was defined as no history of DM and no HbA1c ≥6.5% before treatment, and a pre-treatment HbA1c value of ≥5.7% and <6.5%.~The incidence rate per 100 patient years (pt-yrs) is presented and calculated as followed:~Incidence rate per 100 pt-yrs = 100 * number of patients with event / time at risk [years].~Time at risk [years] = Sum of time at risk [days] over all patients in a treatment group / 365.25.~Patients without a specific endpoint event were censored at the last date the patient was known to be free of the event or at the end of the planned treatment period, whichever was earlier." (NCT03057951)
Timeframe: From randomization until completion of the planned treatment phase, to 1403 days.
| Intervention | Patients with event /100 pt-yrs at risk (Number) |
|---|---|
| Placebo | 7.39 |
| 10 mg Empagliflozin | 6.12 |
"Chronic dialysis was defined as dialysis with a frequency of twice per week or more for at least 90 days.~Sustained was determined by two or more consecutive post-baseline central laboratory measurement separated by at least 30 days.~Reduction in glomerular filtration rate estimated by the chronic kidney disease epidemiology collaboration formula with serum creatinine measurement (eGFR (CKD-EPI)cr) was defined as reduction in eGFR from baseline ≥40%, eGFR <15 mL/min/1.73 m^2 for patients with baseline eGFR ≥30 mL/min/1.73 m^2, or eGFR <10 mL/min/1.73 m^2 for patients with baseline eGFR <30 mL/min/1.73 m^2.~The incidence rate per 100 patient years (100 * number of patients with event / time at risk [years]) is reported. Time at risk [year] is calculated as: Sum of time at risk [days] over all patients in a treatment group / 365.25.~Abbreviation:~Patient-years (pt-yrs)." (NCT03057951)
Timeframe: From randomization until completion of the planned treatment phase, up to 1403 days.
| Intervention | Patients with event /100 pt-yrs at risk (Number) |
|---|---|
| Placebo | 2.23 |
| 10 mg Empagliflozin | 2.13 |
Heart rate was measured after 10 minutes resting in a supine position (3 measurements taken approximately 2 minutes apart). The changes in heart rate were recorded and the mean of the three measurements was analyzed. (NCT01951625)
Timeframe: Baseline, Week 12
| Intervention | Beats per minute (Mean) |
|---|---|
| Placebo | -0.562 |
| BAY1021189 1.25 Milligram (mg) | -0.352 |
| BAY1021189 2.5 mg | -1.556 |
| BAY1021189 From 2.5 to 5 mg | -0.99 |
| BAY1021189 From 2.5 to 10 mg | 0.545 |
Log-Transformed N-Terminal Pro-Brain Natriuretic Peptide (NTproBNP) is a circulating plasma biomarker of cardiovascular function and prognosis in heart failure. (NCT01951625)
Timeframe: Baseline, Week 12
| Intervention | log-transformed picograms per milliliter (Mean) |
|---|---|
| Placebo | -0.28 |
| BAY1021189 1.25 Milligram (mg) | -0.265 |
| BAY1021189 2.5 mg | -0.32 |
| BAY1021189 From 2.5 to 5 mg | -0.353 |
| BAY1021189 From 2.5 to 10 mg | -0.529 |
| Pooled 2.5 mg up to 10 mg | -0.402 |
cGMP: cyclic guanosine monophosphate (NCT01951625)
Timeframe: Baseline, Week 12
| Intervention | picomole(s)/milliliter (pmol/mL) (Mean) |
|---|---|
| Placebo | 78.874 |
| BAY1021189 1.25 Milligram (mg) | 79.767 |
| BAY1021189 2.5 mg | 92.352 |
| BAY1021189 From 2.5 to 5 mg | 80.888 |
| BAY1021189 From 2.5 to 10 mg | 63.563 |
Gal-3: Galectin-3 (NCT01951625)
Timeframe: Baseline, Week 12
| Intervention | mcg/L (Mean) |
|---|---|
| Placebo | 0.802 |
| BAY1021189 1.25 Milligram (mg) | 0.233 |
| BAY1021189 2.5 mg | -0.287 |
| BAY1021189 From 2.5 to 5 mg | 0.064 |
| BAY1021189 From 2.5 to 10 mg | -0.38 |
GDF-15: growth differentiation factor 15 (NCT01951625)
Timeframe: Baseline, Week 12
| Intervention | pg/mL (Mean) |
|---|---|
| Placebo | 429.432 |
| BAY1021189 1.25 Milligram (mg) | 496.456 |
| BAY1021189 2.5 mg | 285.472 |
| BAY1021189 From 2.5 to 5 mg | 468.369 |
| BAY1021189 From 2.5 to 10 mg | 244.63 |
(NCT01951625)
Timeframe: Baseline, Week 12
| Intervention | nanogram(s)/milliliter (ng/mL) (Mean) |
|---|---|
| Placebo | 2.79 |
| BAY1021189 1.25 Milligram (mg) | 3.812 |
| BAY1021189 2.5 mg | 3.266 |
| BAY1021189 From 2.5 to 5 mg | 8.485 |
| BAY1021189 From 2.5 to 10 mg | 3.709 |
PIIINP: pro-collagen III N-terminal peptide (NCT01951625)
Timeframe: Baseline, Week 12
| Intervention | microgram(s)/liter (mcg/L) (Mean) |
|---|---|
| Placebo | -0.701 |
| BAY1021189 1.25 Milligram (mg) | 0.092 |
| BAY1021189 2.5 mg | 0.106 |
| BAY1021189 From 2.5 to 5 mg | -0.71 |
| BAY1021189 From 2.5 to 10 mg | -0.321 |
ST2: suppression of tumorigenicity 2 (NCT01951625)
Timeframe: Baseline, Week 12
| Intervention | pg/mL (Mean) |
|---|---|
| Placebo | 9457.677 |
| BAY1021189 1.25 Milligram (mg) | 1623.869 |
| BAY1021189 2.5 mg | -1217.77 |
| BAY1021189 From 2.5 to 5 mg | 6933.941 |
| BAY1021189 From 2.5 to 10 mg | 3681.668 |
TIMP-4: tissue inhibitor of matrix metalloproteinases 4 (NCT01951625)
Timeframe: Baseline, Week 12
| Intervention | picogram(s)/millilitre (pg/mL) (Mean) |
|---|---|
| Placebo | 451.889 |
| BAY1021189 1.25 Milligram (mg) | 1128.635 |
| BAY1021189 2.5 mg | 643.626 |
| BAY1021189 From 2.5 to 5 mg | 876.584 |
| BAY1021189 From 2.5 to 10 mg | 397.603 |
The left ventricular ejection fraction work index (LVEF) is a calculated echocardiography parameter. LVEF is derived from the directly measured parameters left ventricular end-diastolic volume (LVEDV) and left ventricular end-systolic volume (LVESV). These 2 parameters are acquired during a noninvasive echocardiography examination. Formula: LVEF = 100*(LVEDV - LVESV)/LVEDV. (NCT01951625)
Timeframe: Baseline, Week 12
| Intervention | percentage (Mean) |
|---|---|
| Placebo | 1.515 |
| BAY1021189 1.25 Milligram (mg) | 2.84 |
| BAY1021189 2.5 mg | 2.741 |
| BAY1021189 From 2.5 to 5 mg | 2.07 |
| BAY1021189 From 2.5 to 10 mg | 3.682 |
An adverse event (AE) was any untoward medical occurrence in a subject who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; and another medically important serious event as judged by the investigator. AEs are considered to be treatment-emergent if they have started or worsened after first application of study drug up to 5 days after end of treatment with study drug. (NCT01951625)
Timeframe: From the start of study treatment upto 5 days after the last dose of study drug
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 66 |
| BAY1021189 1.25 Milligram (mg) | 60 |
| BAY1021189 2.5 mg | 62 |
| BAY1021189 From 2.5 to 5 mg | 62 |
| BAY1021189 From 2.5 to 10 mg | 56 |
Blood pressure was measured by monitor measurements after 10 minutes resting in a supine position (3 measurements taken approximately 2 minutes apart).The changes in blood pressure were recorded and the mean of the three measurements was analyzed. (NCT01951625)
Timeframe: Baseline, Week 12
| Intervention | millimeter of mercury (mmHg) (Mean) | |
|---|---|---|
| Change in SBP | Change in DBP | |
| BAY1021189 1.25 Milligram (mg) | -4.033 | -0.486 |
| BAY1021189 2.5 mg | -3.733 | -2.938 |
| BAY1021189 From 2.5 to 10 mg | -5.64 | -4.045 |
| BAY1021189 From 2.5 to 5 mg | -3.043 | -1.338 |
| Placebo | -5.142 | -4.173 |
Left Ventricular End-Diastolic Volume (LVEDV) and Left ventricular end-systolic volume (LVESV) are measured echocardiography parameter. These are acquired during a non-invasive echocardiography examination. (NCT01951625)
Timeframe: Baseline, Week 12
| Intervention | milliliter (Mean) | |
|---|---|---|
| Change in LVEDV | Change in LVESV | |
| BAY1021189 1.25 Milligram (mg) | -5.525 | -8.585 |
| BAY1021189 2.5 mg | -9.632 | -10.935 |
| BAY1021189 From 2.5 to 10 mg | -7.324 | -11.017 |
| BAY1021189 From 2.5 to 5 mg | -17.093 | -15.485 |
| Placebo | -7.259 | -6.83 |
Clinical events (heart failure and mortality) were analyzed as CV death, and HF hospitalization at specified time points. (NCT01951625)
Timeframe: Baseline until 16 weeks
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| HF hospitalizations | CV death | |
| BAY1021189 1.25 Milligram (mg) | 18 | 5 |
| BAY1021189 2.5 mg | 20 | 4 |
| BAY1021189 From 2.5 to 10 mg | 9 | 4 |
| BAY1021189 From 2.5 to 5 mg | 10 | 2 |
| Placebo | 21 | 6 |
34 reviews available for uric acid and Heart Failure
| Article | Year |
|---|---|
Hyperuricemia and the Risk of Heart Failure: Pathophysiology and Therapeutic Implications.
Topics: Heart Failure; Humans; Hyperuricemia; Oxidative Stress; Reactive Oxygen Species; Risk Factors; Uric | 2021 |
SGLT2 Inhibitors: Benefits for CKD and Cardiovascular Disease in Type 2 Diabetes.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Heart Failure; Humans; Male; Renal Insuf | 2022 |
Association of Dapagliflozin Use With Clinical Outcomes and the Introduction of Uric Acid-Lowering Therapy and Colchicine in Patients With Heart Failure With and Without Gout: A Patient-Level Pooled Meta-analysis of DAPA-HF and DELIVER.
Topics: Aged; Colchicine; Gout; Heart Failure; Humans; Male; Stroke Volume; Uric Acid; Ventricular Function, | 2023 |
Advances in pharmacotherapies for hyperuricemia.
Topics: Enzyme Inhibitors; Gout Suppressants; Heart Failure; Humans; Hyperuricemia; Kidney; Uric Acid | 2023 |
Hyperuricemia: a novel old disorder-relationship and potential mechanisms in heart failure.
Topics: Angiotensin II Type 1 Receptor Blockers; Cardiovascular Diseases; Disease Progression; Gout; Gout Su | 2020 |
Effect of Uric Acid-Lowering Agents on Cardiovascular Outcome in Patients With Heart Failure: A Systematic Review and Meta-Analysis of Clinical Studies.
Topics: Allopurinol; Enzyme Inhibitors; Febuxostat; Heart Failure; Humans; Oxypurinol; Uric Acid; Xanthine O | 2020 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Network Meta-Analysis of Drug Therapies for Lowering Uric Acid and Mortality Risk in Patients with Heart Failure.
Topics: Allopurinol; Gout Suppressants; Heart Failure; Humans; Hyperuricemia; Network Meta-Analysis; Uric Ac | 2021 |
Role of comorbidities in heart failure prognosis Part 2: Chronic kidney disease, elevated serum uric acid.
Topics: Biomarkers; Comorbidity; Heart Disease Risk Factors; Heart Failure; Humans; Hyperuricemia; Prognosis | 2020 |
Uric acid as a cardiorenal mediator: pathogenesis and mechanistic insights.
Topics: Cardiovascular Diseases; Heart Failure; Humans; Hyperuricemia; Kidney Diseases; Uric Acid | 2021 |
Prognostic value of serum uric acid in patients with acute heart failure: A meta-analysis.
Topics: Aged; Aged, 80 and over; Biomarkers; Female; Heart Failure; Humans; Hyperuricemia; Male; Middle Aged | 2019 |
[Hyperuricemia and cardiovascular continuum].
Topics: Cardiovascular Diseases; Heart Failure; Humans; Hyperuricemia; Uric Acid | 2013 |
Uric acid and risk of heart failure: a systematic review and meta-analysis.
Topics: Global Health; Heart Failure; Humans; Hyperuricemia; Incidence; Prognosis; Risk Factors; Uric Acid | 2014 |
Clinical diagnosis of pulmonary hypertension.
Topics: Age Distribution; Age of Onset; Cardiac Catheterization; Diagnostic Techniques, Cardiovascular; Elec | 2014 |
Uric acid and xanthine oxidase in heart failure - Emerging data and therapeutic implications.
Topics: Heart Failure; Humans; Prognosis; Reactive Oxygen Species; Risk Factors; Uric Acid; Xanthine Oxidase | 2016 |
Role of Uric Acid Metabolism-Related Inflammation in the Pathogenesis of Metabolic Syndrome Components Such as Atherosclerosis and Nonalcoholic Steatohepatitis.
Topics: Animals; Atherosclerosis; Disease Progression; Free Radicals; Heart Failure; Humans; Inflammasomes; | 2016 |
Uric acid: A marker of increased cardiovascular risk.
Topics: Biomarkers; Cardiovascular Diseases; Carotid Artery Diseases; Coronary Artery Disease; Female; Heart | 2009 |
The ACTION study: nifedipine in patients with symptomatic stable angina and hypertension.
Topics: Angina Pectoris; Blood Pressure; Calcium Channel Blockers; Cardiovascular Diseases; Comorbidity; Cor | 2008 |
[Biomarkers in heart failure: are they clinically useful?].
Topics: Anemia; Biomarkers; Chronic Disease; Creatinine; Diagnosis, Differential; Heart Failure; Hemoglobins | 2009 |
Biomarkers of oxidative stress in heart failure.
Topics: Biomarkers; Heart Failure; Hemoglobins; Humans; Lipoproteins, LDL; Oxidative Stress; Peroxidase; Uri | 2009 |
[Hyperuricemia in chronic heart failure].
Topics: Age Factors; Biomarkers; Chronic Disease; Diuretics; Echocardiography; Free Radicals; Heart Failure; | 2011 |
[The role of uric acid in heart failure].
Topics: Animals; Biomarkers; Chronic Disease; Heart Failure; Humans; Oxidative Stress; Uric Acid; Xanthine O | 2011 |
Xanthine oxidase and uric acid in cardiovascular disease: clinical impact and therapeutic options.
Topics: Biomarkers; Cardiovascular Diseases; Heart Failure; Humans; Hyperuricemia; Reactive Oxygen Species; | 2011 |
Uric acid in heart failure: a biomarker or therapeutic target?
Topics: Biomarkers; Heart Failure; Humans; Hyperuricemia; Prognosis; Severity of Illness Index; Uric Acid | 2013 |
The management of hyperuricemia and gout in patients with heart failure.
Topics: Cardiovascular Agents; Comorbidity; Gout; Gout Suppressants; Heart Failure; Humans; Risk Factors; Ur | 2002 |
Uric acid in chronic heart failure.
Topics: Allopurinol; Animals; Biomarkers; Blood Flow Velocity; Blood Vessels; Chronic Disease; Disease Progr | 2005 |
The increase in serum uric acid concentration caused by diuretics might be beneficial in heart failure.
Topics: Allopurinol; Diuretics; Free Radical Scavengers; Heart Failure; Humans; Kidney; Oxidative Stress; Ur | 2005 |
[Uric acid as a marker of pathophysiological mechanisms in patients with cardiovascular disease].
Topics: Biomarkers; Cardiovascular Diseases; Heart Failure; Humans; Myocardial Ischemia; Prognosis; Uric Aci | 2005 |
The paradoxical relationship between serum uric acid and cardiovascular disease.
Topics: Animals; Antioxidants; Cardiovascular Diseases; Heart Failure; Humans; Hypertension; Hyperuricemia; | 2008 |
[Pharmacological characteristics and clinical application of losartan, an orally active AT1 angiotensin II receptor antagonist].
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Chronic Disease; Clinical Trials | 1999 |
Pearls and pitfalls in the use and abuse of diuretics for chronic congestive heart failure.
Topics: Animals; Calcium; Cardiac Output; Chronic Disease; Contraindications; Digitalis; Diuretics; Drug Int | 1999 |
The elderly patient. A special case for diuretic therapy.
Topics: Aged; Aging; Cerebrovascular Disorders; Diuretics; Heart Failure; Humans; Hyperglycemia; Hyperlipide | 1986 |
Combinations of diuretics in the treatment of edema.
Topics: Acetazolamide; Benzothiadiazines; Chlorthalidone; Diuretics; Edema; Ethacrynic Acid; Furosemide; Glu | 1970 |
Diuretics. II. Clinical considerations.
Topics: Administration, Oral; Aminophylline; Ascites; Calcium; Carbohydrate Metabolism; Carbonic Anhydrase I | 1971 |
42 trials available for uric acid and Heart Failure
| Article | Year |
|---|---|
Comparison between febuxostat and allopurinol uric acid-lowering therapy in patients with chronic heart failure and hyperuricemia: a multicenter randomized controlled trial.
Topics: Allopurinol; Febuxostat; Heart Failure; Humans; Hyperuricemia; Uric Acid | 2021 |
Dapagliflozin reduces uric acid concentration, an independent predictor of adverse outcomes in DAPA-HF.
Topics: Aged; Benzhydryl Compounds; Female; Glucosides; Heart Failure; Humans; Male; Middle Aged; Stroke Vol | 2022 |
Mediators of ertugliflozin effects on heart failure and kidney outcomes among patients with type 2 diabetes mellitus.
Topics: Biomarkers; Bridged Bicyclo Compounds, Heterocyclic; Diabetes Mellitus, Type 2; Double-Blind Method; | 2022 |
Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the EMPEROR-reduced trial.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Female; Glucose; Glucosides; Heart Failure; Humans; | 2022 |
Effects of Empagliflozin in Women and Men With Heart Failure and Preserved Ejection Fraction.
Topics: Benzhydryl Compounds; Cardiomyopathies; Female; Glucosides; Heart Failure; Humans; Male; Stroke Volu | 2022 |
High- versus low-dose losartan and uric acid: An analysis from HEAAL.
Topics: Heart Failure; Humans; Hyperuricemia; Losartan; Stroke Volume; Uric Acid; Ventricular Function, Left | 2023 |
Uric acid-lowering therapy with benzbromarone in hypertension with asymptomatic hyperuricemia: a randomized study focusing left ventricular diastolic function.
Topics: Benzbromarone; Heart Failure; Humans; Hypertension; Hyperuricemia; Stroke Volume; Uric Acid | 2023 |
Elevated Uric Acid Prevalence and Clinical Outcomes in Patients with Heart Failure with Preserved Ejection Fraction: Insights from RELAX.
Topics: Aged; Double-Blind Method; Female; Heart Failure; Humans; Male; Middle Aged; Sildenafil Citrate; Uri | 2020 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Associations of methyl donor and methylation inhibitor levels during anti-oxidant therapy in heart failure.
Topics: Aged; Allopurinol; Female; Free Radical Scavengers; Heart Failure; Humans; Hyperuricemia; Male; Meth | 2021 |
Prevalence of Hyperuricemia in Patients With Acute Heart Failure With Either Reduced or Preserved Ejection Fraction.
Topics: Acute Disease; Aged; Aged, 80 and over; Double-Blind Method; Female; Follow-Up Studies; Heart Failur | 2017 |
Sacubitril/valsartan reduces serum uric acid concentration, an independent predictor of adverse outcomes in PARADIGM-HF.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biomarkers; Biphenyl Compounds; Double-Blind Metho | 2018 |
Prognostic impact of elevated serum uric acid levels on long-term outcomes in patients with chronic heart failure: A post-hoc analysis of the GISSI-HF (Gruppo Italiano per lo Studio della Sopravvivenza nella Insufficienza Cardiaca-Heart Failure) trial.
Topics: Aged; Cause of Death; Chronic Disease; Fatty Acids, Omega-3; Female; Heart Failure; Humans; Italy; M | 2018 |
Safety of add-on tolvaptan in patients with furosemide-resistant congestive heart failure complicated by advanced chronic kidney disease: a sub-analysis of a pharmacokinetics/ pharmacodynamics study.
Topics: Adult; Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Blood Press | 2015 |
Serum uric acid is associated with mortality and heart failure hospitalizations in patients with complicated myocardial infarction: findings from the High-Risk Myocardial Infarction Database Initiative.
Topics: Aged; Biomarkers; Female; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Myocardial Infa | 2015 |
Determinants and Prognostic Impact of Hyperuricemia in Hospitalization for Acute Heart Failure.
Topics: Acute Disease; Aged; Aged, 80 and over; Disease-Free Survival; Female; Follow-Up Studies; Heart Fail | 2016 |
Prognostic Significance of Hyperuricemia in Patients With Acute Heart Failure.
Topics: Acute Disease; Aged, 80 and over; Biomarkers; Female; Follow-Up Studies; Heart Failure; Humans; Hype | 2016 |
Prednisone lowers serum uric acid levels in patients with decompensated heart failure by increasing renal uric acid clearance.
Topics: Anti-Inflammatory Agents; Biomarkers; Dose-Response Relationship, Drug; Female; Heart Failure; Human | 2016 |
Impact of oxypurinol in patients with symptomatic heart failure. Results of the OPT-CHF study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Double-Blind Method; Enzyme Inhibitors; Female; Health S | 2008 |
Uric acid-lowering treatment with benzbromarone in patients with heart failure: a double-blind placebo-controlled crossover preliminary study.
Topics: Aged; Benzbromarone; Double-Blind Method; Female; Heart Failure; Humans; Hyperuricemia; Male; Middle | 2010 |
Elevated levels of asymmetric dimethylarginine in chronic heart failure: a pathophysiologic link between oxygen radical load and impaired vasodilator capacity and the therapeutic effect of allopurinol.
Topics: Aged; Allopurinol; Arginine; Chronic Disease; Citrulline; Cross-Sectional Studies; Double-Blind Meth | 2010 |
The independent impact of congestive heart failure status and diuretic use on serum uric acid among men with a high cardiovascular risk profile: a prospective longitudinal study.
Topics: Adult; Diuretics; Heart Failure; Humans; Hyperuricemia; Longitudinal Studies; Male; Middle Aged; Pro | 2011 |
Clinical effects of enhanced external counterpulsation treatment in patients with ischemic heart failure.
Topics: Aged; Blood Pressure; Cohort Studies; Counterpulsation; Electrocardiography; Female; Heart Failure; | 2012 |
Biomarkers in acutely decompensated heart failure with preserved or reduced ejection fraction.
Topics: Aged; Aged, 80 and over; Aldosterone; Biomarkers; Blood Pressure; Cystatin C; Diuretics; Double-Blin | 2012 |
Nutrition intervention to decrease symptoms in patients with advanced heart failure.
Topics: Biomarkers; Carotenoids; Diet, Sodium-Restricted; Dietary Supplements; Dinoprost; Fatty Acids, Omega | 2013 |
Prednisone in Uric Acid lowering in Symptomatic Heart Failure Patients With Hyperuricemia (PUSH-PATH) study.
Topics: Adult; Allopurinol; Creatinine; Dyspnea; Female; Glomerular Filtration Rate; Glucocorticoids; Gout S | 2013 |
Prednisone in Uric Acid lowering in Symptomatic Heart Failure Patients With Hyperuricemia (PUSH-PATH) study.
Topics: Adult; Allopurinol; Creatinine; Dyspnea; Female; Glomerular Filtration Rate; Glucocorticoids; Gout S | 2013 |
Prednisone in Uric Acid lowering in Symptomatic Heart Failure Patients With Hyperuricemia (PUSH-PATH) study.
Topics: Adult; Allopurinol; Creatinine; Dyspnea; Female; Glomerular Filtration Rate; Glucocorticoids; Gout S | 2013 |
Prednisone in Uric Acid lowering in Symptomatic Heart Failure Patients With Hyperuricemia (PUSH-PATH) study.
Topics: Adult; Allopurinol; Creatinine; Dyspnea; Female; Glomerular Filtration Rate; Glucocorticoids; Gout S | 2013 |
Effect of selective and nonselective beta-blockers on resting energy production rate and total body substrate utilization in chronic heart failure.
Topics: Adipose Tissue; Adrenergic beta-Antagonists; Aged; Basal Metabolism; Bisoprolol; Blood Pressure; Bod | 2002 |
[Endothelial protection in patients with apparent cardiac failure in long-term therapy by carvedilol].
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Dose-Response Relationship, Drug; Drug Therapy, | 2003 |
The effect of xanthine oxidase inhibition upon ejection fraction in heart failure patients: La Plata Study.
Topics: Aged; Double-Blind Method; Enzyme Inhibitors; Female; Heart Failure; Humans; Male; Oxypurinol; Physi | 2006 |
[Short and long term treatment of cardiac edemas with ethacrynic acid].
Topics: Adult; Aged; Blood Pressure; Diuresis; Ethacrynic Acid; Female; Heart Failure; Humans; Hypokalemia; | 1967 |
The Persantine-aspirin reinfarction study. The Persantine-aspirin Reinfarction Study (PARIS) research group.
Topics: Aspirin; Blood Pressure; Blood Urea Nitrogen; Cerebrovascular Disorders; Clinical Trials as Topic; C | 1980 |
Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as a bolus, in refractory congestive heart failure.
Topics: Aged; Aged, 80 and over; Blood Pressure; Body Weight; Creatinine; Diuresis; Diuretics; Drug Therapy, | 2000 |
Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as a bolus, in refractory congestive heart failure.
Topics: Aged; Aged, 80 and over; Blood Pressure; Body Weight; Creatinine; Diuresis; Diuretics; Drug Therapy, | 2000 |
Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as a bolus, in refractory congestive heart failure.
Topics: Aged; Aged, 80 and over; Blood Pressure; Body Weight; Creatinine; Diuresis; Diuretics; Drug Therapy, | 2000 |
Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as a bolus, in refractory congestive heart failure.
Topics: Aged; Aged, 80 and over; Blood Pressure; Body Weight; Creatinine; Diuresis; Diuretics; Drug Therapy, | 2000 |
Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies.
Topics: Administration, Oral; Aged; Allantoin; Allopurinol; Blood Flow Velocity; Chronic Disease; Cross-Over | 2002 |
Renal function during therapy in patients with congestive cardiac failure. Ticrynafen vs. hydrochlorothiazide.
Topics: Clinical Trials as Topic; Diuretics; Female; Heart Failure; Humans; Hydrochlorothiazide; Male; Middl | 1979 |
A single dose comparison of piretanide and bumetanide in congestive cardiac failure.
Topics: Aged; Bumetanide; Calcium; Clinical Trials as Topic; Diuretics; Female; Heart Failure; Humans; Male; | 1979 |
Safety of tienilic acid.
Topics: Clinical Trials as Topic; Glycolates; Heart Failure; Humans; Hydrochlorothiazide; Hypertension; Kidn | 1979 |
[Tienilic acid in the treatment of arterial hypertension and congestive cardiac insufficiency].
Topics: Adult; Aged; Diuresis; Drug Evaluation; Female; Glycolates; Heart Failure; Humans; Hydrochlorothiazi | 1979 |
Comparison of muzolimine and furosemide in heart failure.
Topics: Aged; Electrolytes; Female; Furosemide; Heart Failure; Humans; Kidney; Male; Middle Aged; Muzolimine | 1985 |
Effects of treatment on morbidity in hypertension. 3. Influence of age, diastolic pressure, and prior cardiovascular disease; further analysis of side effects.
Topics: Adult; Age Factors; Aged; Aneurysm; Atrial Fibrillation; Blood Glucose; Blood Pressure; Cerebrovascu | 1972 |
[MK 87O. A new potassium-retaining diuretic].
Topics: Aged; Anuria; Chlorides; Clinical Trials as Topic; Diuretics; Drug Synergism; Ethacrynic Acid; Femal | 1968 |
The combination of guanethidine and hydrochlorothiazide in the treatment of arterial hypertension with and without renal failure.
Topics: Adult; Analysis of Variance; Blood Pressure; Clinical Trials as Topic; Creatine; Drug Synergism; Fem | 1968 |
[The effect of a new diuretic (furosemide) on the uric acid metabolism].
Topics: Clinical Trials as Topic; Furosemide; Heart Failure; Humans; Uric Acid | 1965 |
237 other studies available for uric acid and Heart Failure
| Article | Year |
|---|---|
The prognostic impact of uric acid in acute heart failure according to coexistence of diabetes mellitus.
Topics: Aged; Biomarkers; Diabetes Mellitus; Female; Heart Failure; Hospitalization; Humans; Male; Prognosis | 2021 |
Impact of serum uric acid levels on cardiovascular events and quality of life in patients with chronic coronary syndromes: Insights from a contemporary, prospective, nationwide registry.
Topics: Heart Failure; Humans; Quality of Life; Registries; Risk Factors; Syndrome; Uric Acid | 2022 |
Uric acid associated with acute heart failure presentation in Acute Coronary Syndrome patients.
Topics: Acute Coronary Syndrome; Aged; Cross-Sectional Studies; Female; Heart Failure; Humans; Longitudinal | 2022 |
Association between higher serum uric acid levels and plasma N-terminal pro-B-type natriuretic peptide concentrations in patients with coronary artery disease and without overt heart failure.
Topics: Biomarkers; Coronary Artery Disease; Heart Failure; Humans; Natriuretic Peptide, Brain; Peptide Frag | 2022 |
Association between higher serum uric acid levels and plasma N-terminal pro-B-type natriuretic peptide concentrations in patients with coronary artery disease and without overt heart failure.
Topics: Biomarkers; Coronary Artery Disease; Heart Failure; Humans; Natriuretic Peptide, Brain; Peptide Frag | 2022 |
Sodium-glucose cotransporter 2 inhibition, uric acid, and heart failure: correlation without causation?
Topics: Diabetes Mellitus, Type 2; Glucose; Heart Failure; Humans; Sodium; Uric Acid | 2022 |
Abnormal ADAMTS2 and VSIG4 in Serum of HF Patients and their Relationship with CRP, UA, and HCY.
Topics: ADAMTS Proteins; Biomarkers; C-Reactive Protein; Heart Failure; Homocysteine; Humans; Natriuretic Pe | 2022 |
Serum urate and heart failure: a bidirectional Mendelian randomization study.
Topics: Genome-Wide Association Study; Heart Failure; Humans; Mendelian Randomization Analysis; Odds Ratio; | 2022 |
Effectiveness and safety of sacubitril/valsartan for patients with hypertension and heart failure in the real-world setting: A retrospective study in China.
Topics: Adult; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Creatinine; Drug Combin | 2022 |
Patient profiles on outcomes in patients hospitalized for heart failure: a 10-year history of the Malaysian population.
Topics: Aged; Creatinine; Heart Failure; Hospitalization; Humans; Kidney Failure, Chronic; Male; Middle Aged | 2022 |
Risk factors of short-term, intermediate-term, and long-term cardiac events in patients hospitalized for HFmrEF.
Topics: Aged; Biomarkers; Creatinine; Female; Heart Failure; Humans; Male; Middle Aged; Prognosis; Retrospec | 2022 |
Controversial relationship between serum urate and heart failure?
Topics: Heart Failure; Humans; Mendelian Randomization Analysis; Risk Factors; Uric Acid | 2022 |
Serum uric acid lowering with empagliflozin in heart failure with reduced ejection fraction: a sweet added benefit?
Topics: Benzhydryl Compounds; Glucose; Glucosides; Heart Failure; Humans; Sodium; Uric Acid | 2022 |
Sodium-glucose cotransporter 2 inhibitor treatment lowers serum uric acid in patients with heart failure with reduced ejection fraction - lessons from clinical trials. Letter regarding the article 'Dapagliflozin reduces uric acid concentration, an indepen
Topics: Diabetes Mellitus, Type 2; Glucose; Heart Failure; Humans; Sodium; Stroke Volume; Uric Acid; Ventric | 2022 |
Reply to 'Sodium-glucose cotransporter 2 inhibitor treatment lowers serum uric acid in patients with heart failure with reduced ejection fraction - lessons from clinical trials'.
Topics: Glucose; Heart Failure; Humans; Sodium; Stroke Volume; Uric Acid; Ventricular Dysfunction, Left | 2022 |
Genetic Association of Beta-Myosin Heavy-Chain Gene (MYH7) with Cardiac Dysfunction.
Topics: Cardiac Myosins; Cholesterol, LDL; Heart Diseases; Heart Failure; Humans; Mutation; Myosin Heavy Cha | 2022 |
Serum Uric Acid Is Associated with the Progression of Left Ventricular Diastolic Dysfunction in Apparently Healthy Subjects.
Topics: Healthy Volunteers; Heart Failure; Humans; Stroke Volume; Uric Acid; Ventricular Dysfunction, Left | 2022 |
[Prognostic impact of uric acid in patients with acute decompensated heart failure].
Topics: Diuretics; Female; Glomerular Filtration Rate; Heart Failure; Humans; Hyperuricemia; Male; Middle Ag | 2021 |
Canagliflozin independently reduced plasma volume from conventional diuretics in patients with type 2 diabetes and chronic heart failure: a subanalysis of the CANDLE trial.
Topics: Canagliflozin; Chronic Disease; Diabetes Mellitus, Type 2; Diuretics; Electrolytes; Heart Failure; H | 2023 |
Canagliflozin independently reduced plasma volume from conventional diuretics in patients with type 2 diabetes and chronic heart failure: a subanalysis of the CANDLE trial.
Topics: Canagliflozin; Chronic Disease; Diabetes Mellitus, Type 2; Diuretics; Electrolytes; Heart Failure; H | 2023 |
Canagliflozin independently reduced plasma volume from conventional diuretics in patients with type 2 diabetes and chronic heart failure: a subanalysis of the CANDLE trial.
Topics: Canagliflozin; Chronic Disease; Diabetes Mellitus, Type 2; Diuretics; Electrolytes; Heart Failure; H | 2023 |
Canagliflozin independently reduced plasma volume from conventional diuretics in patients with type 2 diabetes and chronic heart failure: a subanalysis of the CANDLE trial.
Topics: Canagliflozin; Chronic Disease; Diabetes Mellitus, Type 2; Diuretics; Electrolytes; Heart Failure; H | 2023 |
Canagliflozin independently reduced plasma volume from conventional diuretics in patients with type 2 diabetes and chronic heart failure: a subanalysis of the CANDLE trial.
Topics: Canagliflozin; Chronic Disease; Diabetes Mellitus, Type 2; Diuretics; Electrolytes; Heart Failure; H | 2023 |
Canagliflozin independently reduced plasma volume from conventional diuretics in patients with type 2 diabetes and chronic heart failure: a subanalysis of the CANDLE trial.
Topics: Canagliflozin; Chronic Disease; Diabetes Mellitus, Type 2; Diuretics; Electrolytes; Heart Failure; H | 2023 |
Canagliflozin independently reduced plasma volume from conventional diuretics in patients with type 2 diabetes and chronic heart failure: a subanalysis of the CANDLE trial.
Topics: Canagliflozin; Chronic Disease; Diabetes Mellitus, Type 2; Diuretics; Electrolytes; Heart Failure; H | 2023 |
Canagliflozin independently reduced plasma volume from conventional diuretics in patients with type 2 diabetes and chronic heart failure: a subanalysis of the CANDLE trial.
Topics: Canagliflozin; Chronic Disease; Diabetes Mellitus, Type 2; Diuretics; Electrolytes; Heart Failure; H | 2023 |
Canagliflozin independently reduced plasma volume from conventional diuretics in patients with type 2 diabetes and chronic heart failure: a subanalysis of the CANDLE trial.
Topics: Canagliflozin; Chronic Disease; Diabetes Mellitus, Type 2; Diuretics; Electrolytes; Heart Failure; H | 2023 |
Uric acid in advanced heart failure: relation to central haemodynamics and outcome.
Topics: Adult; Female; Heart Failure; Hemodynamics; Humans; Male; Middle Aged; Retrospective Studies; Stroke | 2022 |
Uric acid in advanced heart failure: relation to central haemodynamics and outcome.
Topics: Adult; Female; Heart Failure; Hemodynamics; Humans; Male; Middle Aged; Retrospective Studies; Stroke | 2022 |
Uric acid in advanced heart failure: relation to central haemodynamics and outcome.
Topics: Adult; Female; Heart Failure; Hemodynamics; Humans; Male; Middle Aged; Retrospective Studies; Stroke | 2022 |
Uric acid in advanced heart failure: relation to central haemodynamics and outcome.
Topics: Adult; Female; Heart Failure; Hemodynamics; Humans; Male; Middle Aged; Retrospective Studies; Stroke | 2022 |
Uric acid in advanced heart failure: relation to central haemodynamics and outcome.
Topics: Adult; Female; Heart Failure; Hemodynamics; Humans; Male; Middle Aged; Retrospective Studies; Stroke | 2022 |
Uric acid in advanced heart failure: relation to central haemodynamics and outcome.
Topics: Adult; Female; Heart Failure; Hemodynamics; Humans; Male; Middle Aged; Retrospective Studies; Stroke | 2022 |
Uric acid in advanced heart failure: relation to central haemodynamics and outcome.
Topics: Adult; Female; Heart Failure; Hemodynamics; Humans; Male; Middle Aged; Retrospective Studies; Stroke | 2022 |
Uric acid in advanced heart failure: relation to central haemodynamics and outcome.
Topics: Adult; Female; Heart Failure; Hemodynamics; Humans; Male; Middle Aged; Retrospective Studies; Stroke | 2022 |
Uric acid in advanced heart failure: relation to central haemodynamics and outcome.
Topics: Adult; Female; Heart Failure; Hemodynamics; Humans; Male; Middle Aged; Retrospective Studies; Stroke | 2022 |
Optimal uric acid reduction to improve vascular endothelial function in patients with chronic heart failure complicated by hyperuricemia.
Topics: Chronic Disease; Diuretics; Endothelium, Vascular; Enzyme Inhibitors; Heart Failure; Humans; Hyperem | 2023 |
Tips and pitfalls in uric acid clinical research.
Topics: Chronic Disease; Heart Failure; Humans; Hyperuricemia; Uric Acid | 2023 |
Association between serum uric acid levels and the prevalence of heart failure due to acute coronary syndrome in Chinese hospitalized patients: A cross-sectional study.
Topics: Acute Coronary Syndrome; Cross-Sectional Studies; East Asian People; Heart Failure; Humans; Prevalen | 2023 |
The effect of serum uric acid concentration on the severity of chronic congestive heart failure.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Female; Heart Failure; Humans; Hypertension; Male; Middl | 2022 |
Increased circulating uric acid aggravates heart failure via impaired fatty acid metabolism.
Topics: Animals; Fatty Acid Synthases; Fatty Acids; Heart Diseases; Heart Failure; Humans; Uric Acid; Zebraf | 2023 |
Effects of angiotensin receptor-neprilysin inhibitor on insulin resistance in patients with heart failure.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; | 2023 |
The effects of cardiometabolic factors on the association between serum uric acid and risk of all-cause mortality in adults with congestive heart failure.
Topics: Adult; Cardiovascular Diseases; Heart Failure; Humans; Hyperglycemia; Hypertension; Nutrition Survey | 2023 |
Sodium-glucose co-transporter-2 (SGLT-2) inhibitors and uric acid: More good news!
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucose; Heart Failure; Humans; Hypoglycemic Agents | 2023 |
Hyperuricemia and gout increased the risk of long-term mortality in patients with heart failure: insights from the National Health and Nutrition Examination Survey.
Topics: Gout; Heart Failure; Humans; Hyperuricemia; Nutrition Surveys; Uric Acid | 2023 |
Associations of long-term mortality with serum uric acid at admission in acute decompensated heart failure with different phenotypes.
Topics: Aged; Female; Heart Failure; Humans; Male; Phenotype; Prognosis; Stroke Volume; Uric Acid; Ventricul | 2023 |
Serum HMGB1 is a biomarker for acute myocardial infarction with or without heart failure.
Topics: Biomarkers; Heart Failure; HMGB1 Protein; Humans; Myocardial Infarction; Stroke Volume; Uric Acid; V | 2023 |
Relation of serum uric acid levels to readmission and mortality in patients with heart failure.
Topics: Chronic Disease; Female; Heart Failure; Humans; Male; Patient Readmission; Retrospective Studies; Ur | 2023 |
Predictive value of echocardiography combined with CT angiography for left atrial appendage thrombosis in patients with non-valvular atrial fibrillation.
Topics: Atrial Appendage; Atrial Fibrillation; Computed Tomography Angiography; Echocardiography, Transesoph | 2023 |
Serum uric acid levels and risk of cardiovascular disease in type 2 diabetes: results from a cross-sectional study and Mendelian randomization analysis.
Topics: Cardiovascular Diseases; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Genome-Wide Association | 2023 |
Serum uric acid and outcome in hospitalized elderly patients with chronic heart failure through the whole spectrum of ejection fraction phenotypes.
Topics: Aged; Chronic Disease; Heart Failure; Humans; Prognosis; Stroke Volume; Uric Acid; Ventricular Funct | 2023 |
Uric acid level is positively associated with NT-proBNP concentration in Slovak heart failure patients.
Topics: Aged; Aged, 80 and over; Biomarkers; Confounding Factors, Epidemiologic; Cross-Sectional Studies; Di | 2019 |
Elevated Serum Uric Acid and Self-Reported Heart Failure in US Adults: 2007-2016 National Health and Nutrition Examination Survey.
Topics: Adult; Aged; Female; Heart Failure; Humans; Hyperuricemia; Male; Middle Aged; Nutrition Surveys; Pre | 2019 |
Hyperuricemia in US Population with Heart Failure: Causal or Incidental Bystander?
Topics: Adult; Heart Failure; Humans; Hyperuricemia; Nutrition Surveys; Self Report; Uric Acid | 2019 |
Prognostic Value of Serum Uric Acid in Hospitalized Heart Failure Patients With Preserved Ejection Fraction (from the Japanese Nationwide Multicenter Registry).
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Angiotensin- | 2020 |
Hyperuricemia and mortality in heart failure: Is it time to change the route?
Topics: Heart Failure; Humans; Hyperuricemia; Prognosis; Stroke Volume; Uric Acid | 2020 |
Association of variability in uric acid and future clinical outcomes of patient with coronary artery disease undergoing percutaneous coronary intervention.
Topics: Aged; Aged, 80 and over; Biomarkers; Coronary Artery Disease; Female; Heart Failure; Humans; Hyperur | 2020 |
Asymptomatic hyperuricemia and incident congestive heart failure in elderly patients without comorbidities.
Topics: Age Factors; Aged; Asymptomatic Diseases; Biomarkers; China; Female; Heart Failure; Humans; Hyperuri | 2020 |
Evaluation of high-sensitivity C-reactive protein and uric acid in vericiguat-treated patients with heart failure with reduced ejection fraction.
Topics: Aged; C-Reactive Protein; Female; Heart Failure; Heterocyclic Compounds, 2-Ring; Humans; Male; Middl | 2020 |
Serum uric acid level and subclinical left ventricular dysfunction: a community-based cohort study.
Topics: Aged; Cohort Studies; Echocardiography; Female; Heart Failure; Humans; Male; Middle Aged; Uric Acid; | 2020 |
Comparison of Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection Fraction With Versus Without Hyperuricemia or Gout.
Topics: Aged; Cause of Death; Comorbidity; Echocardiography; Female; Follow-Up Studies; Gout; Heart Failure; | 2020 |
Cancer in chronic heart failure patients in the GISSI-HF trial.
Topics: Aged; Blood Pressure; Cardiovascular Diseases; Cause of Death; Cholesterol; Chronic Disease; Creatin | 2020 |
Association between long-term prescription of febuxostat and the progression of heart failure with preserved ejection fraction in patients with hypertension and asymptomatic hyperuricemia.
Topics: Aged; Asymptomatic Diseases; Biomarkers; Blood Pressure; Databases, Factual; Diastole; Disease Progr | 2020 |
Impact of plasma xanthine oxidoreductase activity in patients with heart failure with preserved ejection fraction.
Topics: Heart Failure; Humans; Hyperuricemia; Stroke Volume; Uric Acid; Xanthine Dehydrogenase | 2020 |
In-Hospital Serum Uric Acid Change Predicts Adverse Outcome in Patients With Heart Failure.
Topics: Aged; Aged, 80 and over; Female; Heart Failure; Hospitals; Humans; Male; Natriuretic Peptide, Brain; | 2020 |
Serum uric acid, predicts heart failure in a large Italian cohort: search for a cut-off value the URic acid Right for heArt Health study.
Topics: Cohort Studies; Heart Failure; Humans; Hypertension; Italy; Risk Factors; Uric Acid | 2021 |
A statistical predictive model consistent within a 5-year follow-up period for patients with acute heart failure.
Topics: Acute Disease; Aged; Atrial Fibrillation; Diabetes Complications; Female; Follow-Up Studies; Heart F | 2020 |
The relationship between serum uric acid and cognitive function in patients with chronic heart failure.
Topics: Aged; Aged, 80 and over; Biomarkers; Chronic Disease; Cognition; Cognition Disorders; Cross-Sectiona | 2020 |
Serum uric acid, influence of sacubitril-valsartan, and cardiovascular outcomes in heart failure with preserved ejection fraction: PARAGON-HF.
Topics: Aged; Aged, 80 and over; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting En | 2020 |
Uric Acid Is a Biomarker of Oxidative Stress in the Failing Heart: Lessons Learned from Trials With Allopurinol and SGLT2 Inhibitors.
Topics: Allopurinol; Biomarkers; Enzyme Inhibitors; Heart Failure; Humans; Oxidative Stress; Sodium-Glucose | 2020 |
Serum Uric Acid Levels among Patients who Died in Recent Year due to Heart Failure with Reduced Ejection Fraction.
Topics: Cross-Sectional Studies; Heart Failure; Humans; Male; Prognosis; Retrospective Studies; Stroke Volum | 2020 |
Association between serum urate, gout and comorbidities: a case-control study using data from the UK Biobank.
Topics: Adult; Aged; Cardiovascular Diseases; Case-Control Studies; Comorbidity; Diabetes Mellitus; Female; | 2021 |
Prognostic impacts of serum uric acid levels in patients with chronic heart failure: insights from the CHART-2 study.
Topics: Aged; Aged, 80 and over; Female; Heart Failure; Humans; Middle Aged; Prognosis; Stroke Volume; Uric | 2021 |
Effect of Topiroxostat on Brain Natriuretic Peptide Level in Patients with Heart Failure with Preserved Ejection Fraction: A Pilot Study.
Topics: Aged; Aged, 80 and over; Biomarkers; Gout; Heart Failure; Humans; Hyperuricemia; Middle Aged; Natriu | 2021 |
The URRAH study.
Topics: Diabetes Mellitus, Type 2; Gout; Heart Failure; Humans; Hypertension; Retrospective Studies; Stroke; | 2021 |
PREVALENCE OF HYPERURICEMIA IN PATIENTS WITH CHRONIC HEART FAILURE.
Topics: Female; Heart Failure; Humans; Hyperuricemia; Prevalence; Uric Acid; Ventricular Dysfunction, Left; | 2021 |
Association between serum uric acid levels and cardiovascular events in hospitalized patients with type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Female; Heart Failure; Humans; Male; Retrospective Studies; Risk Factors; | 2021 |
Serum uric acid and outcomes in patients with chronic heart failure through the whole spectrum of ejection fraction phenotypes: Analysis of the ESC-EORP Heart Failure Long-Term (HF LT) Registry.
Topics: Heart Failure; Humans; Phenotype; Prognosis; Prospective Studies; Registries; Retrospective Studies; | 2021 |
Relation of Serum Uric Acid and Cardiovascular Events in Young Adults Aged 20-49 Years.
Topics: Adult; Atrial Fibrillation; Cardiovascular Diseases; Female; Heart Failure; Humans; Hyperuricemia; I | 2021 |
Association between Uric Acid and In-Hospital Heart Failure in Patients with Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention.
Topics: Aged; Female; Heart Failure; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary | 2021 |
One‑year survival of ambulatory patients with end‑stage heart failure: the analysis of prognostic factors.
Topics: Ambulatory Care; C-Reactive Protein; Female; Heart Failure; Humans; Male; Middle Aged; Poland; Progn | 2017 |
Performance of AHEAD Score in an Asian Cohort of Acute Heart Failure With Either Preserved or Reduced Left Ventricular Systolic Function.
Topics: Acute Disease; Aged; Aged, 80 and over; Asian People; Atrial Fibrillation; Biomarkers; Cardiovascula | 2017 |
Timing on echocardiography and blood laboratory test is important for future outcome association in hospitalized heart failure patients.
Topics: Aged; Aged, 80 and over; Blood Urea Nitrogen; Creatinine; Echocardiography; Female; Heart Failure; H | 2018 |
Serum allantoin and aminothiols as biomarkers of chronic heart failure.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allantoin; Biomarkers; Case-Control Studies; Chronic Dis | 2017 |
Serum uric acid as a potential marker for heart failure risk in men on antihypertensive treatment: The British Regional Heart Study.
Topics: Aged; Antihypertensive Agents; Biomarkers; Cohort Studies; England; Follow-Up Studies; Heart Failure | 2018 |
Uric acid is important, but there is something that matters even more: to deliver sacubitril/valsartan to eligible heart failure patients.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failu | 2018 |
Serum uric acid is associated with incidence of heart failure with preserved ejection fraction and cardiovascular events in patients with arterial hypertension.
Topics: Aged; Echocardiography, Doppler; Female; Heart Failure; Humans; Hypertension; Hyperuricemia; Inciden | 2018 |
Elevated serum uric acid concentration at discharge confers additive prognostic value in elderly patients with acute heart failure.
Topics: Age Factors; Aged; Aged, 80 and over; Biomarkers; Cause of Death; Decision Support Techniques; Disea | 2018 |
LC-MS-based serum fingerprinting reveals significant dysregulation of phospholipids in chronic heart failure.
Topics: Aged; Carnitine; Cholesterol; Chromatography, Liquid; Chronic Disease; Cohort Studies; Fatty Acids; | 2018 |
Association between Serum Uric Acid Level and Ventricular Tachyarrhythmia in Heart Failure Patients with Implantable Cardioverter-Defibrillator.
Topics: Aged; Death, Sudden, Cardiac; Defibrillators, Implantable; Electrocardiography; Female; Heart Failur | 2018 |
Kidney Function, Nutritional Status, and the Left Ventricle Dysfunction Are Associated with Serum Uric Acid Levels in Patients with Heart Failure with Reduced Ejection Fraction.
Topics: Adult; Female; Fuzzy Logic; Glomerular Filtration Rate; Heart Failure; Humans; Male; Middle Aged; Na | 2018 |
A novel validated method for predicting the risk of re-hospitalization for worsening heart failure and the effectiveness of the diuretic upgrading therapy with tolvaptan.
Topics: Aged; Aged, 80 and over; Diabetes Mellitus; Diuretics; Female; Heart Failure; Heart Rate; Hematocrit | 2018 |
Gender differences in association between uric acid and all-cause mortality in patients with chronic heart failure.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Biomarkers; Cause of Death; Chronic Disease; Female; Hea | 2019 |
Plasma xanthine oxidoreductase activity in patients with decompensated acute heart failure requiring intensive care.
Topics: Acute Disease; Aged; Aged, 80 and over; Biomarkers; Critical Care; Female; Follow-Up Studies; Heart | 2019 |
Hyperuricemia predicts adverse clinical outcomes after cardiac resynchronization therapy.
Topics: Aged; Biomarkers; Cardiac Resynchronization Therapy; Female; Follow-Up Studies; Heart Failure; Human | 2018 |
Association of serum uric acid change with mortality, renal function and diuretic dose administered in treatment of acute heart failure.
Topics: Aged; Aged, 80 and over; Biomarkers; Creatinine; Diuresis; Female; Heart Failure; Humans; Hyperurice | 2019 |
Hyperuricemia treatment in acute heart failure patients does not improve their long-term prognosis: A propensity score matched analysis from the AHEAD registry.
Topics: Acute Disease; Aged; Aged, 80 and over; Allopurinol; Biomarkers; Cause of Death; Czech Republic; Dos | 2019 |
Associations of Gout and Baseline Serum Urate Level With Cardiovascular Outcomes: Analysis of the Coronary Disease Cohort Study.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Cardiovascular Diseases; Coronary Artery Disease; | 2019 |
Theacrine attenuates myocardial fibrosis after myocardial infarction via the SIRT3/β-catenin/PPARγ pathway in estrogen-deficient mice.
Topics: Administration, Oral; Animals; Apoptosis; beta Catenin; Disease Models, Animal; Echocardiography; Es | 2019 |
High-dose prednisone in patients with heart failure and hyperuricemia: friend and foe?
Topics: Allopurinol; Female; Glucocorticoids; Gout Suppressants; Heart Failure; Humans; Hyperuricemia; Male; | 2013 |
The effect of continuous flow left ventricular assist device (CF-LVAD) implantation on serum uric acid levels.
Topics: Adult; Aged; Biomarkers; Cohort Studies; Defibrillators, Implantable; Female; Heart Failure; Heart-A | 2013 |
Hypouricemic effects of prednisone and allopurinol: an uneven playing field?
Topics: Allopurinol; Female; Glucocorticoids; Gout Suppressants; Heart Failure; Humans; Hyperuricemia; Male; | 2014 |
Reply to Day et al.--hypouricemic effect of prednisone in heart failure: possible mechanisms.
Topics: Allopurinol; Female; Glucocorticoids; Gout Suppressants; Heart Failure; Humans; Hyperuricemia; Male; | 2014 |
Uric acid levels and atrial fibrillation.
Topics: Atrial Fibrillation; Female; Heart Failure; Humans; Male; Myocardial Ischemia; Uric Acid | 2014 |
Response to the letter: uric acid levels and atrial fibrillation.
Topics: Atrial Fibrillation; Female; Heart Failure; Humans; Male; Myocardial Ischemia; Uric Acid | 2014 |
Uricaemia and ejection fraction in elderly heart failure outpatients.
Topics: Aged; Female; Heart Failure; Humans; Hyperuricemia; Male; Outpatients; Prospective Studies; Stroke V | 2014 |
Predictors of positive response to cardiac resynchronization therapy.
Topics: Aged; Biomarkers; Cardiac Resynchronization Therapy; Chi-Square Distribution; Echocardiography, Dopp | 2014 |
Uric acid elevation in atrial fibrillation: is it simply an epiphenomenon or not?
Topics: Atrial Fibrillation; Biomarkers; Heart Failure; Humans; Uric Acid | 2014 |
Uric acid and gamma-glutamyl transferase activity are associated with left ventricular remodeling indices in patients with chronic heart failure.
Topics: Aged; Biomarkers; Disease Progression; Echocardiography; Female; gamma-Glutamyltransferase; Heart Fa | 2014 |
Renal "hyperfiltrators" are at elevated risk of death and chronic diseases.
Topics: Adult; Aged; Autoimmunity; Blood Pressure; Body Mass Index; Cause of Death; Cholesterol, LDL; Chroni | 2014 |
The effects of carvedilol and nebivolol on oxidative stress status in patients with non-ischaemic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Antioxidants; Carbazoles; Carvedilol; Echocardiography; Female; H | 2015 |
Relation of serum uric acid levels and outcomes among patients hospitalized for worsening heart failure with reduced ejection fraction (from the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan trial).
Topics: Age Factors; Aged; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Black or African America | 2014 |
The association between serum uric acid level and heart failure and mortality in the early period of ST-elevation acute myocardial infarction.
Topics: Adult; Aged; Aged, 80 and over; Female; Heart Failure; Hospitalization; Humans; Male; Middle Aged; M | 2014 |
The association between serum uric acid level and heart failure and mortality in the early period of STEMI.
Topics: Female; Heart Failure; Humans; Male; Myocardial Infarction; Uric Acid | 2014 |
Oxidative stress markers and C-reactive protein are related to severity of heart failure in patients with dilated cardiomyopathy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Biomarkers; C-Reactive Protein; Cardiomyopathy, Dilated; | 2014 |
[Effect of concomitant chronic kidney disease on the xanthine metabolism in patients with chronic heart failure].
Topics: Aged; Chronic Disease; Female; Glomerular Filtration Rate; Heart Failure; Humans; Male; Prognosis; R | 2014 |
Hyperuricemia reflects global Fontan pathophysiology and associates with morbidity and mortality in patients after the Fontan operation.
Topics: Adolescent; Adult; Biomarkers; Child; Female; Follow-Up Studies; Fontan Procedure; Heart Failure; Hu | 2015 |
Prednisone in Uric Acid Lowering in Symptomatic Heart Failure Patients with Hyperuricemia -- The PUSH-PATH3 Study.
Topics: Adult; Aged; Creatinine; Female; Gout Suppressants; Heart Failure; Humans; Hyperuricemia; Male; Midd | 2015 |
Prognostic value of novel biomarkers compared with detailed biochemical evaluation in patients with heart failure.
Topics: Adult; Aged; Biomarkers; Female; Glomerular Filtration Rate; Heart Failure; Humans; Male; Middle Age | 2015 |
Heart failure: not a single organ disease but a multisystem syndrome.
Topics: Endocrine System; Heart Failure; Humans; Kidney; Multiple Organ Failure; Musculoskeletal System; Par | 2015 |
Serum uric acid is associated with cardiac diastolic dysfunction among women with preserved ejection fraction.
Topics: Aged; Aged, 80 and over; Biomarkers; Diastole; Female; Heart Failure; Humans; Hypertrophy, Left Vent | 2015 |
Gender differences in the association between serum uric acid and prognosis in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Cause of Death; Female; Heart Failure; Humans; Incidence; Kaplan-Meie | 2016 |
Allopurinol ameliorates cardiac function in non-hyperuricaemic patients with chronic heart failure.
Topics: Adult; Aged; Allopurinol; Biomarkers; Chronic Disease; Female; Follow-Up Studies; Heart Failure; Hum | 2016 |
Prognostic Role of Hyperuricemia in Acute Heart Failure.
Topics: Acute Disease; Aged; Female; Heart Failure; Humans; Hyperuricemia; Male; Middle Aged; Prognosis; Uri | 2016 |
The prognostic impact of uric acid in patients with severely decompensated acute heart failure.
Topics: Acute Disease; Aged; Aged, 80 and over; Female; Heart Failure; Humans; Hyperuricemia; Japan; Male; M | 2016 |
Are atherosclerotic risk factors associated with a poor prognosis in patients with hyperuricemic acute heart failure? The evaluation of the causal dependence of acute heart failure and hyperuricemia.
Topics: Acute Disease; Aged; Atherosclerosis; Cause of Death; Female; Heart Failure; Humans; Hyperuricemia; | 2017 |
Association of serum calcium and heart failure with preserved ejection fraction in patients with type 2 diabetes.
Topics: Aged; Aged, 80 and over; Area Under Curve; Biomarkers; Blood Glucose; Calcium; China; Cross-Sectiona | 2016 |
Association Between Hyperuricemia and Major Adverse Cardiac Events in Patients with Acute Myocardial Infarction.
Topics: Adult; Aged; Cardiovascular Diseases; Diabetes Complications; Female; Heart Failure; Humans; Hyperte | 2017 |
Uric acid may be protective against cognitive impairment in older adults, but only in those without cardiovascular risk factors.
Topics: Aged; Aged, 80 and over; Cognitive Dysfunction; Dementia; Female; Heart Failure; Humans; Hypertensio | 2017 |
The prognostic impact of uric acid in patients with severely decompensated acute heart failure; Methodological issues.
Topics: Diuretics; Heart Failure; Humans; Prognosis; Uric Acid | 2017 |
Response to letter regarding article, "The prognostic impact of uric acid in patients with severely decompensated acute heart failure".
Topics: Diuretics; Heart Failure; Humans; Prognosis; Uric Acid | 2017 |
Evaluation of the Relationship Between Serum Uric Acid Levels and Cardiovascular Events in Patients With Gout: A Retrospective Analysis Using Electronic Medical Record Data.
Topics: Adult; Electronic Health Records; Female; Gout; Heart Failure; Humans; Kidney Diseases; Male; Middle | 2017 |
Study of Serum Uric Acid Levels in Myocardial Infarction and Its Association With Killip Class.
Topics: Acute Disease; Aged; Analysis of Variance; Case-Control Studies; Echocardiography; Female; Heart Fai | 2017 |
[High Serum Concentrations of Uric Acid: Clinical and Prognostic Significance in Chronic Heart Failure].
Topics: Chronic Disease; Heart Failure; Humans; Hyperuricemia; Prognosis; Uric Acid | 2016 |
The ongoing search for a stratified medicine approach in heart failure.
Topics: Enzyme Inhibitors; Heart Failure; Humans; Natriuretic Peptide, Brain; Oxypurinol; Risk Factors; Syst | 2008 |
Serum uric acid correlates with extracellular superoxide dismutase activity in patients with chronic heart failure.
Topics: Case-Control Studies; Chronic Disease; Female; Heart Failure; Humans; Male; Middle Aged; Oxidative S | 2008 |
Uric acid in chronic heart failure--current pathophysiological concepts.
Topics: Endothelium, Vascular; Heart Failure; Humans; Hyperuricemia; Risk Factors; Superoxide Dismutase; Uri | 2008 |
Uric acid, xanthine oxidase and heart failure: unresolved issues.
Topics: Endothelium, Vascular; Heart Failure; Humans; Risk Assessment; Superoxide Dismutase; Uric Acid; Vaso | 2008 |
The profile and prognosis of patients hospitalised with heart failure. The value of discharge blood pressure amd cholesterol.
Topics: Age Factors; Aged; Blood Pressure; Cholesterol; Chronic Disease; Creatinine; Female; Heart Failure; | 2008 |
Natriuretic peptides and other biomarkers in chronic heart failure: from BNP, NT-proBNP, and MR-proANP to routine biochemical markers.
Topics: Anemia; Biomarkers; Cachexia; Cystatin C; Growth Differentiation Factor 15; Heart Failure; Humans; H | 2009 |
Clinical significance of heart rate turbulence assessment in patients with chronic heart failure.
Topics: Adult; Aged; Aged, 80 and over; Arrhythmias, Cardiac; Case-Control Studies; Causality; Chronic Disea | 2008 |
Uric acid and cardiovascular risk.
Topics: Biomarkers; Cardiovascular Diseases; Heart Failure; Humans; Hyperuricemia; Prognosis; Risk Factors; | 2009 |
Association between hyperuricemia and incident heart failure among older adults: a propensity-matched study.
Topics: Aged; Aged, 80 and over; Biomarkers; Female; Heart Failure; Humans; Hyperuricemia; Incidence; Kaplan | 2010 |
Hyperuricemia in acute heart failure. More than a simple spectator?
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Cause of Death; Female; Follow-Up Studies; Heart Fail | 2009 |
Combination of conventional biomarkers for risk stratification in chronic heart failure.
Topics: Aged; Biomarkers; C-Reactive Protein; Chronic Disease; Creatinine; Female; Follow-Up Studies; Heart | 2009 |
Uric acid and risk of myocardial infarction, stroke and congestive heart failure in 417,734 men and women in the Apolipoprotein MOrtality RISk study (AMORIS).
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Confidence Intervals; Female; Heart Failure; Humans; Ma | 2009 |
[Association of serum uric acid, plasma NT-proBNP, Hs-C reactive protein and invasive hemodynamic parameters in patients with heart failure].
Topics: Adolescent; Adult; Aged; C-Reactive Protein; Female; Heart Failure; Hemodynamics; Humans; Male; Midd | 2009 |
Elevated serum uric acid levels following heart transplantation predict all-cause and cardiac mortality.
Topics: Biomarkers; Cause of Death; Cohort Studies; Female; Graft Rejection; Graft Survival; Heart Failure; | 2009 |
Pancreatic gout masquerading as pancreatic cancer in a heart transplant candidate.
Topics: Diagnosis, Differential; Gout; Heart Failure; Heart Transplantation; Humans; Male; Middle Aged; Panc | 2009 |
Lipoprotein components and risk of congestive heart failure in 84,740 men and women in the Apolipoprotein MOrtality RISk study (AMORIS).
Topics: Apolipoprotein A-I; Apolipoproteins B; Blood Glucose; Female; Haptoglobins; Heart Failure; Humans; L | 2009 |
Diagnostic and prognostic value of uric acid in patients with acute dyspnea.
Topics: Acute Disease; Aged; Aged, 80 and over; Biomarkers; Diagnosis, Differential; Dyspnea; Female; Follow | 2009 |
Is there a difference between patients with peak oxygen consumption below 10 ml/kg/min versus between 10 and 14 ml/kg/min? Does the "Grey Zone" really exist?
Topics: Blood Pressure; C-Reactive Protein; Creatinine; Exercise; Heart Failure; Heart Rate; Heart Transplan | 2009 |
Hyperuricemia and incident heart failure.
Topics: Adult; Biomarkers; Female; Heart Failure; Humans; Hyperuricemia; Incidence; Kaplan-Meier Estimate; M | 2009 |
High-dose versus low-dose losartan in patients with heart failure.
Topics: Angiotensin II Type 1 Receptor Blockers; Heart Failure; Humans; Losartan; Uric Acid | 2010 |
Hyperuricemia predicts adverse outcomes in patients with heart failure.
Topics: Aged; Cause of Death; Disease Progression; Female; Follow-Up Studies; Heart Failure; Humans; Hyperur | 2011 |
Combination of uric acid and NT-ProBNP: a more useful prognostic marker for short-term clinical outcomes in patients with acute heart failure.
Topics: Aged; Aged, 80 and over; Biomarkers; Female; Heart Failure; Humans; Kaplan-Meier Estimate; Male; Mid | 2010 |
Effect of serum insulin on the association between hyperuricemia and incident heart failure.
Topics: Aged; Biomarkers; Female; Heart Failure; Humans; Hyperinsulinism; Hyperuricemia; Incidence; Insulin; | 2010 |
Serum YKL-40 predicts adverse clinical outcomes in patients with chronic heart failure.
Topics: Adipokines; Aged; Biomarkers; Case-Control Studies; Chitinase-3-Like Protein 1; Creatinine; Enzyme-L | 2010 |
Prognostic significance of serum uric acid in outpatients with chronic heart failure is complex and related to body mass index: data from the IN-CHF Registry.
Topics: Aged; Aged, 80 and over; Ambulatory Care; Body Mass Index; Female; Heart Failure; Humans; Hyperurice | 2012 |
Chlorthalidone reduces cardiovascular events compared with hydrochlorothiazide: a retrospective cohort analysis.
Topics: Adult; Angina Pectoris; Antihypertensive Agents; Blood Pressure; Chlorthalidone; Cholesterol; Heart | 2011 |
Predictors of clinical outcomes in elderly patients with heart failure.
Topics: Aged; Aged, 80 and over; Bundle-Branch Block; Comorbidity; Creatinine; Female; Heart Atria; Heart Fa | 2011 |
Prognostic value of uric acid in patients with ST-elevated myocardial infarction undergoing primary coronary intervention.
Topics: Age Factors; Angioplasty, Balloon, Coronary; Diabetes Mellitus; Female; Follow-Up Studies; Heart Fai | 2012 |
[Application of ¹H-NMR-based pattern recognition in serum metabolomics of patients with chronic heart failure].
Topics: Aged; Chronic Disease; Female; Heart Failure; Humans; Least-Squares Analysis; Magnetic Resonance Spe | 2012 |
Prognostic value of cardiac magnetic resonance imaging for idiopathic pulmonary arterial hypertension before initiating intravenous prostacyclin therapy.
Topics: Adult; Antihypertensive Agents; Biomarkers; Epoprostenol; Exercise Test; Exercise Tolerance; Familia | 2012 |
Serum uric acid levels are associated with atrial fibrillation in patients with ischemic heart failure.
Topics: Aged; Atrial Fibrillation; Biomarkers; Chronic Disease; Female; Heart Atria; Heart Failure; Humans; | 2013 |
Uric acid, allopurinol therapy, and mortality in patients with acute heart failure--results of the Acute HEart FAilure Database registry.
Topics: Acute Disease; Age Factors; Aged; Aged, 80 and over; Allopurinol; Female; Glomerular Filtration Rate | 2012 |
Significance of serum uric acid levels on the risk of all-cause and cardiovascular mortality.
Topics: Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Cause of Death; Female; Heart Failure; Huma | 2013 |
Changes in uric acid levels and allopurinol use in chronic heart failure: association with improved survival.
Topics: Aged; Allopurinol; Confidence Intervals; Enzyme Inhibitors; Female; Glomerular Filtration Rate; Hear | 2012 |
Beyond atrial fibrillation and heart failure: the evolving role of uric acid in cardio- vascular pathologies and morbidity.
Topics: Atrial Fibrillation; Heart Failure; Humans; Morbidity; Uric Acid | 2012 |
Is serum uric acid level an independent predictor of heart failure among patients with coronary artery disease?
Topics: Aged; Biomarkers; Chi-Square Distribution; Coronary Artery Disease; Female; Heart Failure; Humans; H | 2013 |
Uric acid--a marker for systemic inflammatory response in patients with congestive heart failure?
Topics: Aged; Aldosterone; Creatinine; Female; Heart Failure; Humans; Leukocyte Count; Male; Middle Aged; Pr | 2002 |
Effect of anemia on exercise tolerance in chronic heart failure in men.
Topics: Age Factors; Aged; Anemia; Biomarkers; Chronic Disease; Creatinine; Exercise Test; Exercise Toleranc | 2003 |
Uric acid predicts clinical outcomes in heart failure: insights regarding the role of xanthine oxidase and uric acid in disease pathophysiology.
Topics: Adenosine Triphosphate; Heart Failure; Humans; Kidney; Nitric Oxide; Predictive Value of Tests; Prog | 2003 |
Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging.
Topics: Biomarkers; Chronic Disease; Comorbidity; Female; Follow-Up Studies; Heart Failure; Hemodynamics; Hu | 2003 |
TREATMENT OF CONGESTIVE HEART FAILURE WITH TRIAMTERENE.
Topics: Blood; Diuresis; Diuretics; Drug Therapy; Gout; Heart Failure; Humans; Hydrochlorothiazide; Potassiu | 1965 |
Uric acid and prognosis in chronic heart failure.
Topics: Bias; Chronic Disease; Clinical Trials as Topic; Creatinine; Follow-Up Studies; Heart Failure; Human | 2003 |
Association of biochemical values with morbidity in the elderly: a population-based Swedish study of persons aged 82 or more years.
Topics: Aged; Aged, 80 and over; Biomarkers; Blood Chemical Analysis; Body Mass Index; Cholesterol; Creatine | 2003 |
The European Society of Cardiology working group on heart failure: Heart Failure Update 2003.
Topics: Carbazoles; Cardiac Pacing, Artificial; Carvedilol; Eplerenone; Europe; Heart Failure; Humans; Metop | 2003 |
Increased F2 isoprostane plasma levels in patients with congestive heart failure are correlated with antioxidant status and disease severity.
Topics: Aged; Aged, 80 and over; Antioxidants; Ascorbic Acid; Biomarkers; Carotenoids; Dinoprost; F2-Isopros | 2004 |
Xanthine oxidase inhibitors: an emerging class of drugs for heart failure.
Topics: Allopurinol; Animals; Enzyme Inhibitors; Heart Failure; Humans; Mechanoreceptors; Nitric Oxide; Uric | 2005 |
Uric acid renal excretion and renal insufficiency in decompensated severe heart failure.
Topics: Female; Heart Failure; Humans; Male; Middle Aged; Prognosis; Renal Insufficiency; ROC Curve; Uric Ac | 2005 |
Prognostic usefulness of serum uric acid after acute myocardial infarction (the Japanese Acute Coronary Syndrome Study).
Topics: Aged; Biomarkers; Coronary Angiography; Creatine Kinase; Electrocardiography; Female; Follow-Up Stud | 2005 |
Serum uric acid levels as a predictor of in-hospital death in patients hospitalized for decompensated heart failure.
Topics: Aged; Aged, 80 and over; Biomarkers; Female; Heart Failure; Hospital Mortality; Humans; Logistic Mod | 2005 |
Allopurinol or oxypurinol in heart failure therapy - a promising new development or end of story?
Topics: Allopurinol; Antioxidants; Enzyme Inhibitors; Heart Failure; Humans; Oxypurinol; Randomized Controll | 2005 |
Hyperuricemia associated with high cardiac event rates in the elderly with chronic heart failure.
Topics: Aged; Biomarkers; Female; Heart Failure; Humans; Hyperuricemia; Male; Middle Aged; Multivariate Anal | 2006 |
Hyperuricaemia predicts poor outcome in patients with mild to moderate chronic heart failure.
Topics: Chronic Disease; Female; Heart Failure; Humans; Hyperuricemia; Male; Middle Aged; Prognosis; Severit | 2007 |
Uric acid in CHF: marker or player in a metabolic disease?
Topics: Biomarkers; Heart Failure; Humans; Uric Acid; Xanthine Oxidase | 2007 |
Serum level of uric acid, partly secreted from the failing heart, is a prognostic marker in patients with congestive heart failure.
Topics: Aged; Biomarkers; Case-Control Studies; Data Interpretation, Statistical; Female; Heart Failure; Hum | 2006 |
Hyperuricaemia and long-term outcome after hospital discharge in acute heart failure patients.
Topics: Acute Disease; Aged; Aged, 80 and over; Biomarkers; Case-Control Studies; Female; Follow-Up Studies; | 2007 |
Heart failure, dementia, and diuretics: is uric acid involved?
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antihypertensive Agents; Cohort Studies; Dementia; Femal | 2006 |
Increased levels of uric acid predict haemodynamic compromise in patients with heart failure independently of B-type natriuretic peptide levels.
Topics: Blood Pressure; Female; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Stroke | 2007 |
Uric acid as a prognostic marker in acute heart failure--new expectations from an old molecule.
Topics: Acute Disease; Biomarkers; Heart Failure; Humans; Hyperuricemia; Patient Discharge; Prognosis; Survi | 2007 |
Letter by Kielstein et al regarding article, "High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid".
Topics: Allopurinol; Glomerular Filtration Rate; Heart Failure; Humans; Kidney; Kidney Diseases; Oxidative S | 2007 |
Is uric acid itself a player or a bystander in the pathophysiology of chronic heart failure?
Topics: Chronic Disease; Endothelium, Vascular; Heart Failure; Humans; Hyperuricemia; Uric Acid; Xanthine Ox | 2008 |
Serum uric acid and risk of cardiovascular mortality: a prospective long-term study of 83,683 Austrian men.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Austria; Biomarkers; Cardiovascular Diseases; Coronary D | 2008 |
Xanthine oxidase inhibitors the unappreciated treatment for heart failure.
Topics: Allopurinol; Animals; Controlled Clinical Trials as Topic; Enzyme Inhibitors; Female; Heart Failure; | 2007 |
Serum uric acid: novel prognostic factor in primary systemic amyloidosis.
Topics: Adult; Aged; Aged, 80 and over; Amyloidosis; Biomarkers; Confidence Intervals; Disease Progression; | 2008 |
[Serum uric acid levels correlate with left ventricular ejection fraction and systolic pulmonary artery pressure in patients with heart failure].
Topics: Aged; Blood Pressure; Echocardiography; Female; Heart Failure; Humans; Male; Multivariate Analysis; | 2007 |
Relationship between serum uric acid levels and urinary albumin excretion in patients with heart failure.
Topics: Aged; Albuminuria; Biomarkers; Disease Progression; Female; Follow-Up Studies; Glomerular Filtration | 2008 |
Inflammation in chronic heart failure.
Topics: Anti-Inflammatory Agents; Antihypertensive Agents; C-Reactive Protein; Chronic Disease; Heart Failur | 2008 |
[Experiences with ethacrynic acid, a new diuretic].
Topics: Creatine; Edema; Ethacrynic Acid; Glycosuria; Heart Failure; Humans; Liver Function Tests; Myocardia | 1966 |
Clinical trial of a potassium-sparing saluretic pyrazine derivative (MK-870).
Topics: Adult; Aged; Carbon Dioxide; Chlorides; Creatine; Diuretics; Edema; Female; Heart Failure; Humans; L | 1967 |
Intravenous administration of furosemide in heart failure.
Topics: Blood Chemical Analysis; Blood Glucose; Blood Proteins; Blood Urea Nitrogen; Blood Volume; Ethacryni | 1967 |
[Therapy of heart failure with combined furosemide retard/triamterene].
Topics: Aged; Cholesterol; Creatinine; Delayed-Action Preparations; Drug Combinations; Female; Furosemide; H | 1984 |
[Therapy of cardiac insufficiency with diuretics].
Topics: Amiloride; Benzothiadiazines; Blood Glucose; Diuretics; Drug Administration Schedule; Female; Furose | 1982 |
[Tienilic acid, hyperuricemia and kidney function].
Topics: Aged; Creatinine; Female; Furosemide; Glycolates; Heart Failure; Humans; Hydrochlorothiazide; Kidney | 1981 |
[Secondary diseases complicating cancer].
Topics: Cardiovascular Diseases; Coronary Disease; Diabetes Complications; Female; Heart Failure; Humans; Li | 1981 |
[Cardiovascular diseases in Vienna. Epidemiological results of the "Vienna Health Study 1979"].
Topics: Adult; Austria; Cardiovascular Diseases; Cerebrovascular Disorders; Cholesterol; Coronary Disease; F | 1981 |
[Clinical risk factors in transient global amnesia and in transient ischaemic attacks (author's transl)].
Topics: Adult; Aged; Amnesia; Diabetes Complications; Female; Heart Failure; Humans; Hypercholesterolemia; H | 1980 |
[Study of associated risk factors and prevalence of heart diseases in patients with arterial hypertension].
Topics: Aged; Alcohol Drinking; Atrial Fibrillation; Coronary Disease; Data Interpretation, Statistical; Dia | 1995 |
Uric acid, anion gap and urea concentration in the diagnostic approach to hyponatremia.
Topics: Acid-Base Equilibrium; Diuretics; Heart Failure; Humans; Hyponatremia; Hypopituitarism; Inappropriat | 1994 |
Stereoselective disposition of ibuprofen in patients with compromised renal haemodynamics.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Coronary Disease; Diabetes Mellitus; Female; Heart Fa | 1995 |
Serum uric acid as an index of impaired oxidative metabolism in chronic heart failure.
Topics: Aged; Carbon Dioxide; Cardiomyopathy, Dilated; Chronic Disease; Energy Metabolism; Exercise Test; Fe | 1997 |
Relation between serum uric acid and lower limb blood flow in patients with chronic heart failure.
Topics: Biomarkers; Blood Glucose; Diuretics; Exercise Test; Heart Failure; Humans; Insulin; Leg; Middle Age | 1997 |
Uric acid in chronic heart failure: a measure of the anaerobic threshold.
Topics: Anaerobiosis; Blood Pressure; Chronic Disease; Heart Failure; Humans; Middle Aged; Multivariate Anal | 1998 |
Hyperuricaemia and congestive heart failure: causation or association?
Topics: Heart Failure; Humans; Uric Acid; Xanthine Oxidase | 1998 |
Uric acid in chronic heart failure: a marker of chronic inflammation.
Topics: Cardiomyopathy, Dilated; Case-Control Studies; Coronary Disease; Cytokines; Glucose Tolerance Test; | 1998 |
[Level of blood uric acid in patients with postinfarction heart failure].
Topics: Acid-Base Equilibrium; Adult; Aged; Carbon Dioxide; Heart Failure; Humans; Hydrogen-Ion Concentratio | 2000 |
Uric acid in cachectic and noncachectic patients with chronic heart failure: relationship to leg vascular resistance.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Blood Flow Velocity; Blood Pressure; Cachexia; Confidenc | 2001 |
Elevated serum uric acid levels are associated with diastolic dysfunction in patients with dilated cardiomyopathy.
Topics: Aged; Biomarkers; Diastole; Female; Follow-Up Studies; Heart Failure; Humans; Male; Middle Aged; Mit | 2002 |
The cause of the raised plasma urea of acute heart failure.
Topics: Acute Disease; Adult; Aged; Creatinine; Female; Heart Failure; Humans; Kidney; Male; Middle Aged; Ph | 1979 |
[Excretion of uric acid in cardiac decompensation].
Topics: Adolescent; Adult; Cardiomyopathies; Chronic Disease; Female; Glomerular Filtration Rate; Heart Defe | 1979 |
Evaluation of a new uricosuric diuretic--ticrynafen.
Topics: Diuretics; Drug Evaluation; Glycolates; Gout; Heart Failure; Humans; Hypertension; Ticrynafen; Uric | 1979 |
[Diuretics in cardiac insufficiency].
Topics: Alkalosis; Benzothiadiazines; Carbonic Anhydrase Inhibitors; Diuretics; Diuretics, Osmotic; Heart Fa | 1977 |
Biochemical and clinical effects of metolazone in congestive heart failure.
Topics: Aged; Alkaline Phosphatase; Blood Glucose; Blood Pressure; Blood Urea Nitrogen; Calcium; Creatinine; | 1975 |
Panniculitis of the legs with urate crystal deposition.
Topics: Aged; Arthritis; Diagnosis, Differential; Female; Furosemide; Gout; Heart Failure; Humans; Lipase; S | 1977 |
Long survival in sickle cell anemia.
Topics: Age Factors; Aged; Anemia, Aplastic; Anemia, Sickle Cell; Chronic Disease; Electrophoresis, Starch G | 1975 |
[Acute renal failure secondary to hyperuricemia after the use of a diuretic].
Topics: Acute Kidney Injury; Aged; Furosemide; Heart Failure; Humans; Male; Peritoneal Dialysis; Uric Acid | 1976 |
[Hereditary xanthinuria. A clinical case report].
Topics: Aged; Biopsy, Needle; Heart Failure; Humans; Hypoxanthines; Liver; Liver Diseases, Alcoholic; Male; | 1989 |
[Changes in xanthine oxidase activity in patients with circulatory failure].
Topics: Female; Heart Failure; Humans; Male; Rheumatic Heart Disease; Uric Acid; Xanthine Oxidase | 1989 |
Study to compare the relative hyperuricaemic effects of frusemide and bumetanide.
Topics: Aged; Bumetanide; Diuretics; Edema; Female; Furosemide; Heart Failure; Humans; Hypertension; Male; M | 1986 |
[Bilateral retinal vein occlusions and general risk factors].
Topics: Aged; Constriction, Pathologic; Diabetic Retinopathy; Female; Heart Failure; Humans; Hypercholestero | 1985 |
Rapid development of gouty tophi after diuretic therapy.
Topics: Aged; Diuretics; Female; Furosemide; Gout; Heart Failure; Humans; Uric Acid | 1985 |
Diuretic therapy update.
Topics: Acid-Base Imbalance; Acute Kidney Injury; Diet, Sodium-Restricted; Diuretics; Ear Diseases; Heart Fa | 1985 |
Serum enzymes and uric acid during treatment with amiloride.
Topics: Adult; Aspartate Aminotransferases; Diuretics; Guanidines; Heart Failure; Humans; L-Lactate Dehydrog | 1968 |
The negative effects of supervoltage external irradiation in prostatic carcinoma: report of 2 cases.
Topics: Acid Phosphatase; Adenocarcinoma; Aged; Anorexia Nervosa; Barium Sulfate; Biopsy, Needle; Blood Urea | 1974 |
Nongouty crystal deposit arthritis.
Topics: Adrenocorticotropic Hormone; Aspirin; Bursitis; Chondrocalcinosis; Colchicine; Heart Failure; Humans | 1971 |
Diuretics versus digitalis in the treatment of congestive heart failure.
Topics: Administration, Oral; Blood Glucose; Digitalis Glycosides; Diuretics; Heart Failure; Humans; Natriur | 1972 |
Recognition of myocardial infarction after cardiac surgery and its relation to cardiopulmonary bypass.
Topics: Alanine Transaminase; Angiography; Arrhythmias, Cardiac; Aspartate Aminotransferases; Cardiac Cathet | 1974 |
Blood volume, hemodynamic, and metabolic changes in hemorrhagic shock in normal and splenectomized dogs.
Topics: Acid-Base Equilibrium; Animals; Blood Glucose; Blood Pressure; Blood Proteins; Blood Viscosity; Bloo | 1973 |
Increased lactate dehydrogenase isoenzyme-5 (LD5) activity evidently caused by persistent diaphragmatic pressure on a congested liver.
Topics: Aged; Aspartate Aminotransferases; Autopsy; Blood Urea Nitrogen; Bradycardia; Creatine Kinase; Creat | 1973 |
Primary and secondary renal failure in a total community (Tecumseh, Michigan): preponderance in the elderly and possible antecedent factors.
Topics: Age Factors; Aged; Blood Glucose; Blood Pressure; Blood Urea Nitrogen; Cholesterol; Coronary Disease | 1974 |
Clinical evaluation of parenteral polythiazide (P-2525) administration.
Topics: Blood; Blood Glucose; Chlorides; Heart Failure; Humans; Injections, Intramuscular; Liver Diseases; O | 1965 |
Metabolic effects of ethacrynic acid in the aged.
Topics: Aged; Blood Urea Nitrogen; Chlorides; Diabetes Complications; Ethacrynic Acid; Female; Glucose Toler | 1970 |
[On the clinical and metabolic effects of mefruside].
Topics: Adult; Aged; Ascites; Blood Glucose; Carbohydrate Metabolism; Diabetes Mellitus; Diuresis; Diuretics | 1971 |
Comparison of the action of two new oral diuretics, the 4-chloro-N-methyl-3-(methylsulfamoly) benzamide and 4-chloro-3-sulfamylbenzoic acid 2,2-dimethylhydrazide (a study on 102 patients).
Topics: Adult; Aged; Arteries; Blood Glucose; Blood Pressure; Body Weight; Diuretics; Edema; Heart Failure; | 1968 |
Hypertension, hyperuricemia and iatrogenic disease.
Topics: Aged; Allopurinol; Aortic Diseases; Arteriosclerosis; Brain; Catheterization; Chlorothiazide; Diagno | 1970 |
Clinical significance of hyperuricemia in routinely screened hospitalized men.
Topics: Acidosis; Adult; Aged; Autoanalysis; Diuretics; Gout; Heart Failure; Hospitalization; Humans; Kidney | 1970 |
Hyperuricemia and chronic renal disease.
Topics: Adult; Aged; Alcohol Drinking; Chronic Disease; Creatinine; Diabetes Mellitus; Diuretics; Female; Go | 1971 |
The causes of nonazotemic hyperuricemia.
Topics: Adult; Age Factors; Animals; Arteriosclerosis; Blood Urea Nitrogen; Computers; Coronary Disease; Dia | 1971 |
[Ethacrynic acid: research on the mechanism of action and clinical use].
Topics: Adolescent; Adult; Aged; Child; Diabetes Insipidus; Diuresis; Edema; Ethacrynic Acid; Female; Heart | 1968 |
Hyperuricaemic and hyperglycaemic effects of thiazides in non-prediabetics.
Topics: Blood; Diabetes Mellitus; Heart Failure; Humans; Hydrochlorothiazide; Polythiazide; Prediabetic Stat | 1965 |
Cardiorenal hemodynamic effects of ethacrynic acid.
Topics: Chlorothiazide; Diabetes Insipidus; Edema; Electrolytes; Ethacrynic Acid; Heart; Heart Failure; Hear | 1966 |